Clarity and Openness in Reporting: E3-based

An Open Access Resource to Support Authoring of Clinical Study Reports for Interventional Studies

Version 1.0 03-May-2016

Downloaded from: http://www.core-reference.org
Preface to CORE Reference

What is CORE Reference?
The CORE (Clarity and Openness in Reporting: E3-based) Reference is a user manual to help medical writers navigate relevant guidelines as they create clinical study report (CSR) content relevant for today’s studies.

CORE Reference comprises this Preface followed by the actual resource, which includes the following, distinguished from one another through the use of shading:

- **ICH E3** guidance text. Text from the original ICH E3 guidance document is shown in unboxed grey shading.
- **ICH E3 Question & Answer 2012**-derived guidance text. Text from the ICH E3 Question & Answer 2012 guidance document is shown in italics with grey shading and a boxed outline.
- CORE Reference text. CORE Reference text is not shaded and not boxed.

All ICH E3 guidance text is either included as original wording; or is included as modified wording and the modification is explained; or is omitted, the omission is shown and the reason for the omission is explained.

All ICH E3 Question & Answer 2012-derived guidance text is included and explained.

In addition, relevant regional (EU and USA) regulatory guidances are integrated into the resource.

Further value-added insights, based on extensive collective experience, are included.

Rationale comments - in ‘comment’ format on the right hand side of each page - are used for explanation and clarification purposes.

A key explaining text shading and comments is included in the footer of each page of CORE Reference.

Where alternative presentations of the same information would work equally well in a CSR, they are shown with an explanation provided in the ‘Rationale comments’ to allow CSR authors to make informed authoring choices relevant for their particular study.

A separate mapping tool comparing ICH E3 sectional structure and CORE Reference sectional structure is also provided to support the utility of the CORE Reference.

Together, CORE Reference and the mapping tool constitute the user manual.
Why is CORE Reference needed?

Since ICH E3 was published in 1995, other guidance documents have been issued, including the ICH E3 Question & Answer guidance document in 2012. In addition, there has been heightened awareness of the importance of disclosure of clinical study results. The use of the CSR as a key source document to fulfil emerging obligations has resulted in a re-examination of how the ICH guidelines are applied in the preparation of CSRs in this new context. The dynamic regulatory and modern drug development environments create emerging reporting challenges.

Single CSR, Two Uses, Two Audiences

The CSR can be considered as a single document with two uses, each with a distinct purpose and audience:

- The ‘primary use CSR’ (the European Medicines Agency [EMA] term is scientific review version) is a technical document for regulatory review and comprises full CSR text and all CSR appendices. The information reported must not constrain the review process.
- The ‘secondary use CSR’ (the EMA term is redacted clinical report) is for public disclosure and comprises redacted CSR text and selected appendices. Sensitive information presented in the ‘primary use CSR’ is redacted in the ‘secondary use CSR’.

CORE Reference makes content suggestions for the ‘primary use CSR’. Comments are used to indicate individual CSR text portions that may potentially impact the ‘secondary use CSR’ and should therefore be considered for redaction in the ‘secondary use CSR’.

It is assumed that data, including for example patient identification numbers, are not proactively anonymised. Over time, anonymisation techniques may allow appropriate proactive anonymisation of data that could be used to author ‘primary use CSRs’. If proactively anonymised data is used to author the ‘primary use CSR’, then certain redactions may not be necessary in the ‘secondary use CSR’ for public disclosure.

When it is necessary to discuss any sensitive information, including individual subject level information in the text of the ‘primary use CSR’, the authors of CORE Reference recommend data and text presentations that maintain data meaning, remain in context AND conform to current standards for de-identifying data, because achievement of subject anonymity in the ‘primary use CSR’ for regulatory review will minimise the need for piecemeal redaction in the ‘secondary use CSR’ for public disclosure. This approach brings efficiencies to the wider preparation of disclosure-ready documents.

---

1 External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use. 2 March 2016. (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf [Accessed 04 April 2016]). Chapter 2, Section 3.3.1.9 states the cover letter including declaration will include ‘Confirmation that the clinical reports submitted for scientific evaluation are the same as that submitted for publication…except for the redactions’.
This ‘proactive’ authoring approach is encouraged by EMA. Refer to ‘External
guidance on the implementation of the European Medicines Agency policy on the
l_guideline/2016/03/WC500202621.pdf (henceforth referred to as ‘March 2016 EMA
guidance on use of Policy 0070’) Chapter 3, Section 5.1 ‘Data utility’ states: ‘EMA
understands that in an initial phase redaction techniques are likely to be used by
applicants/marketing authorisation holders (MAHs), taking into account that for a
certain period, pharmaceutical companies will have to anonymise their data
retrospectively (reactive data anonymisation), i.e. after the clinical report has already
been submitted for scientific review. Importantly, redaction alone is more likely to
decrease the clinical utility of the data compared to other techniques. Therefore, EMA
is of the view that applicants/MAHs, after experience has been accumulated in the
de-identification of clinical reports, should transition to other anonymisation
techniques that are more favoured in order to optimise the clinical usefulness of the
data published (proactive data anonymisation). Pharmaceutical companies are
encouraged to use these anonymisation techniques as soon as possible, whilst
ensuring data anonymisation is achieved’.

It is important to understand that although it is acceptable to disclose anonymised data
that includes data that has been aggregated (i.e. tabular summary data), such data
should be critically evaluated to determine the risk of de-anonymisation, considering
the following, which may influence the risk of de-anonymisation from aggregated
data, and may therefore influence the anonymisation technique:

- Is it possible to single out an individual?
- It is possible to link records relating to an individual?
- Can information be inferred concerning an individual?

It is expected that over time, more protected personal data (PPD) will be managed by
anonymisation techniques that retain data utility prior to CSR authoring, resulting in
fewer necessary redactions in the future.

Note that ‘redaction’ is the process of irreversibly blocking out sensitive information.

**General Clarifications about CORE Reference**

1. **CORE REFERENCE IS A USER MANUAL, NOT A TEMPLATE:** The
CORE Reference presents suggestions and best practices that add value for
medical writers creating ICH-compliant CSRs. **CORE Reference is not a
template.** It offers suggestions for content, but does not mandate a particular
sequence or organisation of the individual CSR sections. However, to allow easy
mapping to the original ICH E3 guidance document and to avoid conflict with
guidance documents that refer to ICH E3 sectional numbering, CORE Reference
maintains the level 1 heading hierarchy of ICH E3. It remains at the author’s

---

2 Opinion 05/2014 on anonymisation techniques, adopted on 10 April 2014 by the Article 29 Data
Protection Working Party.
(http://ec.europa.eu/justice/data-protection/article-29/documentation/opinion-
recommendation/files/2014/wp216_en.pdf [Accessed 04 April 2016]).
discretion to decide on the most appropriate CSR structure. Take, for example, ICH E3 ‘Section 15 References’. Logically, these should directly follow the CSR text as Section 14 content, so the order of ICH E3 Sections 14 and 15 would be switched. We have deliberately not switched these two sections in CORE Reference to avoiding conflicting with ICH E3, which might confound interpretation of other guidance documents that refer to ‘ICH E3 Section 14 Tables and Figures’. This, of course, does not mean that in any given CSR the order should not be switched so that ‘References’ appear before ‘Tables and Figures’. The CSR author may, with reference to the content guidance, place the content where he or she sees fit. Also consider that the CORE Reference suggested placement of sections cannot work in every conceivable situation, and is not ‘the only way’. CSR authors should use their judgment, and above all, make sensible structuring choices, based on their particular study.

2. **LANGUAGE SELECTION**: Language of the collected data should not affect the language in the CSR. For example, UK English or US English should be used consistently within and across documents comprising a submission, or within a company. The exception is for the Medical Dictionary for Regulatory Activities i.e. MedDRA coding terms, which use UK English. It is recommended that these are not changed, even in a CSR written in US English.

3. **TO LINK OR NOT TO LINK**
   **Appendices**: Years may elapse between a CSR being finalised and subsequently integrated into a dossier with its CSR appendices. During this intervening period, the CSR text and appendices may not necessarily be electronically linked to one another. CORE Reference does not support using links from the CSR to appendix information if that information is necessary for comprehending the results in context, for example, inclusion and exclusion criteria should be placed directly in the text of the CSR and not via a link to the relevant protocol section.

   **External documents**: In the ‘primary use CSR’ for regulatory review, only non-active web addresses (i.e. not hyperlinked) supported by a digital object identifier (DOI), where possible, should be included, because active web links may become redundant or broken over time. This could compromise electronic upload of the submission dossier. Including DOIs in the ‘primary use CSR’ minimises the work that needs to be done in the ‘secondary use CSR’ for public disclosure. In the ‘secondary use CSR’, the non-active web addresses may be made into active web links (including the date the link was accessed). All references or publicly available guidelines in the ‘secondary use CSR’ should be supported by a DOI in the event that active web links become redundant over time. Note that users without institutional resources may not be able to access restricted articles.

4. **KEY TERMINOLOGY CHOICES**: In some cases, there are differences and discrepancies among the terminology used in authoritative sources in providing consistent concepts and definitions. This necessitates an explanation for use of some of the general terms used consistently in CORE Reference. Unless otherwise stated, CORE Reference terminology is per Clinical Data Interchange Standards
In some cases, the term used is not in the CDISC glossary, in which case it is defined using other authoritative sources. In other cases, multiple definitions exist for a single intended meaning, in which case only one term is used consistently.

Key terms used in CORE Reference are presented below with reasons for their selection. Other choices may be equally acceptable in a CSR. The general rule is that language should be appropriate for the study in question and should be consistent within any given CSR.

a. **Study** or **trial**:
   - See ICH E6 Good Clinical Practice Guidelines, Section 1.12:
     - ICH E6: Guideline for Good Clinical Practice E6(R1) - Step 4, 10 June 1996
     - Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) - Step 2, 11 June 2015

   Both the original and addendum guidance state that study and trial are synonymous.

   - The European Clinical Trials Directive Amendment 291 dated 26 March 2014
     ([http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML+AMD+A7-2013-0208+291-291+DOC+PDF+V0/EN_(Accessed 04 April 2016]) clarifies the concept of clinical study of which the clinical trial is a category (see page 3 of the directive). The broad concept is that ‘clinical study’ includes the categories ‘clinical trial’ and ‘non-interventional (observational) study’.

   - The “PASS” Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies, 26 September 2012

The use of the term ‘study’ as both the over-arching term and as a sub-term may cause interpretational difficulty. This simple diagram may aid interpretation:
Therefore mixed use of ‘study’ and ‘trial’ is acceptable in a typical CSR (i.e. interventional and pre-authorisation).

Note: The term ‘study’ is used in CORE Reference.

b. **Patient, subject, participant** etc:
   
   

   A patient is a person being treated. Until an investigational product is approved for an indication, ‘subject’ is a reasonable choice for use in a CSR (i.e. interventional and pre-authorisation). ‘Patient’ is also a reasonable choice except in early phase ‘healthy-volunteer’ studies. Note that vaccine trials use the term ‘volunteers’. Alternatively, ‘participant’ may be used.

   Note: The term ‘subject’ is used throughout CORE Reference.

c. **Investigational Product, study medication, study treatment, study drug** etc:
   
   

   The term used in CORE Reference is ‘Investigational Product’, selected from the CDISC glossary terms below, and by considering the definition of Investigational Medicinal Product in The European Commission’s ‘Definition of Investigational Medicinal Products (IMPs) and Non Investigational Medicinal Products (NIMPs)’ (http://ec.europa.eu/health/files/pharmacos/docs/doc2006/07_2006/def_imp_2006_07_27_en.pdf [Accessed 04 April 2016]).

   ‘Study medication’ is not defined in CDISC Glossary, nor is it used in CORE Reference.

**CDISC Glossary definitions:**

**Investigational product**: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorisation (MA) when used or assembled (formulated or
packaged) in a way that is different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use (ICH E6 Integrated Addendum to ICH E6[R1]: Guideline for Good Clinical Practice E6[R2] - Step 2, 11 June 2015 [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf], Section 1.33). Note: CDISC includes test articles in its definition of investigational products.

**Study treatment**: See intervention (modified from CDISC Glossary)

**Therapeutic intervention**: See intervention.

**Intervention**: The drug, device, therapy, or process under investigation in a clinical study that is believed to have an effect on outcomes of interest in a study (for example, health-related quality of life, efficacy, safety, pharmacoeconomics). Synonyms: therapeutic intervention, medical product. See also: test articles; devices; drug product; medicinal product; combination product (refer to CDISC Glossary for definitions of these terms).

**Medical product**: See intervention.

**Medicinal product**: Synonym for therapeutic intervention, but usually a drug.

**Drug**:

1. Article other than food intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease; or intended to affect the structure or any function of the body. Not a device or a component, part, or accessory of a device.

2. Substance recognized by an official pharmacopeia or formulary, from Food and Drug Administration (FDA) Glossary of Terms. (http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm [Accessed 04 April 2016]).

This simple diagram may aid interpretation:
Note: The over-arching term ‘Investigational Product’ is used throughout CORE Reference unless it is necessary to make specific reference to any lower level term shown in the diagram above to aid understanding.

Other general terms are defined in CORE Reference at appropriate points in the text to aid usability. This includes the terms in the CORE Reference Terminology Page in Section 9.5.

d. Selected terms used in the context of public disclosure:

In some cases, there are differences and discrepancies among the terminology used in authoritative sources in providing consistent concepts and definitions around public disclosure of clinical-regulatory documents. This necessitates an explanation for language used in CORE Reference for such terms.

Where a definition is taken directly, or adapted from an external source to best represent the anticipated use of CORE Reference, the source is identified. Otherwise, the definition is attributable to the European Medical Writers Association (EMWA)-American Medical Writers Association (AMWA) Budapest Working Group.

Protected personal data (PPD) (also referred to as personal protected information [PPI], and individual personal data [IPD]): Any information relating to an identified or identifiable natural person who can be identified, directly or indirectly, in particular by reference to an identification number or to one or more factors specific to his physical, physiological, mental, economic, cultural or social identity (adapted from the Heads of Medicines Agencies [HMA]/EMA Guidance document on the identification of commercially confidential information and personal data within the structure of the MA application - release of information after the granting of an MA; http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/03/WC500124536.pdf page 2 [Accessed 04 April 2016]), either from the data or from the data in conjunction with other information, for example: phone numbers, names, addresses, email addresses, regional location, age, gender, race/ethnicity, other demographic, or medical information.3

Commercially confidential information (CCI): Any information that is not in the public domain or publicly available and where disclosure may undermine the legitimate economic interest of the owner of the information (adapted from EMA policy on publication of clinical data for medicinal products for human use. Policy 0070, 01 January 2015.

---

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf [Accessed 04 April 2016]). This includes, for example, unprotected intellectual property and trade secrets.

**Anonymised/de-identified data:** Data in a form that does not identify individuals and where identification through its combination with other data is not likely to take place (March 2016 EMA guidance on use of Policy 0070. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf, Chapter 1, Section 3).

- **Anonymisation:** The process of rendering data into a form which does not identify individuals and where identification is not likely to take place (March 2016 EMA guidance on use of Policy 0070. Chapter 1, Section 3). Anonymisation can be performed using techniques such as:
  - **Masking:** The removal of values for variables which allow direct or indirect identification of an individual from the data (March 2016 EMA guidance on use of Policy 0070. Chapter 3, Section 5.3.2). Note that masking can sometimes be redaction or may involve data transformation.
  - **Redaction:** The process of irreversibly blocking out sensitive information.

Other anonymisation techniques include - but are not limited to - generalisation and randomisation. For further information see the March 2016 EMA guidance on use of Policy 0070.

The processes that result in anonymised/de-identified data may be applied to datasets as well as documents.

Note: Awareness comments are included in CORE Reference (PPD in blue text and CCI in red text) to indicate ‘primary use CSR’ text portions that should be considered for PPD or CCI impact in the ‘secondary use CSR’.

**References**

CORE Reference aims to be globally acceptable. The following guidance documents were used to develop CORE Reference (Version 1.0, dated 03 May 2016).

**Regulatory Resources**

Where regulatory documents are region-specific, this is indicated:


Note that Step 4 [Final] is expected in November 2016. Awareness comments are included in CORE Reference in green bold text, pending finalisation of this ICH guidance document.


4. ICH E3 Guideline: Structure and Content of Clinical Study Reports Questions & Answers (R1), 6 July 2012


6. Final concept paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials, 22 October 2014

   Awareness comments are included in CORE Reference in green bold text, pending finalisation of this ICH guidance document.


This Regulation becomes applicable no earlier than 28 May 2016.

See items listed in Annex IV Section A: ‘content of the summary of the results of the clinical trial’. Relevant items are included in the example CSR synopsis within CORE Reference to facilitate dual use for posting via the European Union (EU) portal. These items are tagged with explanatory comments and may be omitted for non-EU studies, or if the CSR synopsis is not intended for dual use.


This is region-specific (EU).

9. Study Data Tabulation Model (SDTM) data tabulations may be provided in place of US Archival Listings, which may mean that US Archival Listings may not be required in Appendix 16.4. This can also depend on drug and therapeutic area, and requires confirmation from your regulator. See FDA resources for data standards http://www.fda.gov/ForIndustry/DataStandards/. Accessed 04 April 2016.

This is region-specific (US).


This is region-specific (EU).


See ‘32. How are initial Marketing Authorisation Applications validated at the EMA: How to avoid most common Good Clinical Practice (GCP) validation issues’. This document details additional information on Appendix 16.1.4 requirements not described elsewhere.

This is region-specific (EU).


This US-specific guidance is widely adopted in practice in multiple regions.
Other relevant regulatory guidance documents, which may be country- or region-, therapeutic area- or study design-specific, should be followed for the reporting of individual studies.

**Data Privacy**

Selected relevant data privacy references:


   These are region-specific (US).


   This is region-specific (EU).


   This is region-specific (EU).


This is country-specific (Canada).

**Commercially Confidential Information**

Selected relevant references describing and defining CCI; all are EU region-specific:


   This document states “…the EMA will refrain from disclosing commercially confidential information when it might hurt the interest or, in other words, prejudice to an unreasonable degree the commercial interests, of individuals or companies concerned.”


   This document gives guidance on what regulators will consider to be CCI in an MA application.


   This document gives guidance on what regulators will consider to be CCI and PPD in a marketing authorisation application (MAA).


Annex 3 titled ‘Information contained in the sections of the clinical reports that may be considered CCI’ - see table, column 2 (pages 19 and 20) for information that may be considered CCI in CSRs. The clinical information items listed that potentially contain CCI relate broadly to agreements relating to the protocol development between the Sponsor and regulators; exploratory objectives,
endpoints and variables (including biomarkers); information driving the sample size calculation and analytical methods of pharmacokinetic/pharmacodynamic determination.

These clinical items - summarised from the EMA guidance – are those that the authors of CORE Reference consider most relevant when writing a CSR. Refer to the guidance for full details.

Subsequently, in March 2016 the EMA released guidance on the implementation of Policy 0070. This guidance is shown below in 7.


This guidance is composed of procedural aspects, anonymisation of personal data and redaction of CCI.

Chapter 4, Section 3.2 lists ‘Information that EMA does not consider to be CCI’. See Section 3.2.3 Additional information the disclosure of which would be in the public interest – Rejection Code 03’ – page 49/91.

EMA do not consider that information in the public domain is CCI. Refer to the guidance for full details.

This effectively removes from CCI the clinical information items listed in Policy 0070 as potentially containing CCI (see point 5 above). As a result of these CCI clarifications, these clinical information items are NOT flagged in CORE Reference.

Later in 2016, EMA is expected to announce the date of a webinar on the clinical data publication policy implementation.

This is region-specific (EU). See page 88 of 91: ‘To be noted that the same CCI, PPD and publication principles will apply to EU as well as non-EU studies in the context of Policy 0070’.

Disclosure

Calls for responsible clinical trial data sharing:
1. Joint EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing. Our Commitment to Patients and Researchers. 1 January 2014


The International Committee of Medical Journal Editors (ICJME) proposal for manuscript publication requirements to help meet the obligation to responsibly share data generated by interventional clinical trials.

Current status of clinical trial data sharing:


This rule requires the registration and submission of summary results information to ClinicalTrials.gov for certain clinical trials of drugs (including biologic products) and devices. Summary results include four modules in tabular format: the numbers and flow of participants in the trial; baseline demographic and clinical characteristics of the participants according to study group; primary and secondary outcomes; and adverse events.

This is region-specific (US).


Health and Human Services Department proposes additional specificity to the FDAAA provisions and proposes further enhancements to the data for public disclosure. The public comment period ended on 23 March 2015. There is currently no timetable for amendment to the rule.

This is region-specific (US).

This guideline requires mandatory posting of clinical trial results using the European Union Drug Regulating Authorities Clinical Trials (EudraCT) database.

This is region-specific (EU).


This Policy mandates that publicly disclosed CSRs will include the following elements (identified per ICH E3 guideline numbering system):
- CSR text portion (Sections 1–15),
- Appendix 16.1.1 (protocol and protocol amendments),
- Appendix 16.1.2 (sample case report form), and
- Appendix 16.1.9 (documentation of statistical methods).

Patient data listings (Appendix 16.2) will not be disclosed.

Policy 0070 mandates that from 01 July 2015, CSRs from extension of indication and line extension applications are made publicly available, bringing them into alignment with CSRs in new MA applications, which were made publicly available from 01 January 2015.

This is region-specific (EU).


This guidance is composed of procedural aspects, anonymisation of personal data and redaction of CCI.

Chapter 2, Section 2.2 states that full redaction of narratives in the CSR for public disclosure is not allowed, and that ‘Case narratives should not be removed or redacted in full regardless of their location within the clinical reports (body of the report or listings). They should be instead anonymised. Regardless of the anonymisation technique used by the applicant/MAH, EMA cannot accept the redaction of the entire case narrative by default (as a rule). If, exceptionally, the entire case narrative needs to be redacted to ensure anonymisation, i.e. all identifiers (direct and indirect) need to be redacted, it has to be clearly justified in the anonymisation report. Likewise, patient level information referred to in the free text should not be redacted in full but instead anonymised’. 

Chapter 3: ‘External guidance on the anonymisation of clinical reports for the
PREFACE
Version 1.0
03-May-2016

purpose of publication in accordance with EMA Policy 0070’ describes PPD items as:

- Subject-level data (will not be disclosed)
- Personal data of investigators, Sponsor staff and applicant/MAH staff – page 43/91
  - Sponsor signatory of CSR will be disclosed. Contact details and signature will not be disclosed
  - Name of investigators and their sites will be disclosed. Contact details will not be disclosed.

These items - summarised from the EMA guidance – are those that the authors of CORE Reference consider most relevant when writing a CSR. Refer to the EMA guidance for full details.

Later in 2016, EMA is expected to announce the date of a webinar on the clinical data publication policy implementation.

This is region-specific (EU). See page 88 of 91: ‘To be noted that the same CCI, PPD and publication principles will apply to EU as well as non-EU studies in the context of Policy 0070’.


This is country-specific (Canada).

The data sharing requirements of the relevant region if not the US or EU, or country, should be followed.

Redaction
CORE Reference makes content suggestions for the ‘primary use CSR’. Comments are used to indicate individual CSR text portions that may potentially impact the ‘secondary use CSR’ and should therefore be considered for redaction in the ‘secondary use CSR’. See also ‘Single CSR, Two Uses, Two Audiences’.

The redaction suggestions cannot be exhaustive, as items for redaction will also be company- and study-specific.
Where possible, segregating or appending information in the ‘primary use CSR’ that may require redaction in the ‘secondary use CSR’ is advised to minimise the number of text sections that potentially require redaction. It will be easier to redact or remove an entire section or annexed/appended section from a ‘primary use CSR’ than to redact information piecemeal within the report. A specific example of this relates to narratives. ICH E3 states that narratives may be placed in E3 Section 12.3.2 or in Section 14.3.3. The authors of CORE Reference suggest that narratives are placed in Section 14.3.3 for two reasons: a) to streamline processes across regions and b) to ensure that CSR text flow is not interrupted, particularly for studies with large numbers of narratives. Note that full redaction of narratives in the ‘secondary use CSR’ for public disclosure is not allowed in the EU as clarified in the March 2016 EMA guidance on use of Policy 0070. (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf).

Given the lag between ‘primary use CSR’ finalisation and ‘secondary use CSR’ public posting, standards for redaction may have changed between the final CSR date and the date of posting. Care must be taken to ensure that the ‘secondary use CSR’ follows relevant current standards at the time it is posted.


   This paper explains general issues of public sharing of certain data combinations that might result in identification of individual subjects.


   Any data listings presented in the text of a publicly disclosed CSR should conform to current minimum standards for de-identifying data. The latest available standards are described in Opinion 05/2014. Opinion will inevitably be revised over time, and publicly disclosed data must take account of the evolving technological landscape and updated opinion on anonymisation techniques.

   This is region-specific (EU).


   De-identified protected health information is defined in this rule, with 2 alternative approaches to de-identification: Safe Harbor Method and Expert Determination Method.

   This is region-specific (US).

This document explains CCI and PPD, and removal and redaction of information, stating: ‘The protection of CCI is a matter for individual companies, and further discussions and considerations are needed on this topic. In contrast, privacy considerations are not company specific and, because the global privacy landscape is diverse, they can be region or country specific… adjustments need to be made for local national privacy laws and regulations’.

Note that in Section 5.1 of this document, full patient narratives are recommended to be removed. This is not allowed in the EU per March 2016 EMA guidance on use of Policy 0070.


This paper gives specific methods for handling sensitive data in datasets including identifiers, dates, date of birth, age, medical dictionaries and coding, free text verbatim fields, and sensitive information and low frequency events. Quality checks and process recommendations are also covered. Note that although this paper handles anonymisation for the purpose of data analysis, insights could be directly applicable to the CSR, in the case of narratives that need redaction.

CORE Reference Technical Format Supports On Screen and Print Readability

**Rationale Comment Anchoring and Positioning**

Rationale comments are anchored to single blank spaces within the text. This avoids any word, phrase or passage of text being comment-highlighted (only the blank space is highlighted), but still allows a clear anchoring of the comment, without obscuring the text shading.

Each comment is positioned following the word, or the last word of the phrase, or the last word of the passage of text in need of the comment.

Where a comment follows an entire passage of text, the start and end points of the passage may be referenced within the comment itself if this adds clarity.

**Unshaded Terms not Supported with a Rationale Comment**

In CORE Reference, ICH E3 text is shaded and CORE Reference text is unshaded.
Consistent substitution of the following (shaded) ICH E3 terms with (unshaded) CORE Reference terms means that unshaded terms appear in text.

- ICH E3 uses both 'stud[y]/[ies]' and 'trial(s)'; CORE Reference uses 'stud[y]/[ies]'
- ICH E3 uses ‘patients’; CORE Reference uses ‘subjects’.

For these substituted terms only, the unshaded terms are not further supported by a Rationale comment, to support readability.

**No Colour Shading**

To support printing of CORE Reference with even the most basic printer hardware, text shading is deliberately monochrome. Colour shading and/or highlighting is not used in the body text.

Colour coding of text is limited to the Rationale comments, in order to indicate potential CCI and PPD items, and **non-final ICH guidance**. This minimal use of colour within CORE Reference should not unduly impact readability or printing.

**Author Information**

In May 2014, at the European Medical Writers Association (EMWA) Conference in Budapest, the lead author of CORE Reference and EMWA Vice President (SH) - convened the Budapest Working Group (BWG), a group of experts from the Medical Writing community, to address current controversies and limitations in the field of reporting clinical studies, and offer potential solutions. The BWG are the authors of CORE Reference.

The BWG comprises nine authors with between 17 and 40 years of experience in the pharmaceutical industry. Seven authors are either members of EMWA, AMWA or both organisations. The two remaining authors are members of Statisticians in the Pharmaceutical Industry (PSI). All nine authors gave their time and expertise to this project, voluntarily, in the belief that an open-access user manual to support clinical study reporting would benefit today’s healthcare industry. Four authors have been (or currently are) officers of either AMWA or EMWA. Six authors have headed one or more Medical Writing departments. Six authors are regulatory medical writers who write and/or review CSRs in their professional lives, which extend to writing and/or reviewing the full range of clinical-regulatory documents contributing to the licensing of new medicines. Two authors individually contributed expertise for the entire body of work in the specialist areas of statistics and clinical pharmacology. Four authors contributed insight on transparency and public disclosure of clinical-regulatory documents, with one expert author taking overall responsibility for public disclosure considerations.


CORE Reference has no official relationship with ICH or any regulatory/competent authority.
The authors accept no liability for CSRs written using CORE Reference.

At the time of publication, all URLs are functional. Use of web browsers that may not support URL functionality is outside the control of the authors of CORE Reference.
1. **TITLE PAGE**

The title page should contain the following information:

- Study title
- Name of Test Product
- Indication studied (where available)
- If not apparent from the title, a brief (one to two sentences) description giving design (parallel, crossover, blinding, randomised), comparison (placebo, active, dose/response), duration, dose, and subject population
- Name of the Sponsor
- Protocol identification (code or number) and trial registry name(s) and number(s)
- Development phase of study
- Study initiation date (first subject enrolled, or any other verifiable definition)
- Date of early study termination, if any. In the case of studies where the Investigational Product development is terminated, indicate the date of Investigational Product termination
- Study completion date (last subject completed) or data cut-off date for long duration studies with interim reporting of data

---

**Comment [A1]**: Title Page does not need to be numbered Section 1 - see example title page below. Clinical study report (CSR) section numbering should be carefully considered from the outset to avoid possible conflict with numbering of end of text tables, figures and listings.

**Comment [A2]**: Mixed terminology use in International Council for Harmonisation (ICH) documents, e.g. study/trial, subject/patient, test drug/investigational product/investigational medicinal product, is standardised in CORE Reference, mostly to that used in the Clinical Data Interchange Standards Consortium (CDISC) Glossary. Applied Clinical Trials, December 2011: http://www.cdisc.org/system/files/all/standard_category/application/pdf/act1211_011_043_gr_glossary.pdf or an alternative authoritative source. Study, subject and Investigational Product are used in CORE Reference. ICH E3 mixed use of ‘applicant’ and ‘Sponsor’ is standardised to ‘Sponsor’ because only a fraction of CSRs eventually end up in regulatory submission dossiers. Note that substitution of the ICH E3 terms ‘trial’ and ‘patient’ with CORE Reference terms ‘study’ and ‘subject’, using unshaded CORE Reference text, are not further commented on.


**Comment [A4]**: Clarification as may not be available in some early phase studies.

**Comment [A5]**: Transparency is aided by inclusion of the registry name(s) (e.g. Clinicaltrials.gov, European Union Drug Regulating Authorities Clinical Trials [EudraCT] Database) and identifier(s) to allow linkage of the CSR to the registered protocol.

**Comment [A6]**: Data cut-off date(s) is important for pharmacovigilance. Transparency is aided by improved tracking of study data from the current study that might be included in other reports.
The name, qualifications and affiliation of Principal Investigator (PI) (for single-centre studies) or Coordinating Investigator (CI) (for multi-centre studies), or the Sponsor’s Responsible Medical Officer (SRMO).

Comment [A7]: See Preface for concept and definitions of commercially confidential information (CCI [red comments in CORE Reference]) and protected personal data (PPD [blue comments in CORE Reference]) and how these relate to the ‘secondary use CSR’ for public disclosure.

Comment [A8]: Qualifications, e.g. MD, MBBS etc. assure that individuals are suitably qualified. This is an important requirement for the ‘secondary use CSR’ for public disclosure.

Comment [A9]: Clarification on how an investigator is designated PI or CI. This depends on whether the study is single- or multi-centre.

Comment [A10]: Consider for CCI and PPD impact. Individual name(s) and affiliation(s) may be considered for CCI and PPD impact in the ‘secondary use CSR’ for public disclosure.

Note that the European Medicines Agency (EMA) does not consider PI/CI and Sponsor Signatory name as CCI and will not allow redaction in the ‘secondary use CSR’ (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 43 and page 50 of 91.

Note that the Sponsor’s Responsible Medical Officer (SRMO) and the Sponsor Signatory may not always be the same individual. If the SRMO is an externally-contracted designer, the Sponsor may have their own employee as the Sponsor Signatory.
Title page continued:

- The name of company/Sponsor signatory (the person responsible for the clinical study report [CSR] within the company/Sponsor) should appear on this page; the name, telephone number and email of the company/Sponsor contact persons for questions arising during review of the CSR should be included in Appendix 16.1.4 and must be included in the letter of application if the CSR is included in a submission dossier.

Comment [A11]: ICH E3 specifies ‘fax number’, but this is superseded by ‘email’.

Comment [A12]: Consider for CCI and PPD impact: CSR text and CSR Appendices 16.1.1, 16.1.2 and 16.1.9 will be publicly disclosed (EMA Policy 0070 effective 1 Jan 2015: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC50033796.pdf) and March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 88 of 91: “To be noted that the same CCI, PPD and publication principles will apply to EU as well as non-EU studies in the context of Policy 0070.”

Suggest to include named individuals (other than the PI/CI and Sponsor Signatory in Appendix 16.1.4) to minimise redaction need in the ‘secondary use CSR’ for public disclosure.

Comment [A13]: ICH E3 gives the option to include contact information for the ‘CSR contact’ either on the CSR title page or in the ‘letter of application’.

Comment [A14]: Consider for PPD impact: Suggest to exclude ‘CSR contact’ from the CSR title page to minimise redaction need in the ‘secondary use CSR’ for public disclosure.

Comment [A15]: To ensure that the ‘CSR contact’ remains linked with the CSR, suggest inclusion of their details in Appendix 16.1.4.
Title page continued:

- Statement indicating whether the study was performed in compliance with International Council for Harmonisation (ICH) guideline on Good Clinical Practice (GCP), including the archiving of essential documents.
- Version and date of the report: identify any earlier reports from the same study by title, version and date. Indicate that this is the ‘primary use CSR’ for regulatory submission.

An example Title Page follows:


Comment [A17]: Statement to the effect that the study was conducted according to the ethical principles that have their origin in the Declaration of Helsinki (DoH) is common. Add if appropriate. Note that Food and Drug Administration (FDA) do not support the DoH in its entirety.

Comment [A18]: Consider for CCI and PPD impact: Inclusion of report version (final version to regulatory authorities should always be ‘approved’). Omission may result in precursor (draft) reports being submitted and, eventually might end in the incorrect report version being redacted and publicly posted.

Comment [A19]: Consider for CCI and PPD impact: For the ‘secondary use CSR’ for public disclosure, indicate that this is a redacted version CSR for public disclosure.

Additional insight note: March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500070261.pdf Chapter 2, Section 3.1 for a summary of the submission process for the entire Marketing Authorisation Application (MAA) for public disclosure (of which the ‘secondary use CSR’ is a component), in the EU. Applicants are required to submit 2 packages to EMA:
- ‘Redaction Proposal Version’ package

Refer to the ‘Redaction Proposal Version’ process (page 14 of 91) and ‘Final Redacted Version’ process (page 26 of 91) packages and follow the requirements.

Brief process description: Complete the relevant template from the ‘Redaction Proposal Version’ package with a summary of CSR redacted information - one justification table is required per CSR (note this is a separate document to the CSR submitted with the ‘Redaction Proposal Version’ package and is not published). The ‘Final Redacted Version’ package includes the cover letter including “Confirmation that the clinical reports submitted for scientific evaluation are the same as that submitted for publication, in the Redaction Proposal and Final Redacted Versions, except for the redactions”. PPD anonymisation methodology is included in a separate anonymisation report which is published.


This additional insight note may be disregarded for CSRs intended for submission in regions outside the EU.
Example Title Page

CLINICAL STUDY REPORT:
FULL VERSION FOR REGULATORY SUBMISSION/
REDACTED VERSION FOR PUBLIC DISCLOSURE

STUDY TITLE

Test Product: Drug name

(If not apparent from title, include brief description of development phase, indication studied, study design and type, duration, dose, and subject population.)

Sponsor’s Responsible Medical Officer name and qualifications
Sponsor name
Sponsor address
or
Principal or Coordinating Investigator name and qualifications
Principal or Coordinating Investigator affiliation

Sponsor’s Signatory name

Protocol Number: [Trial Registry] Number(s):

Study Initiation Date: dd-Mmm-yyyy (Early Termination Date: dd-Mmm-yyyy)
(Data Cut-off Date: dd-Mmm-yyyy) (Product Termination Date: dd-Mmm-yyyy)

Study Completion Date: dd-Mmm-yyyy

Study Phase:

This study was/was not conducted in compliance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP), including the archiving of essential documents.

Report Version and Date
(Earliest reports from the same study by version and date)

<Comment [A20]: Can be prefixed with 'abbreviated' if the CSR is abbreviated.}
<Comment [A21]: Delete as applicable to the document version.
Note that CORE Reference makes content suggestions for the 'primary use CSR'. Comments within CORE Reference indicate individual CSR text portions that may potentially impact the 'secondary use CSR', which will be publicly disclosed, and should therefore be considered for modification or reduction in the 'secondary use CSR'.

<Comment [A22]: Consider for PPD and CCI impact: Individual name and qualification will not be redacted in the 'secondary use CSR' for public disclosure. The address may be redacted if it is not an address of the Sponsor.

<Comment [A23]: Consider for PPD and CCI impact: Individual name(s) and affiliation(s) may be considered for CCI impact in the 'secondary use CSR' for public disclosure. Note that EMA does not consider PI/CI name and address as CCI and will not allow redaction in the 'secondary use CSR'.

<Comment [A24]: If not the SRMO.

<Comment [A25]: Consider for PPD and CCI impact: Individual name may require redaction in the 'secondary use CSR' for public disclosure. Note that EMA does not consider Sponsor signatory name as PPD or CCI and will not allow redaction in the 'secondary use CSR'. See March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 43 of 93.

<Comment [A26]: Delete as applicable. Regulatory authority quality assurance (QA) auditors are known to question how the claim of study conduct in compliance with GCP is supported.

<Comment [A27]: Consider for CCI and PPD impact: Confidentiality statement may be added for 'primary use CSR' for regulatory submission, but not for redacted 'secondary use CSR'.

<Comment [A28]: Consider for PPD and CCI impact: Individual name(s) and affiliation(s) may be considered for CCI impact in the 'secondary use CSR' for public disclosure. Note that EMA does not consider PI/CI name and address as CCI and will not allow redaction in the 'secondary use CSR'.

<Comment [A29]: Consider for PPD and CCI impact: Individual name may require redaction in the 'secondary use CSR' for public disclosure. Note that EMA does not consider Sponsor signatory name as PPD or CCI and will not allow redaction in the 'secondary use CSR'. See March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 43 of 93.

<Comment [A30]: Delete as applicable.
2. **SYNOPSIS**

A brief *stand-alone* synopsis without cross-reference to other sections of the CSR or other documents (usually limited to three pages, although longer is acceptable for more complex studies) that summarises the study should be provided. In addition to a brief description of the study design and critical methodological information (what was actually done), the synopsis should provide a summary of all relevant results (e.g. if there are multiple endpoints, consider limiting to primary and secondary) obtained during the study, as well as other critical information, including data on the study population, disposition of subjects, important protocol deviations and treatment compliance. The synopsis should include numerical data to illustrate results, not just text or p-values (consider presenting results as summary tables to reduce the amount of text in the synopsis). The conclusions should exactly match the overall conclusions in the body of the report. *The use of a tabular format synopsis is not mandatory.*

An example Synopsis follows:**

*Comment [A28]:* Per ICH E3 2012 Questions & Answers (Q & A) Point 2 for CSR synopsis:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/Step4/Q&A_R1_Synopsis_r4.pdf which updated this ICH E3 instructional text to state:
Since the synopsis will be used as a stand-alone document within a Common Technical Document, it should be written so that it can be understood and interpreted on its own, i.e. without reference to other sections of a CSR.
Clarification is added to this effect, and to remind that ‘other’ documents should not be referenced either.

*Comment [A29]:* Per ICH E3 2012 Q & A Point 2 which updated ICH E3 instructional text to state the synopsis can be longer than 3 pages if it needs to be:
Awareness comment pending finalisation of ICH guidance: An example of ‘10 pages’ (see also [updated since 2012 Q & A] ICH M4E, R2:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_QAs_R1_Synopsis_r4 EP_3.pdf) is described as acceptable for more complex studies, with the proviso that 10 pages is not an absolute requirement or limit, but should not need to be exceeded considerably.

*Comment [A30]:* Per ICH E3 2012 Q & A Point 2:
…The synopsis should provide efficacy and safety results, as well as… To ensure no relevant results are omitted inadvertently, this requirement is captured by ‘all relevant results’.

*Comment [A31]:* Per ICH E3 Q & A Point 2:

*Comment [A32]:* Suggestion to add clarity to presentation format.

*Comment [A33]:* Annex 1 referenced in ICH E3 and described as ‘an example of a synopsis format used in Europe’ is placed in situ in CORE: Reference to ensure all relevant information is captured. The example Synopsis below includes all ICH E3 items and further enhancements with rationales for their inclusion.

*Comment [A34]:* For EU studies, also see:
Additional items are required by the Clinical Trials Regulation (CTR) EU No. 536-2014:
Annex IV Section A page 1, 158-159 – ‘content of the summary of the results of the clinical trial’. Relevant additional items are suggested for inclusion in the example CSR synopsis below to facilitate dual use for posting via the EU portal. These items are indicated with explanatory comments and may be omitted for non-EU studies, or if the CSR synopsis is not intended for dual use.

Such items are marked in the Example Synopsis below as ‘…required by CTR EU 536-2014. Omit for non-EU studies, or if no direct posting of synopsis’.
<table>
<thead>
<tr>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example Synopsis</td>
<td>Name of Sponsor/Company (and Scientific and Public Contact Points, if applicable)</td>
<td>Name of Finished Product: [may vary across regions]</td>
<td>Name of Active Ingredient:</td>
</tr>
<tr>
<td>TITLE OF STUDY (protocol number; trial registry name and number); [paediatric investigation plan (PIP) number if applicable]:</td>
<td>[Deliberate empty cell to allow comments on right hand side of this page to be shown in full]</td>
<td>PRINCIPAL/COORDINATING INVESTIGATOR NAME, NUMBER OF STUDY CENTRE(S) AND COUNTRIES: [Only count study centre(s) that entered subjects. Do not include individual centre Investigator names or addresses.]</td>
<td>[Right margin comment=RATIONALE]</td>
</tr>
<tr>
<td>PUBLICATION (REFERENCES) (if any): [Any publications – including abstracts or posters – of the study, as well as publications describing interim or post-hoc analyses]</td>
<td>STUDY PERIOD (defined as appropriate for study design); [Use same dates as on title page]</td>
<td>REPORTING PERIOD (include the date of the first and the last data collection included in this report; [include information about intermediate data analysis date, interim or final analysis stage, date of global end of the study])</td>
<td></td>
</tr>
</tbody>
</table>
**BACKGROUND AND RATIONALE FOR THE STUDY**: [in brief, e.g. 1 paragraph, including any limitations: sources of potential bias and imprecisions and caveats; include measures of protection of subjects; include standard of care therapy]

**OBJECTIVES:**

**METHODOLOGY**: [brief description of the study design and critical methodological information]

**NUMBER OF SUBJECTS (planned and analysed):** [population of subjects (including actual number of subjects included in the clinical trial in the Member State concerned, in the Union and in third countries); age group breakdown, gender breakdown]

**DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION AND EXCLUSION** [Summarise only – do not list all inclusion/exclusion criteria]:

**TEST PRODUCT, DOSE, MODE OF ADMINISTRATION, BATCH NUMBER(S):**

**DURATION OF TREATMENT:**

**CONTROL PRODUCT, DOSE, MODE OF ADMINISTRATION, BATCH NUMBER(S):**

<Deliberate empty cell to allow comments on right hand side of this page to be shown in full>

**Comment [A45]**: Background and rationale information, and all example elements are required by CTR EU 536-2014. Suggest to include all such information universally.

**Comment [A46]**: Suggested length for new section is 1 paragraph to limit overall synopsis length.

**Comment [A47]**: Required by CTR EU 536-2014. Omit for non-EU studies, or if no direct synopsis posting. Regulation uses ‘Background therapy’ (not a CDISC term and not widely understood) which is substituted with ‘standard of care therapy’ based on this definition from page L/158/7 (54) of the Regulation: ‘... auxiliary medicinal products (medicinal products used in the context of a clinical trial but not as investigational medicinal products), such as medicinal products used for background treatment, challenge agents, rescue medication, or used to assess end-points in a clinical trial. Auxiliary medicinal products should not include concomitant medications, that is medications unrelated to the clinical trial and not relevant for the design of the clinical trial’.

**Comment [A48]**: Number of subjects analysed may be considered part of the results. Present in Results ‘Subject Disposition’ if not here.

**Comment [A49]**: Required by CTR EU 536-2014. Omit for non-EU studies, or if no direct synopsis posting.

**Comment [A50]**: Suggest to mention important exclusion criteria if they help define the population better than only the summarised inclusion criteria. Delete ‘AND EXCLUSION’ as appropriate.

**Comment [A51]**: The ICH E3 term ‘reference therapy’ is standardised throughout CORE Reference to ‘Control Product’. See Preface for explanation of terms related to Investigational Product.
ENDPOINTS:

Efficacy (if applicable):
Pharmacokinetics (if applicable):
Pharmacodynamics (if applicable):
Safety (include those measures taken to protect subjects):
Other endpoints (if applicable – may include quality of life, pharmacoeconomics, pharmacogenomics etc.):

STATISTICAL METHODS: [in brief, e.g. state the statistical analysis method used to analyse each primary and secondary endpoint. Details of covariates, adjustments for multiplicity etc. are not required. State if interim analyses were conducted.]

SUMMARY OF RESULTS AND CONCLUSIONS: [May include summary tables. All objectives and endpoints stated in the methodology part of the synopsis must be addressed in the results part of the synopsis. If an endpoint was not analysed, or results were not available at the time of the report, this should be stated. Post-hoc results and conclusions may be included, but must be clearly identified as being post-hoc with appropriate rationale.]

Subject Disposition: [brief summary only (to include number of subjects analysed if not included above, data on the study population and treatment compliance), and a 1-2 line summary of any important protocol deviations that affected the study.]

Demography and Baseline Characteristics: [brief summary only.]

Efficacy Results: [Must include primary efficacy result. May include summary of other efficacy results.]

Comment [A52]: In ICH E3 there is no requirement to present endpoints in the synopsis. Suggest endpoints should be presented with clear linkage to the underlying objective – example sub-headings are given.

Inclusion of endpoints section renders ICH E3 ‘Criteria for evaluation’ (omitted) redundant with no loss of information.

Comment [A53]: Awareness comment pending finalisation of ICH guidance: Final concept paper E9(R1) Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials:
http://www.ich.org/fileadmin/Public_Web_Site/ICHTP_Products/Guidelines/Efficacy/E9/E9__R1__Final_Concept_Paper_October_23_2014.pdf states ‘(mid page 2)” In defining an appropriate ‘estimand’ for each primary and secondary endpoint, and in determining a strategy for statistical analysis to derive estimated effects…”

The definition of ‘estimand’ is on slide 8 of the 2015 ICH Presentation:

Estimands are expected to be considered at the study design stage, may be described in the protocol, and should be included in this section of the Synopsis, if available. See comment in Section 9.5 (Efficacy and Safety Variables), Terminology Table for further detail on estimand.

Comment [A54]: Suggestion to present results in table format to reduce the amount of text and add presentational clarity.

Comment [A55]: Alternative placement of ‘subjects analysed’ if not included in ‘Number of Subjects (planned and analysed)’ above.

Comment [A56]: Suggest that if important protocol deviations did affect the study, a brief explanation of the impact on results and conclusions only should be added.

Comment [A57]: The results structuring should reflect that of the endpoints presented in the Synopsis methods.
Pharmacokinetic Results (if applicable):

Pharmacodynamic Results (if applicable):

Safety Results:

Other Results (if applicable): [May include quality of life, pharmacoconomics, pharmacogenomics, post-hoc results etc. If post-hoc results are included, they must be clearly identified as being post-hoc.]

Post-hoc Results (if applicable and if not integrated into Efficacy Results or included under ‘Other Results’): [Any post-hoc results must be clearly indicated as being post-hoc.]

Conclusions: [see Section 13.2 (Conclusions)] For clinical studies replicating studies on already authorised Investigational Products and used in accordance with the terms of the marketing authorisation, summarise identified concerns in the overall results of the clinical study relating to relevant aspects of the efficacy of the Investigational Product. [Any post-hoc conclusions must be clearly identified as being post-hoc.]

DATE AND VERSION OF THIS REPORT: [Include any earlier final reports from the same study by date, as applicable.]

Comment [A58]: Post-hoc results may be integrated with Other Results or may be presented separately. Further discussion around this topic is given in Section 11.1 of CORE Reference. Regardless of where post-hoc data is presented in the Synopsis, it must be clearly identified as being post-hoc.

Comment [A59]: Suggest that the conclusions here match those in, for example, Section 13.2.

Comment [A60]: Required by CTR EU 536-2014. Omit for non-EU studies, or if no direct synopsis posting. Summary text for identified concerns should be in brief in the Synopsis, and can be supported with a more complete presentation in, for example, Section 13.

Comment [A61]: Suggest that date and version information should appear on all pages of the CSR, in addition to here. Consider for CCI and PPD impact: This is also an extra safeguard to ensure the appropriate CSR version is publicly posted.
# TABLE OF CONTENTS

The automatic table of contents should include:

- The page number or other locating information of each CSR text section, including tables and figures embedded in the text (in-text tables and figures)
- A list and the locations within the CSR of appendices, tabulations and any case report forms (CRFs) provided.

Example table of contents:

1. TITLE PAGE ..............................................................1
2. SYNOPSIS ..................................................................6
3. TABLE OF CONTENTS ...................................................11
4. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ....15
5. ETHICS .......................................................................15
   5.1 INDEPENDENT ETHICS COMMITTEE AND/OR INSTITUTIONAL REVIEW BOARD ........................................15
   5.2 ETHICAL CONDUCT OF THE STUDY ...............................15
   5.3 SUBJECT INFORMATION AND CONSENT .........................15
6. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE .................................................................16
7. INTRODUCTION ..........................................................19
8. STUDY OBJECTIVES AND ENDPOINTS ..........................20
   8.1 OBJECTIVES ..........................................................20
   8.2 ENDPOINTS ..........................................................20
9. INVESTIGATIONAL PLAN ...............................................20
   9.1 OVERALL STUDY DESIGN AND PLAN .........................21
   9.2 DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS ........................................22
   9.3 SELECTION OF STUDY POPULATION ...........................24
      9.3.1 Inclusion Criteria ...............................................24
      9.3.2 Exclusion Criteria ..............................................24
      9.3.3 Removal of Subjects from Therapy or Assessment ....24
      9.3.4 Stopping or Suspending the Study ..........................25
   9.4 TREATMENT ..........................................................25
      9.4.1 Treatments Administered ......................................25
         9.4.1.1 Investigational Product(s) .................................25
         9.4.1.2 Non-Investigational Product(s) .........................25
      9.4.2 Identity of Investigational Product(s) .......................26
      9.4.3 Avoidance of Bias ..............................................27
         9.4.3.1 Methods of Assigning Subjects to Treatment Groups ........27
         9.4.3.2 Blinding and Unblinding ..................................27
      9.4.4 Selection of Dose(s) and Timing of Dose for Each Subject ....29
      9.4.5 Treatment Compliance ..........................................29
      9.4.6 Prior and Concomitant Therapy ................................30
   9.5 EFFICACY AND SAFETY VARIABLES ..........................31
      9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments 33
         9.5.1.1 Primary Efficacy Measurement ..........................33
         9.5.1.2 Secondary Efficacy Measurements .......................33

---

Comment [A62]: Omission of the second part of the ICH E3 title which is ‘...for the individual clinical study report’, as this is considered unnecessary.
9.5.1.3 Other Efficacy Measurements ................................................. 33
9.5.1.4 Safety – Adverse Events .................................................. 33
9.5.1.5 Safety – Clinical Laboratory Evaluation ................................ 33
9.5.1.6 Safety – Vital Sign Measurements .................................... 33
9.5.1.7 Safety – Physical Examination ......................................... 33
9.5.2 Appropriateness of Measurements ........................................... 35
9.5.3 Pharmacokinetic and Pharmacodynamic Measurements .............. 36
9.5.3.1 Pharmacokinetic Measurements ....................................... 36
9.5.3.2 Pharmacokinetic Parameters ......................................... 36
9.5.3.3 Pharmacodynamic Measurements .................................... 36
9.5.3.4 Pharmacodynamic Parameters ....................................... 37
9.5.4 Other Measurements .......................................................... 37
9.6 DATA QUALITY ASSURANCE ...................................................... 37
9.7 STATISTICAL ANALYSIS METHODS PLANNED IN THE PROTOCOL AND DETERMINATION OF SAMPLE SIZE ......................................................... 38
9.7.1 Statistical Plans .................................................................... 38
9.7.1.1 General Approaches ..................................................... 39
9.7.1.2 Primary Efficacy Endpoint Methodology .............................. 39
9.7.1.3 Secondary Efficacy Endpoint Methodology .......................... 39
9.7.1.4 Other Efficacy Endpoint Methodology ............................... 39
9.7.1.5 Safety Endpoint Methodology ......................................... 39
9.7.1.6 Pharmacokinetic and Pharmacodynamic Endpoints Methodology ......................................................... 39
9.7.1.7 Other Endpoint Methodology ....................................... 39
9.7.2 Determination of Sample Size ................................................. 44
9.8 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES ............................................................................ 44
9.8.1 Changes in the Conduct of the Study ....................................... 45
9.8.2 Changes in the Planned Analyses .......................................... 45
9.8.3 Changes Following Study Unblinding and Post-hoc Analyses .......... 45
10. STUDY SUBJECTS ..................................................................... 47
10.1 DISPOSITION OF SUBJECTS .................................................. 48
10.2 PROTOCOL DEVIATIONS ...................................................... 50
10.3 DATA SETS ANALYSED ........................................................ 51
10.4 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS .... 52
10.4.1 Demography .................................................................... 53
10.4.2 Baseline Disease Characteristics ....................................... 53
10.4.3 Medical History and Concurrent Illnesses .............................. 53
10.4.4 Prior and Concomitant Treatments ..................................... 53
10.5 MEASUREMENTS OF TREATMENT COMPLIANCE .................... 53
10.6 EXTENT OF EXPOSURE .......................................................... 53
11. EFFICACY AND OTHER EVALUATIONS ..................................... 55
11.1 EFFICACY RESULTS ............................................................. 55
11.1.1 Primary Efficacy Endpoint ................................................. 57
11.1.2 Secondary Efficacy Endpoints .......................................... 57
11.1.3 Other Efficacy Endpoints ............................................... 57
11.1.4 Post-hoc Analyses ............................................................ 57
11.2 RESULTS OF STATISTICAL ISSUES ENCOUNTERED DURING THE ANALYSIS .......................................................... 57
11.2.1 Adjustments for Covariates ............................................... 58
11.2.2 Handling of Withdrawals, Discontinuations or Missing Data........ 58
11.2.3 Interim Analyses and Data Monitoring .................................................. 58
11.2.4 Multicentre Studies .............................................................................. 58
11.2.5 Multiple Comparison/Multiplicity .......................................................... 59
11.2.6 Use of an “Efficacy Subset” of Subjects .............................................. 59
11.2.7 Examination of Subgroups .................................................................. 59
11.2.8 Tabulation of Individual Response Data ............................................ 60
11.3 PHARMACOKINETIC, PHARMACODYNAMIC AND OTHER
    ANALYSES RESULTS .................................................................................. 60
11.3.1 Drug Dose, Drug Concentration and Relationships to Response .......... 61
11.3.2 Drug-Drug and Drug-Disease Interactions ........................................... 61
11.3.3 Other Endpoints ................................................................................... 62
11.4 EFFICACY RESULTS SUMMARY .............................................................. 62
12. SAFETY EVALUATION ............................................................................... 63
12.1 ADVERSE EVENTS .................................................................................... 65
12.1.1 Brief Summary of Adverse Events ....................................................... 66
12.1.2 Most Frequently Reported Adverse Events ......................................... 67
12.1.3 Categorisation of All Adverse Events .................................................. 67
12.2 ANALYSIS OF DEATHS, OTHER SERIOUS ADVERSE EVENTS, AND
    OTHER CLINICALLY MEANINGFUL ADVERSE EVENTS ...................... 68
12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse
    Events and Other Adverse Events of Special Interest ................................ 68
12.2.1.1 Deaths .............................................................................................. 69
12.2.1.2 Other Serious Adverse Events .......................................................... 69
12.2.1.3 Discontinuations Due to Adverse Events ......................................... 69
12.2.1.4 Other Adverse Events of Special Interest ....................................... 70
12.2.2 Narratives of Deaths, Other Serious Adverse Events, and Certain Other
    Clinically Meaningful Adverse Events ....................................................... 70
12.3 CLINICAL LABORATORY EVALUATION .................................................. 73
12.3.1 Individual Laboratory Measurements by Subject and Abnormal
    Laboratory Values ....................................................................................... 73
12.3.2 Evaluation of Laboratory Values ....................................................... 73
12.3.2.1 Laboratory Values Over Time ......................................................... 74
12.3.2.2 Individual Subject Changes in Laboratory Values ............................ 74
12.3.2.3 Individual Clinically Meaningful Laboratory Abnormalities ................ 75
12.4 VITAL SIGNS, PHYSICAL EXAMINATIONS, AND OTHER
    OBSERVATIONS RELATED TO SAFETY ................................................. 76
12.4.1 Vital Signs ........................................................................................... 76
12.4.2 Physical Examination Findings ............................................................. 76
12.4.3 Other Observations Related to Safety .................................................. 76
12.5 SAFETY RESULTS SUMMARY ................................................................. 77
13. DISCUSSION AND OVERALL CONCLUSIONS ..................................... 77
13.1 DISCUSSION ............................................................................................ 77
13.2 CONCLUSIONS ....................................................................................... 79
14. TABLES AND FIGURES .......................................................................... 80
14.1 DEMOGRAPHIC DATA ............................................................................ 80
14.2 EFFICACY DATA ..................................................................................... 80
14.3 SAFETY DATA ......................................................................................... 80
14.3.1 Displays of Adverse Events ................................................................. 80
14.3.2 Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events
    .................................................................................................................. 80
14.3.3 Narratives of Deaths, Other Serious Adverse Events and Certain Other Clinically Meaningful Adverse Events ........................................81
14.3.4 Data Listings (Each Subject) for Abnormal Clinically Meaningful Laboratory Values, Vital Signs, Physical Examinations and Other Observations Related to Safety .......................................................... 82

14.4 OTHER DATA ........................................................................................................ 82

15. REFERENCE LIST .................................................................................................. 83

16. APPENDICES ......................................................................................................... 83

16.1 STUDY INFORMATION .........................................................................................

16.2 SUBJECT DATA LISTINGS ..................................................................................

16.3 CASE REPORT FORMS .........................................................................................

16.4 INDIVIDUAL SUBJECT DATA LISTINGS .........................................................

<table>
<thead>
<tr>
<th>LIST OF IN-TEXT TABLES AND FIGURES</th>
</tr>
</thead>
</table>

**TABLES**

Example Table 9.1 Schedule of Study Events and Assessments in Protocol xxx ..........35
Example Table 10.1 Exclusions From Analysis Sets in Protocol xxx .......................52

**FIGURES**

Example Figure 10.1 Disposition of Subjects in Protocol xxx .................................49

Comment [A63]: ICH E3 requires ‘… a list and the locations within the study report of appendices, tabulations and any case report forms provided’.

The CSR text comprises a Synopsis and the main body text. The tables, figures, listings (TFLs) and appendices including selected CRFs - are often held separately in electronic folders at the time the CSR is finalised. Many years may elapse between finalisation of a CSR and subsequent inclusion of CSR text and appendices in a submission dossier.

The page locations of appendices, TFLs and CRFs may therefore be better defined later in the process. The CSR table of contents (ToC) may therefore only list these items without a page by page specification of their locations at the ‘final CSR’ stage of the documentary process.

Comment [A64]: Searchable datasets may be submitted in some regions (e.g. US), removing the need for content in Appendix 16.4. Appendix 16.4 may still be used in other regions, so this appendix is left in situ.
### 4. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

A list of the abbreviations, and lists and definitions of specialised or unusual terms or unusual measurements units used more than once in the once in the main CSR should be provided. On first mention (in both the synopsis and again in the main CSR text), abbreviated terms should be spelled out and the abbreviation indicated in parentheses. Common abbreviations (e.g. UK, USA) need not be defined. In the case where an abbreviation is the same for two different terms, e.g. American Diabetes Association (ADA) and Antidiabetic Agents (ADAs), one of the two terms should be written out in full in all instances to avoid any confusion.

Example:

<table>
<thead>
<tr>
<th>ABBREVIATIONS</th>
<th>DEFINITIONS OF TERMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>QT interval</td>
<td>The portion of an electrocardiogram between the onset of the Q wave and the end of the T wave.</td>
</tr>
</tbody>
</table>

### 5. ETHICS

#### 5.1 INDEPENDENT ETHICS COMMITTEE AND/OR INSTITUTIONAL REVIEW BOARD

It should be confirmed that the protocol and any of its amendments, as well as information provided to subjects and any recruitment advertisements etc., were reviewed by an Independent Ethics Committee (IEC) and/or Institutional Review Board (IRB), or any other Ethics Committee (EC). A list of all IECs, IRBs, or ECs consulted should be given in Appendix 16.1.3 and, if required by the regulatory authority, the name of the committee Chair should be provided.

#### 5.2 ETHICAL CONDUCT OF THE STUDY

It should be confirmed that the study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki (version as specified in the study protocol or if not specified, include the version here) and in accordance with ICH GCP.

#### 5.3 SUBJECT INFORMATION AND CONSENT

How and when informed consent was obtained in relation to subject enrolment (e.g. at allocation, pre-screening) should be described. Representative written information for the subject (information sheet [PIS]) and a sample informed consent form (ICF), designated as the master versions, must be provided in the trial master file (TMF).
6. **INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE**

The administrative structure of the study (e.g. Principal Investigator, Coordinating Investigator(s), steering committee, administration, monitoring and evaluation committees, institutions, statistician, central laboratory facilities, contract research organisation [CRO], clinical study supply management) should be described briefly in the body of the report, without mention of individual names or contact details (with some exceptions such as the name of the PI [for single-centre studies] or CI [for multi-centre studies]). Indicate the location of the trial master file (TMF).

In Appendix 16.1.4, provide a list of the investigators, abbreviated for studies with many centres to only the PIs of each centre and a list of other persons whose participation materially affected the conduct of the study, each with general statements of qualifications for persons carrying out particular roles in the study, with only the name, degree, institutional affiliation and roles in the study. The listing should include:

*Comment [A78]: Consider for PPD impact:*
In the EU, see March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_ library/Regulatory_and_procedural_guideline/2016/ 03/WC500202621.pdf) Chapter 3, Section 6 (Redaction of personal data of investigators, sponsor staff and applicant/marketing authorisation holder [MAH] staff) states: 'Personal data of individuals other than patients, i.e. investigators, sponsor staff and applicant/MAH staff will not be published with the following exceptions: The sponsor and CI signatories of the CSR and the identities of the investigator(s) who conducted the trial and their sites. However, their contact details and signature should be redacted. Personal data relating to all other clinical study personnel should also be redacted. Data pertaining to the above exceptions in other parts of the CSR will be redacted as they may give away geographical information (e.g. site number, site address, investigator names) that could be linked to patients and hence may enable their identification'. The ‘take-home message’ is that only the names of the PI, CI and Sponsor signatory should be disclosed in the ‘secondary use CSR’ for public disclosure.

*Comment [A79]: Consider for PPD and CCI impact:*
Individual name(s) and affiliation(s) may be considered for CCI impact in the ‘secondary use CSR’ for public disclosure.

Note that EMA does not consider PI/CI name and address as CCI and will not allow redaction in the ‘secondary use CSR’ (http://www.ema.europa.eu/docs/en_GB/document_ library/Regulatory_and_procedural_guideline/2016/ 03/WC500202621.pdf) page 50 of 91.


*Comment [A81]: Slight rewording of ICH E3 text with no loss of meaning.*

*Comment [A82]: Suggest to restrict Investigator list for studies with many investigators, in the spirit of ICH E3 Q & A. All investigator names and their curricula vitae (CVs) will in any case be in the TMF.*

*Comment [A83]: Amalgamation of Investigator and ‘other person’ requirements into a consolidated statement with improved readability.*

*Comment [A84]: The requirement for CVs in Appendix 16.1.4 has been removed as per the ICH E3 2012 Q & A which states that CVs can be included in the TMF only.*
a) Principal Investigators

b) Any other person carrying out observations of primary or other major efficacy variables, such as a nurse, physician's assistant, clinical psychologist, clinical pharmacist or house staff physician. It is not necessary to include in this list a person with only an occasional role, e.g. an on-call physician who dealt with a possible adverse event (AE) or a temporary substitute for any of the above.

c) The author(s) of the report, including the responsible biostatistician(s).

Where signatures of the principal signatory investigators (PI or CI) are required by regulatory authorities, these should be included in Appendix 16.1.5 (see Annex I for an example signature form). Where these are not required, the signature of the Sponsor's responsible medical officer should be provided in Appendix 16.1.5.

Comment [A85]: For studies with many centres, the possible list of all Investigators will be extensive. All Investigator details will be in the TMF in any case, so in the spirit of the ICH E3 2012 Q & A, suggest there is no need to duplicate in the CSR.

Comment [A86]: Consider for PPD impact:
In the EU, see March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf). Persons under b) and c) will be listed only in (non-disclosed) Appendix 16.1.4 so there is no impact in the 'secondary use CSR' for public disclosure.

Comment [A87]: ICH E3 Annex II is CORE Reference Annex I.

Example administrative structure for inclusion in the CSR text, with roles and responsibilities:

PRINCIPAL INVESTIGATOR (for single-centre studies): [Name] and country in which the PI is based only; refer to Appendix 16.1.4 for details.

COORDINATING INVESTIGATOR (for multi-centre studies): [Name] and country in which the CI is based only; refer to Appendix 16.1.4 for details – delete if not applicable.

DATA MONITORING AND EVALUATION COMMITTEE(S): [Mention if used and refer to protocol, and amendments, in Appendix 16.1.1 for details – delete if not applicable].

CLINICAL LABORATORIES: [Mention if a central laboratory was used and include institution name(s) and address(es) only; refer to Appendix 16.1.1/16.1.4/16.1.10 for details].

CONTRACT RESEARCH ORGANISATIONS (CROs): [Mention if used; link CROs to study activities and include report authoring and biostatistics; include institution name(s) and address(es) only; refer to Appendix 16.1.1/16.1.4 for details].

OTHER ORGANISATIONS: [Mention if used and include institution name(s) and address(es) only; and refer to Appendix 16.1.1/16.1.4 for details, as applicable].

<Deliberate white space to allow comments on right hand side of next page to be shown in full>
7. **INTRODUCTION**

The Introduction should contain a brief statement (1 to 3 pages) placing the study in the context of the development of the Investigational Product, relating the critical features of the study to that development. Include a brief statement on the drug being studied. Include the medical rationale for the development of the study (avoiding commercially confidential information [CCI] not specifically needed to explain the medical need) and including brief text on current treatments, i.e. available at the time of protocol design.

Any guidelines that were followed in the development of the protocol or any other agreements/meetings between the Sponsor and regulatory authorities that are relevant to the particular study, should be identified or described. Especially for studies with multiple consecutive analyses and reports, the introduction should contain a clear statement on which cut-off date(s) is(are) used for the analyses reported (e.g. date of database release). If the study is terminated before its planned end, this should be noted and explained.

---

Comment [A93]: ICH E3 gives a maximum of 1 page. Suggest a reasonable maximum is 3 pages, given the additional CORE Reference suggested information for inclusion.


Comment [A95]: ICH E3 also lists: ‘aims, target population, treatment, duration, primary endpoints’. All this information is included in the sections that follow and is repetitive, so it is suggested that this can be omitted from the Introduction.

Comment [A96]: Consider for CCI impact. Possible sensitive company information (i.e. CCI) could be revealed in the ‘secondary use CSR’ for public disclosure, so care taken to avoid this in the Introduction of the CSR for regulatory submission will remove the need for piecemeal redaction in the ‘secondary use CSR’ for public disclosure.

Comment [A97]: Transparency is aided by explaining currently available treatments.

Comment [A98]: Any such agreements/meetings should also be cross-referred to in, for example, Section 9.5.1 (Efficacy and Safety Measurements Assessed and Schedule of Assessments), or to any other relevant section, as appropriate.

Comment [A99]: Cut-off dates and early termination dates, if applicable, are also recommended for placement in, for example, Section 9.6 Data Quality Assurance.
8. STUDY OBJECTIVES AND ENDPOINTS

8.1 OBJECTIVES

A statement describing the overall purpose(s) of the study should be provided. The objectives should be per protocol (and any global amendments), with only minor adjustments for tense and grammar permitted.

8.2 ENDPOINTS

Endpoints should be per protocol (and include any global amendments), with only minor adjustments for tense and grammar permitted.

9. INVESTIGATIONAL PLAN

The investigational plan description must be based on the protocol and all of its amendments. It should reflect the situation after implementation of the last amendment. It is particularly important to clarify features that are not well described in the protocol or its amendments. Throughout, it should be made clear which key procedures or analyses had been planned in the original protocol and which had been introduced via subsequent protocol amendments.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A100]: Brief, bullet-point objectives, divided into primary, secondary and exploratory objectives and with a primary, secondary and exploratory hierarchy to match those of endpoints and variables – are typically expected in the protocol. The key CORE Reference message is that the CSR sections should match each other starting with the objectives which drive the endpoints, which in turn inform the content of, for example, Section 9.5.

Comment [A101]: Awareness comment pending finalisation of ICH guidance: Final concept paper E9(R1) Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials: http://www.ich.org/fileadmin/Public_Website/ICH_Products/Guidelines/Efficacy/E9/E9__R1_Final_Concept_Paper_October_23_2014.pdf states ‘(mid page 2) “In defining an appropriate ‘estimand’ for each primary and secondary endpoint, and in determining a strategy for statistical analysis to derive estimated effects…” The definition of ‘estimand’ is on slide 8 of the 2015 ICH Presentation: https://www.efspi.org/Documents/Leaders%20Meetings/6th/8.%20Chrissie%20Fletcher%20EFSPI%20Statistics%20Leaders%202015%20Estimands.pdf. Estimands are expected to be considered at the study design stage, may be described in the protocol, and should be included in this section, if available. See comment in Section 9.5 (Efficacy and Safety Variables), Terminology Table for further detail on estimand.

Comment [A102]: In ICH E3 there is no requirement to present endpoints in the CSR. Suggest endpoints should be presented and clear linkage should be made to the underlying objective.

Comment [A103]: See, for example, Section 9.8 (Changes in the Conduct of the Study or Planned Analyses).
9.1 OVERALL STUDY DESIGN AND PLAN

The overall study plan and design (configuration) of the study (e.g. parallel, crossover) should be described briefly but clearly. Include a schematic of the study design (see Example Figure 9.1) in most cases, even if not provided in the protocol. The schematic should be presented early in the ‘Overall study design and plan’. If other studies used a very similar protocol, it may be useful to note this and describe any important differences.

The actual protocol and any changes should be included as Appendix 16.1.1 and a sample CRF (unique pages only; i.e. it is not necessary to include identical pages from forms for different evaluations or visits) as Appendix 16.1.2: see (Section 16 Appendices). If any of the information in this section comes from sources other than the protocol, these should be identified.

Brief summary information should be provided (limited to one or two pages) as follows:

- Treatments studied (specific drugs, doses and procedures)
- Subject population studied and the number of subjects to be included in each treatment group and overall
- Level and method of blinding/masking (e.g. open, double-blind, single-blind, blinded evaluators and unblinded subjects and/or Investigators)
- Kind of control(s) (e.g. placebo, no treatment, active drug, dose-response, historical) and study configuration (parallel, crossover)
- Method of assignment to treatment (randomisation, stratification)
- Sequence and duration of all study periods, including pre-randomisation and post-treatment periods, treatment withdrawal periods and single- and double-blind treatment periods. When subjects are randomised should be specified. It is usually helpful to display the design with a schematic (see Example Figure 9.1)
- Any safety, data monitoring or special steering or evaluation committee(s)
- Any interim analyses, including data cut-off dates
- If the study is terminated (before its planned end), this should be noted.

An accounting of tests performed by visit is not required.

(Illustration: Deliberate white space to allow comments on right hand side of this page to be shown in full)
Example Figure 9.1. Schematic of Study Design for Protocol xxx

<table>
<thead>
<tr>
<th>Study Period I</th>
<th>Study Period II</th>
<th>Study Period III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>Treatment</td>
<td>Follow-up</td>
</tr>
<tr>
<td></td>
<td>Test Product and Dose per Day</td>
<td></td>
</tr>
<tr>
<td>All Subjects</td>
<td>Control Product (active comparator) and Dose per Day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control Product (placebo)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Time</td>
<td>Time</td>
</tr>
</tbody>
</table>

Visit | Visit | Visit | Visit |

Randomisation

Figure footnote, if needed

9.2 DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS

The specific control chosen and the study design used should be discussed, as necessary, including details of statistical support for those choices. Examples of design issues requiring discussion follow.

Generally, the control (comparison) groups that are recognised are placebo concurrent control, no treatment concurrent control, or active comparator concurrent control, dose comparison concurrent control, and historical control. The rationale for the choice of Control Product should be provided (e.g. if the Control Product was placebo, explain why an active comparator was not used). If an active comparator was used, state whether the dose was the standard recommended dose. If not, it is important to explain why. For a historically controlled study, it is important to explain how the particular control was selected, what other historical experiences were examined, if any, and how their results compared to the control used. In addition to the type of control, other critical design features that may need discussion are use of a crossover design and selection of subjects with particular prior history, such as response or non-response to a specific drug or member of a drug class. If randomisation was not used, it is important to explain how other techniques, if any, guarded against systematic selection bias.

Comment [A114]: Suggest to include protocol number in figure title to aid regulatory reviewers who often copy and paste key CSR information into their own summary documents.

Similarly, this is suggested for all in-text tables and figures (see later in CORE Reference).


Estimands are expected to be considered at the study design stage, may be described in the protocol, and relevant text could be placed in this section, if not in Section 8, and if available.

Note that Health Canada, refer specifically to the E9 Addendum, and advise that the estimand, how it was derived/decided and rationales/reasoning behind it, need to be explained well in the CSR.

Comment [A116]: Suggest to include brief early phase summary data to support later phase study design if it is helpful for study design justification.

Comment [A117]: ICH E3 uses ‘active treatment’ which is replaced with ‘active comparator’ throughout CORE Reference. See Preface for explanation of ‘Investigational product’ terminology choices.

Comment [A118]: ICH E3 text (single sentence) relocated here from Section 9.4.3 Method of assigning patients to treatment groups.
Known or potential problems associated with the study design or control group chosen should be discussed in light of the specific disease and therapies being studied. For a crossover design, for example, there should be consideration, among other things, of the likelihood of spontaneous change in the disease and of carry-over effects of treatment during the study.

If efficacy was to be demonstrated by showing equivalence, i.e. the absence of a specified degree of inferiority of the new treatment compared to an established treatment, problems associated with such study designs should be addressed. Specifically, a basis for considering the study capable of distinguishing active from inactive treatment should be provided. Support may be provided by an analysis of previous studies similar to the present study with respect to important design characteristics (subject selection, study endpoints, duration, dose of active comparator, concomitant therapy, etc.) showing a consistent ability to demonstrate superiority of the active comparator to placebo. How to assess the ability of the present study to distinguish effective from ineffective therapy should also be discussed. For example, it may be possible to identify a treatment response (based on past studies) that would clearly distinguish between the treated population and an untreated group. Such a response could be the change of a measure from baseline or some other specified outcome like healing rate or survival rate. Attainment of such a response would support the expectation that the study could have distinguished the active drug from an inactive drug. There should also be a discussion of the degree of inferiority of the therapy (often referred to as the delta value), namely that the degree of inferiority of the therapy that the study was intended to show was not exceeded. If Number Needed To Treat has been used to measure treatment effect in preference to measures such as relative risk or odds ratio then justification for that decision should be included.

The limitations of historical controls are well known (difficulty of assuring comparability of treated groups, inability to blind Investigators to treatment, change in therapy/disease, difference due to placebo effect, etc.) and deserve particular attention.

Other specific features of the design may also deserve discussion, including an adaptive study design, presence or absence of washout periods and the duration of the treatment period, especially for a chronic illness.

The rationale for dose and the basis for selecting each subject’s dose or dose ranges should be explained, if it is not obvious (e.g. Test Product animal data, prior experience with Test Product in humans). The procedures for selecting each subject’s dose or dose ranges (Test Product or active comparator) should be described. These procedures can vary from simple random assignment to a selected fixed drug/dose regimen, to some specified titration procedure, to more elaborate response-determined selection procedures, e.g. where dose is titrated upward at intervals until intolerance or some specified endpoint is achieved. Procedures for back-titration, if any, should also be described. The procedures used to seek evidence of “escape” from drug effect at the end of the dose interval, such as measurements of effect just prior to dosing, should be described. Similarly, in a parallel design dose-response study, the choice of doses should be explained.

ICH E3 text | ICH E3 2012 Q&A text | CORE Reference text

[Right margin comment=RATIONALE]
The choice of any non-Investigational Product therapy should be justified, and the therapeutic regimen described.

### 9.3 SELECTION OF STUDY POPULATION

#### 9.3.1 Inclusion Criteria

The subject population and the selection criteria used to enter the subjects into the study should be described. The inclusion criteria should be taken from the protocol, including any numbering, with only minor adjustments for tense and grammar permitted.

Screening criteria and any additional criteria for randomisation or entry into the Investigational Product treatment part of the study should be described. If there is reason to believe that there were additional entry criteria not defined in the protocol, the implications of these should be discussed. For example, some Investigators may have excluded, or entered into other studies, subjects who were particularly ill or who had particular baseline characteristics.

#### 9.3.2 Exclusion Criteria

The criteria for exclusion at entry into the study should be specified and the rationale (e.g. safety concerns, administrative reasons or lack of suitability for the study) provided. The exclusion criteria should be taken from the protocol. The impact of exclusions on the generalisability of the study should be included in the discussion (see for example, Section 13 Discussion and Overall Conclusions).

#### 9.3.3 Removal of Subjects from Therapy or Assessment

The predetermined reasons for removing subjects from therapy or assessment observation, if any, should be described, as per protocol, as should the nature and duration of any planned follow-up observations in those subjects. In some studies (e.g. cancer studies) subjects can be withdrawn from treatment (e.g. due to disease progression) but they remain in the study so they can be followed for long-term outcome. In such cases particularly, and in all studies generally, a clear distinction should be made between discontinuations (i.e. stop treatment), where the subject remains in the study and completes some or all of the protocol-defined procedures, and withdrawals (i.e. stop treatment and stop all protocol-defined procedures) from the study, where no further information is collected on the subject.

Deliberate white space to allow comments on right hand side of this page to be shown in full.

---

Comment [A129]: The following ICH E3 text has been omitted "...and the suitability of the population for the purposes of the study should be discussed. In practice, this is often addressed in submission summary documents and is misplaced here."

Comment [A130]: The following ICH E3 text has been omitted 'Specific diagnostic criteria used, as well as specific disease requirements (e.g. disease of a particular severity or duration, results of a particular test or rating scale(s) or physical examination, particular features of clinical history, such as failure or success on prior therapy, or other potential prognostic factors and any age, sex or ethnic factors) should be presented' as this level of detail should be addressed within the protocol.

Comment [A131]: ICH E3 text "...Investigational Product' is substituted with CORE Reference term 'Investigational Product'.

Comment [A132]: The protocol may or may not group the exclusion criteria as reporting requires; see the ICH E3 parenthetic text. Grouping should be considered at reporting.

Comment [A133]: The ICH E3 reference to discussing impact of exclusions on generalisability in an overview of safety and efficacy is omitted as this is considered to be misplaced. The "impact of exclusions" sentence is replicated in Section 13 to avoid inadvertent omission.

ICH E3 phraseology ‘should be included in Section 13 of the study report’ is reworded (to remove misplaced inference of ICH E3 being a template) as ‘...should be included in the discussion’. The reworded text is shaded as ICH E3 text because the meaning is not different.

Comment [A134]: Further clarification is provided on differences between removal from treatment and removal from the study.

Comment [A135]: Post-withdrawal contact with a subject may be protocol-defined.
9.3.4 Stopping or Suspending the Study

Protocol-defined circumstances under which the study would be stopped or suspended should be taken from the protocol with only minor adjustments for tense and grammar permitted.

9.4 TREATMENT

9.4.1 Treatments Administered

The precise treatments or diagnostic agents to be administered in each arm of the study, and for each period of the study, should be described, as per protocol, including route and mode of administration, dose and dosage schedule.

Where the Investigational Product is an add-on treatment to the current standard of care (which may be variable) then the standard of care should be described within the “Treatments Administered” section, but should be clearly distinguished from Investigational Product. These and other non-Investigational Product treatments (such as concomitant therapy, rescue medication, challenge agents etc.) administered should also be described and be clearly distinguished from Investigational Product.

Example subheadings may include:

9.4.1.1 Investigational Product(s)
9.4.1.2 Non-Investigational Product(s)

Treatment options available to subjects post-study (either on completion of study, or after premature withdrawal/termination) should be described.

Comment [A136]: If the study is terminated before its planned end, this should be reflected, for example, in Section 7 (Introduction) and Section 9.1 (Overall Study Design and Plan).

Comment [A137]: Clarification to encourage inclusion of study termination criteria which are not mentioned in ICH E3, but are expected to be included in the protocol.

Comment [A138]: Awareness comment pending finalisation of ICH guidance: Final concept paper E9(R1) Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/E9__R1__Final_Concept_Paper_October_23_2014.pdf states “A clear definition of an estimand is important…since the choice of estimand is linked to important considerations around trial design, conduct and analysis. These include, for example, duration of patient follow-up, adherence to randomised treatment, use of alternative medications after discontinuation of randomised treatment and methods to handle missing data in the statistical analysis.” Such design aspects are expected to be considered at the study design stage, may be described in the protocol, and should be considered for inclusion in this section if relevant to individual study design and if available.

Comment [A139]: See Annex 1 of European Commission guidance on IMPs and NIMPs, 18 March 2011: http://ec.europa.eu/health/files/eudralex/vol-10/imp_03-2011.pdf for examples of non-Investigational Products. These are summarised and clarified as:

- Protocol required underlying therapy
  - Standard of care therapy (protocol required to treat the indication).
  - Concomitant therapy (protocol required for a condition which is not the indication for which the IP is being tested).
- Rescue medication
- Challenge agent
- Medicinal product used to assess endpoints (e.g. PET ligand).
9.4.2 Identity of Investigational Product(s)

In the text of the report, a brief description of the Investigational Product(s) (formulation, strength, batch number(s) (list only without per-subject linkage), source [company name and country of source]) should be given. If the batch number list is extensive, it may be placed in Appendix 16.1.6.

The source (company name and country of source) of placebos and active comparator(s) should be provided. Any modification of active comparator(s) from their usual commercial state should be noted and the steps taken to assure that their bioavailability was unaltered should be described.

For long-duration studies of Investigational Products with limited shelf-lives or incomplete stability data, the logistics of resupply of the materials should be described. Any use of Investigational Product, or any study supplies past their expiry date should be noted and subjects receiving them identified. If there were specific transportation and storage requirements, these should also be described.

Comment [A140]: ICH E3 text 'test/drug/investigational product(s)' is substituted with CORE Reference term 'Investigational Product(s)'.

Comment [A141]: Per ICH E3 2012 Q & A Point 3, replace per subject batch number listing in Appendix 16.1.6 with a simple list of Investigational Product batch numbers (without subject linkage). Although the parenthetic text does not appear verbatim in the ICH E3 2012 Q & A, it is shaded as ICH E3 2012 Q & A text because the text in ICH E3 2015 Q & A reads: 'Supportive documents, such as batch numbers per subject, are in the TMF or clinical supply database and should generally not be included in the CSR appendices.'

Comment [A142]: As Investigational Product is defined as Test Product and Control Product (including active comparator and placebo), all such batch numbers should be listed (without per subject linkage).

Comment [A143]: Consider for CCI impact: Source information detail should be carefully considered with regard for CCI in the ‘primary use CSR’ for regulatory review to minimise piecemeal redaction in the ‘secondary use CSR’ for public disclosure.


Site of manufacture and site of release in Europe (of Investigational Product) is required. This may be omitted for non-EU studies.

Comment [A144]: ICH E3 uses the wording ‘active control/comparator product(s)’ This is clarified as ‘active comparator(s)’ here and throughout.

Comment [A145]: ICH E3 term ‘test materials’ is further clarified.

Comment [A146]: Clarification added to ensure use of any out of date product is not overlooked.
9.4.3 Avoidance of Bias

9.4.3.1 Methods of Assigning Subjects to Treatment Groups

Typical methods for avoidance of selection bias include, but are not limited to, randomisation.

The specific methods used to generate random numbers, assign subjects to treatment groups, e.g. centralised allocation, allocation within sites, adaptive allocation (that is, assignment on the basis of earlier assignment or outcome) should be described, as per protocol. The protocol should also describe any stratification factors necessary and whether blocking procedures should be used. If necessary, any references should be cited.

The process for implementing the randomisation schedule (e.g. interactive voice response system) should be specified. The CSR text should include the information given in the protocol along with any further information on the randomisation method available following study unblinding (e.g. use of mixed block sizes). Any unusual features of the randomisation method should be explained.

A table exhibiting each subject identifier, their randomisation code and treatment assigned should be presented in Appendix 16.1.7. For a multicentre study, the information should be given by centre. If stratification factors were used in the randomisation schedule, the table should include which level of each stratification factor(s) each subject was assigned to.

9.4.3.2 Blinding and Unblinding

A description of the specific procedures used to carry out blinding should be provided (e.g. how bottles were labelled, labels that reveal blind-breakage, sealed code list/envelopes, double-dummy techniques), including the circumstances in which the blind would be broken for an individual or for all subjects, e.g. for serious AEs (SAEs), the procedures used and who had access to subject codes. If the study allowed for some investigators to remain unblinded (e.g. to allow them to adjust medication), the means of shielding other investigators should be explained. Measures taken to ensure that Test Product and Control Product (which may include active comparator(s) and placebo) were indistinguishable and evidence that they were indistinguishable, should be described, as should the appearance, shape, smell, and taste of the test material. Measures to prevent unblinding by laboratory measurements, e.g. by centralised reading, if used, should be described.

"Deliberate white space to allow comments on right hand side of this page to be shown in full"
If there was a data monitoring committee (DMC) and/or an adjudication or evaluation committee, either within or outside the Sponsor’s control, with access to unblinded data, procedures to ensure maintenance of overall study blinding should be described. The procedure to maintain the blinding when interim analyses are performed should also be explained. DMC (or other committee) composition and operating procedures should be briefly described, and planned DMC (or other committee) monitoring of the results of the study should be described. If the committee charter and meeting minutes are to be included in the CSR, these should be included in an optional appendix, e.g. Appendix 16.1.13.

Where appropriate, blinding should be maintained.

Interpretation or observer bias may be introduced if both the Investigator and the subject are not blinded to the treatment being administered and received, respectively. Bias can be introduced if Investigators need to use any form of subjective assessment to obtain a result (such as assessment of a level of severity of an AE) or if the subject is volunteering information (responses to a Quality of Life questionnaire for example). If the study was not blinded then it must be explained why it was felt that the risk of bias was reduced, e.g. use of a random-zero sphygmomanometer eliminates possible observer bias in reading blood pressure, and Holter tapes are often read by automated systems that are presumably immune to observer bias. If blinding was considered desirable but not feasible, the reasons and implications should be discussed. Sometimes blinding is attempted but is known to be imperfect because of obvious drug effects in at least some subjects (e.g. dry mouth, bradycardia, fever, injection site reactions, changes in laboratory data). Such problems or potential problems should be identified and if there were any attempts to assess the magnitude of the problem or manage it (e.g. by having some endpoint measurements carried out by people shielded from information that might reveal treatment assignment), they should be described. In these situations, if Investigational Product cannot be blinded, the blinding of other groups such as data management, statistics and medical writing should have been documented in the clinical study protocol so that decisions could be taken in a blinded manner, reducing the risk of interpretation bias.

For procedures for unblinding in the event of safety need, refer to the protocol (in Appendix 16.1.1).]

NOTE: Masking, while often used synonymously with blinding, usually denotes concealing the specific study intervention used and is often preferred to use of the term ‘blinding’ in the field of ophthalmology (CDISC definition).

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A155]: ICH E3 text from Section 9.7.1 (Statistical and analytical plans) on the DMC is relocated and integrated more appropriately here (as it is not a statistical method). The ICH E3 text is ‘Planned monitoring of the results of the study should be described. If there was a data monitoring committee, either within or outside the sponsor’s control, its composition and operating procedures should be described and procedures to maintain study blinding should be given.’

Comment [A156]: Consider for PPD impact: Data that might identify subjects and names of DMC members are often included in the minutes and charter and since these must not be publicly disclosed, suggest placing them in an optional appendix which will not be publicly disclosed in the ‘Secondary use CSR’.

Comment [A157]: For clarity, the preceding clause substitutes the omitted ICH E3 text which reads: ‘If blinding was considered unnecessary to reduce bias for some or all of the observations, this should be explained.’

Comment [A159]: Suggest procedures for unblinding should accompany the blinding procedures, hence included here.
9.4.4 Selection of Dose(s) and Timing of Dose for Each Subject

The procedures for selecting each subject’s dose or dose ranges of Investigational Product should be described. The timing (time of day, interval) of dosing and the relation of dosing to meals should be described, and if it was not specified, this should be noted. Any specific instructions to subjects about when or how to take the dose(s) should be described, including those in relation to ingestion of food, posture and the possible effects of concomitant medication/alcohol/caffeine/nicotine.

9.4.5 Treatment Compliance

The measures taken to ensure and document Investigational Product compliance should be described, as per protocol, e.g. drug accountability, diary cards, electronic diaries, electronic Patient-Reported Outcomes (PROs), blood, urine or other body fluid drug level measurements, or medication event monitoring, etc. If drug levels in body fluids have been used to determine compliance, the measurements and methodology used should be described.

Comment [A159]: ICH E3 Section 9.4.4 (Selection of Doses in the Study) often overlaps with ICH E3 Section 9.4.5 (Selection and Timing of Doses for Each Patient). Recommend merging the content of the two and adapting the title, appropriately, e.g. Selection of Dose(s) and Timing of Dose for Each Subject.

Comment [A160]: The following is relocated from ICH E3 Section 9.4.4 (Selection of Doses in the Study) and integrated more appropriately with content in CORE Reference Section 9.2 (Discussion of study design, including the choice of control groups) - “These procedures can vary from simple random assignment to a selected fixed drug/dose regimen… Procedures for back-titration, if any, should also be described.”

Comment [A161]: The following ICH E3 Section 9.4.4 (Selection of Doses in the Study) text is relocated and integrated more appropriately with content in CORE Reference Section 9.2 (Discussion of study design including the choice of control groups) - “Any relation of drug administration and sampling to ingestion of food, posture and the possible effects of concomitant medication/alcohol/caffeine/nicotine should also be addressed.”

Comment [A162]: The following ICH E3 Section 9.5.4 (Drug Concentration Measurements) text is relocated here and paraphrased - “Any relation of drug administration and sampling to ingestion of food, posture and the possible effects of concomitant medication/alcohol/caffeine/nicotine should also be addressed.”

Comment [A163]: ICH E3 Section 9.4.6 (Blinding) content is merged with content on avoidance of bias (Section 9.4.3) and omitted from here.

Comment [A164]: 'Treatment compliance’ relates to Investigational Product and therefore sits more logically ahead of ‘Prior and Concomitant Therapy’. The suggested running order of ICH E3 content is therefore switched in CORE Reference.

Comment [A165]: See FDA Guidance for Industry: PRO measures: use in medical product development to support labeling claims, Dec 2009: http://www.fda.gov/downloads/Drugs/Guidances/UCM193292.pdf. Advise that PROs are either efficacy or safety measures and should be fully integrated into the appropriate efficacy or safety sections of the CSR.

Comment [A166]: Suggest that information on drug concentration measurement and methodology is integrated with content on PK measurements, (see, for example, CORE Reference Section 9.5.3 [Pharmacokinetic and Pharmacodynamic Measurements]), rather than being presented under treatment compliance.
9.4.6 Prior and Concomitant Therapy

Which drugs or procedures were allowed before and during the study, whether and how their use was recorded and any other specific rules and procedures related to permitted or forbidden concomitant treatment, should be described, as per protocol. Often some of the allowed or prohibited prior and concomitant treatments are defined in the inclusion/exclusion criteria.

Consider how the allowed concomitant treatment (including non-Investigational Product treatment if used) might affect the outcome due to either drug-drug interaction or direct effects on the study endpoints, and explain how the independent effects of concomitant and Investigational Product could be ascertained. Any such observed effects should be described in, for example, Section 13 (Discussion and Overall Conclusions).

Comment [A167]: ICH E3 Section 9.4.5 (Selection and Timing of Doses for Each Patient) is amalgamated with CORE Reference Section 9.4.4 content above and omitted from here.

Comment [A168]: The choice of non-Investigational Product treatment and its regimen (if used) should be described, for example, under Section 9.4.1 (Treatments Administered). This is a reminder to ensure non-Investigational Product treatment is not overlooked.

Comment [A169]: Clarification that some allowed or prohibited prior and concomitant treatments may be defined in the inclusion/exclusion criteria.

Comment [A170]: Suggest to cross reference, for example, Section 9.3 (Selection of Study Population).

Comment [A171]: Clarification to prompt consideration of such treatment effects here (including possible effects of protocol required underlying therapy), and to discuss them in the Discussion if the possible effect is observed.

Comment [A172]: Slight rewording of ICH E3 text in this paragraph with no loss of meaning.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
### 9.5 EFFICACY AND SAFETY VARIABLES

The title of this section (Efficacy and Safety Variables) may be renamed as appropriate to the individual study. For example, if the study measures drug concentration (pharmacokinetics [PK]), pharmacodynamics (PD), including, for example, an exploratory biomarker, or pharmacoeconomic parameters, adapt the title to ‘Efficacy, Safety and Other Variables’. ‘Other’ variables may be specified in the title.

Note that PROs are either efficacy or safety measures and should be fully integrated into the appropriate efficacy or safety sections of the study report.

Clear distinction should be made between variables (defined in this section), objectives (defined in Section 8.1 [Objectives]) and endpoints (defined in Section 8.2 [Endpoints]), with endpoint analysis methodology described in Section 9.7 [Statistical Analysis Methods Planned in The Protocol and Determination of Sample Size]). A brief description of measurements relating to each endpoint can be made, for example, in Section 9.5.1, Section 9.5.3 and Section 9.5.4 as applicable.

In summary, an objective is addressed by recording an endpoint. For definitions, see ‘Terminology’ below.

---

Comment [A173]: See ICH E3 Q & A Point 1: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidances/ICH_E3/Q&A_E3_R2 histórico.pdf which states: ‘If particular types of information or topics are not addressed in ICH E3 or if these location is not specified, this information or topic should be placed in the section that is most relevant. For example, pharmacokinetic or quality of life results could be placed in appropriately identified sub-sections of the efficacy and safety results sections, or they could be placed in non-appropriately identified results sections.

CORE Reference provides a suggested placement that integrates these other types of information. This should not be considered ‘the only way’. Adapt the report structure in the way that best suits the study.

Adapt this section title as appropriate to the variables for the study presented within this section. For example, if PK, PD and other variables are included, mention these in the title.

Comment [A174]: Clarification on general approach to report structuring.

See ICH E3 2012 Q & A guidance text Points 1 and 4 which clarify that flexibility in the order of presentation of study variables/endpoints is strongly encouraged. For example, if the primary objective of the study is PK/PD, followed by safety objectives, and no efficacy objectives are included in the study, then the logical order of variables would be PK/PD followed by safety variables.

Irrelevant CSR sections may be omitted.

CORE Reference reminder: It should however be noted that statistical output numbering, (traditionally, summary tables numbered 14.x.x and listings numbered 16.2.x.x) may make it preferable not to omit irrelevant sections, but rather mark these as ‘not applicable’, to ensure no mismatch of CSR section numbers and statistical output numbers. Either approach is acceptable.

The presenational order of study endpoints and variables must flow throughout the CSR, with consistent ordering in the methodological, results and conclusions sections.


Comment [A176]: The Terminology page that follows presents relevant definitions used in CORE Reference. These recommended definitions are based on extensive discussions by the authors of CORE Reference.

Comment [A177]: To address the ambiguity regarding the content required, clarification of terminology and example subheadings for each efficacy and safety assessment are provided below.
### Terminology

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective</td>
<td>The goal a trial is designed to achieve in terms of the scientific questions to be answered</td>
<td>Demonstration of anti-hypertensive efficacy of Test Product</td>
</tr>
</tbody>
</table>
| Hypothesis            | Statement relating to the possible different effect of the interventions on an outcome | H₀: The proportion of responders at Week 8 in Group A is lower or equal relative to Group B  
H₁: The proportion of responders at Week 8 in Group A is higher than in Group B |
| Measurement           | Process of recording the value of a variable (a quantitative value requires a unit; the same value may be expressed in different units [e.g. mg/mL vs. mmol/dl]) | Recording of blood pressure (BP) [mmHg]                                  |
| Procedure             | Specific test carried out on the subject, specimen or data | Sphygmonanometry (common method to measure BP)                         |
| Assessment evaluation | Systematic test carried out on the recorded value(s) of a variable. Judgment is based on specific (typically subjective) criteria. | Clinical relevance of diastolic BP values outside of normal ranges at Week 4 and Week 8 (yes/no) |
| Variable              | A measurable attribute, phenomenon or event that have either qualitative or quantitative values which may be expected to vary over time and within and/or between subjects | Recorded (on CRF) - Diastolic blood pressure at Baseline [mmHg]  
- Diastolic blood pressure at Week 4 [mmHg]  
- Diastolic blood pressure at Week 8 [mmHg]  
Derivation Level 1 (subject level) - Absolute change in diastolic BP from Baseline to Week 4 [mmHg]  
- Absolute change in diastolic BP from Baseline to Week 8 [mmHg]  
Derivation Level 2 (subject level) - Responder* at Week 4 [yes/no]  
- Responder* at Week 8 [yes/no]  
Derivation Level 3 (population level) - Proportion of responders* at Week 4 [%]  
- Proportion of responders* at Week 8 [%]  
- Mean change in diastolic BP from Baseline to Week 4 [mmHg]  
- Mean change in diastolic BP from Baseline to Week 8 [mmHg]  
- Mean change in diastolic BP from Baseline to Week 8 [mmHg]  
- Mean change in diastolic BP from Baseline to Week 8 [mmHg]  
| Endpoint              | Variable that pertains to an objective of a trial  
Note: The primary endpoint should be linked to a hypothesis. | Endpoints set in bold ItalicPrimary endpoints underlined |

*Response is defined as reduction (relative to Baseline) in diastolic blood pressure ≥ 15 mmHg.
9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments

The content may use subheadings. Example subheadings (ordered to reflect the design of the individual study) may include:

9.5.1.1 Primary Efficacy Measurement
9.5.1.2 Secondary Efficacy Measurements
9.5.1.3 Other Efficacy Measurements

Include exploratory measurements.

9.5.1.4 Safety – Adverse Events
9.5.1.5 Safety – Clinical Laboratory Evaluation
9.5.1.6 Safety – Vital Sign Measurements
9.5.1.7 Safety – Physical Examination

The specific efficacy, safety and/or any other variables to be assessed, their schedule (days of study, time of day, relation to meals, and the timing of critical measures in relation to Investigational Product administration, e.g. just prior to next dose, two hours after dose), the methods for measuring them and the persons responsible for the measurements, should be described. If there were known changes in personnel carrying out critical measurements, these should be reported.

Comment [A181]: ICH E3 uses the term ‘flow chart’ which may not be as clear as the term ‘schedule of assessments’, suggested here.

Comment [A182]: This section title should be renamed as appropriate to the individual study design, as explained in Section 9.5 above.

Comment [A183]: Clarification on general approach to report structuring: Reminder that flexibility in the order of presentation of study variables/endpoints is strongly encouraged.

The presentational order of study variables/endpoints must flow throughout the CSR, with consistent ordering in the methodological, results and conclusions sections.

Comment [A184]: ICH E3 text: ‘The specific efficacy and safety variables to be assessed and laboratory tests to be conducted…’ is clarified to prevent the inadvertent omission of any relevant assessment variable.

Comment [A185]: In practice, personnel changes can be difficult to ascertain.
Variable(s) associated with the primary endpoint defined in the protocol (which may be efficacy, safety or any other type of variable, depending on the study) should be clearly specified. If the primary variable is an efficacy variable and an efficacy threshold was defined in the protocol, this should be described.

If measurements of data relating to study variables were made more than once, the particular measurements (e.g. average of several measurements over the entire study, values at particular times, or last on-therapy value) planned as the basis for comparison of Test Product and Control Product should be specified. If categorical responses (global scales, severity scores, responses of a certain size) were to be used in analysing responses, they should be clearly defined. The use of validated instruments is encouraged.

It is usually helpful to display a Schedule of Assessments in a tabular format (see Example Table 9.1), with the frequency and timing of efficacy and safety measurements, visit numbers and times shown, or, alternatively, times alone can be used (visit numbers alone are more difficult to interpret). Whether any specific instructions (e.g. guidance or use of a diary) to the subjects were used should also be noted. The inclusion of the Schedule of Assessments (Example Table 9.1) means that a detailed list of tests performed at each visit is not required. The Schedule of Assessments from the protocol should be used, where possible.

Any definitions used to characterise outcome (e.g. criteria for determining occurrence of acute myocardial infarction, designation of the location of the infarction, characterisation of a stroke as thrombotic or haemorrhagic, distinction between transient ischaemic attack and stroke, assignment of cause of death) should be explained in full. Any techniques used to standardise or compare results of laboratory tests or other clinical measurements (e.g. electrocardiogram [ECG], chest x-ray) should also be described. This is particularly important in multicentre studies.

If anyone other than the Investigators was responsible for evaluation of clinical outcomes (e.g. the Sponsor or an external committee to review x-rays or ECGs or to determine whether the subject had a stroke, acute infarction, or sudden death), the person or group should be identified. The procedures, including means of maintaining the blind and centralising readings and measurements, should be described fully.

Procedures for AE and SAE reporting should not be described but rather the appropriate protocol section(s) should be referenced, unless it is critical for the understanding of the reporting procedures, e.g. in a complex or unusual study. The means of obtaining AE data should be described (volunteered, checklist or questioning), as should any specific rating scale(s) used and any specifically planned follow-up procedures for AEs or any planned rechallenge procedure.

Note the alignment of terminology to ‘variable(s)’ associated with the primary endpoint. The intention is to limit terminology to objective, endpoint and variable as far as possible. In practice, the primary variable is expected to be protocol-defined, so the text is simplified accordingly.

Comment [A186]: Primary variable(s) text included in ICH E3 Section 9.5.3 is consolidated here. The ICH E3 text states: 'The primary measurements and endpoints used to determine efficacy should be clearly specified. Although the critical efficacy measurements may seem obvious, when there are multiple variables, or when variables are measured repeatedly, the protocol should identify the primary ones, with an explanation of why they were chosen, or designate the pattern of significant findings or other method of combining information that would be interpreted as supporting efficacy. If the protocol did not identify the primary variables, the study report should explain how these critical variables were selected (e.g. by reference to publications, guidelines or previous actions by regulatory authorities) and when they were identified (i.e. before or after the study was completed and unblinded). If an efficacy threshold was defined in the protocol, this should be described.'
Any rating of AEs by the Investigator, Sponsor or external group (e.g., rating by severity or likelihood of drug causation) should be described. The criteria for such ratings, if any, should be given and the parties responsible for the ratings should be clearly identified. If efficacy or safety was to be assessed in terms of categorical ratings, numerical scores, etc., the criteria used for point assignment (e.g., definitions of point scores) should be provided. For multicentre studies, indicate how methods were standardised.

9.5.2 Appropriate measurements

The use of standard validated instruments should be documented. If any of the efficacy or safety assessments or instruments were not standard, i.e., widely used and generally recognised as reliable, accurate, and relevant (able to discriminate between effective and ineffective agents), its reliability, accuracy and relevance should be documented. It may be helpful to describe alternatives considered but rejected. If these

Comment [A193]: For submissions in the US, FDA holds that the Sponsor (rather than Investigator) should make final decisions on causality given their access to a complete dataset of safety data across multiple sites. See New England Journal of Medicine (NEJM) Perspective article from key FDA Center for Drug Evaluation and Research (CDER) leaders: http://www.nejm.org/doi/full/10.1056/NEJMMp1103462 that explains the reporting regulation [21 CFR 312.32 (c) (A)]: http://www.ecfr.gov/cgi-bin/text-idx?SID=9661aeb85e493caed76a11fa6545dce&mcode=true&node=se21.5.312_132&rgn=div8 associate d with the (at that time) new requirements for clinical trial safety reports.

Comment [A194]: Example Table 9.1 combines and streamlines the information presented in ICH E3 Annex IIIa and IIIb, both of which are examples titled 'Study Design and Schedule of Assessments'.

Comment [A195]: Suggest to include protocol number in table title to aid regulatory reviewers who often copy and paste key CSR information into their own summary documents.

Comment [A196]: Clarification to include description of the use of validated instruments which is not included in ICH E3.

**Example Table 9.1** Schedule of Study Events and Assessments in Protocol xxx

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screen*</th>
<th>Treatment</th>
<th>Evaluations (Week Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 1</td>
<td>1</td>
</tr>
<tr>
<td>Visit</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Inclusion/Exclusion</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital Signs</td>
<td>X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination</td>
<td>X X'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological Examination</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Tests</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Samples</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy Assessment 1</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy Assessment 2</td>
<td>X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy Assessment 3*</td>
<td>X'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X X X X X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Call</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The screening examination occurred within two weeks before injection.
* The termination visit occurred when clinical benefit ceased or four months after the injection (Week 16).
* Only additional information noted since screening was recorded (using the screening CRFs).
* The procedure was performed only if the termination visit occurred prior to or in place of the Week 4 visit.
* Assessments were made separately by the Investigator and the subject.
* The baseline assessment consisted of notes taken by the Investigator only; the purpose was to provide a reference for future assessments.

ICH E3 text  ICH E3 2012 Q&A text  CORE Reference text  [Right margin comment=RATIONALE]
were discussed and agreed *a priori* with the regulators, this should be noted, with reference to date of meeting/discussion. *(If a surrogate endpoint (a laboratory measurement or physical measurement or sign that is not a direct measure of clinical benefit) was used as a study endpoint, this should be justified, e.g., by reference to clinical data, publications, guidelines or previous actions by regulatory authorities.)*

9.5.3 Pharmacokinetic and Pharmacodynamic Measurements

9.5.3.1 Pharmacokinetic Measurements

Any drug concentration measurements, and the sample collection times and periods in relation to the timing of drug administration, should be described. Permitted time deviation(s) in PK blood sample collection from the planned time schedule should also be described for the PK studies. Any relation of sampling to ingestion of food, posture and the possible effects of concomitant medication/alcohol/caffeine/nicotine should also be addressed. The biological sample measured, the handling of samples and the method of measurement used should be described, referring to published and/or internal assay validation documentation for methodological details. Where other factors are believed important in assessing PK (e.g., soluble circulating receptors, renal or hepatic function), the timing and plans to measure these factors should also be specified.

9.5.3.2 Pharmacokinetic Parameters

Include details of parameters measured: area under the curve (AUC), maximum plasma concentration (C<sub>max</sub>), etc., if applicable.

9.5.3.3 Pharmacodynamic Measurements

Include PD and/or biomarker measurements if applicable.

Pharmacodynamics is a branch of pharmacology that studies reactions between drugs and living structures, including the physiological responses to pharmacological, biochemical, physiological, and therapeutic agents (CDISC definition).

The PD measurement may be a biomarker, which can be defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention (National Institutes of Health [NIH] definition). This includes pharmacogenomic assessments to determine any variations of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) characteristics as related to drug response.
Where PD measurements, such as biomarkers or pharmacogenomic assessments, are made, the sample collection times and periods in relation to the timing of drug administration, should be described. The biological sample measured, the handling of samples (including coding) and the method of measurement used should be described, referring to published and/or internal validation documentation for methodological details. Where other factors are believed to be important in assessing the PD observation (e.g. drug concentration, metabolites, isomers and finished products), the timing and plans to measure these factors should also be specified.

9.5.3.4 Pharmacodynamic Parameters
Include details of PD parameters measured, if applicable.

9.5.4 Other Measurements
Include details of other study-specific measurements (for example, quality of life and pharmacoeconomic measurements, and also pharmacogenomics) if not included under the CSR text on PD) if applicable.

9.6 DATA QUALITY ASSURANCE

The quality assurance (QA) and quality control (QC) systems implemented to assure the quality of the data should be described in brief. Describe the quality management approach implemented in the study and summarise important deviations from the predefined quality tolerance limits described in the quality management system for the study.

Any steps taken at the investigation site or centrally to ensure the use of standard terminology and the collection of accurate, consistent, complete and reliable data, such as training sessions, monitoring of Investigators by Sponsor personnel, instruction manuals, data verification, cross-checking, use of a central laboratory for certain tests, centralised ECG reading or data audits, should be described. It should be noted whether Investigator meetings or other steps were taken to prepare Investigators and standardise performance.

Documentation of inter-laboratory standardisation methods and laboratory QA procedures, if used, should be provided in Appendix 16.1.10. Laboratory manuals should not be included. Laboratory standardisation methods and laboratory QA procedures include laboratory validation procedures and/or certificates, equipment calibration, internal QC or external QA procedures.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
The date of database release may be included.

The assurance of overall quality for the study is through audit. If the Sponsor used an independent internal or external auditing procedure, it should be mentioned here and described in Appendix 16.1.8; and audit certificates from each audit, if applicable and available, may be provided in Appendix 16.1.8 (note it is not necessary to include audit report[s] in Appendix 16.1.8).

9.7 STATISTICAL ANALYSIS METHODS PLANNED IN THE PROTOCOL AND DETERMINATION OF SAMPLE SIZE

9.7.1 Statistical Plan

The statistical analyses planned in the protocol and any changes made before outcome results were available should be described. These will have been described in further detail in the final statistical analysis plan (SAP). In this section (Section 9.7), emphasis should be on which analyses, comparisons and statistical tests were planned, not on the ones that were actually used. Planned methods in this context means all methods described in the final SAP.

Comment [A215]: Especially for studies with multiple consecutive analyses and reports, suggest to include which cut-off date(s) is (are) used for the analyses reported (e.g. date of database release).

This key information is also recommended for placement in the Introduction.

Comment [A216]: ICH E3 2012 Q & A reminds that per ICH GCP, audit certificates should be provided when required by applicable law or regulation - this is region and/or country-specific.

Comment [A217]: Per ICH E3 2012 Q & A Point 3: Certain documents may be required for the CSR by individual countries or regions, in which case they should be included. For example, according to ICH-GCP, an audit certificate (16.1.8) should be provided when required by applicable law or regulation. If there is any uncertainty about whether documents should be included or not, the appropriate regulatory agency may be consulted. It is suggested that if audit certificates are in the TMF, they need not be replicated in the CSR appendix, unless there is a specific country requirement to do so.

Comment [A218]: Clarification that audit reports are not to be included in Appendix 16.1.8, only audit certificates.

Comment [A219]: Quality assurance procedures in relation to the entire study are missing from ICH E3, so this, as well as a more detailed explanation of audits is included.

Comment [A220]: Analytical plans are usually described in the PK section. Section title is adjusted to better reflect the general content of this section, with adaptation to use the word ‘analysis’.

Comment [A221]: Omitted the ICH E3 word ‘analytical’ before plans to better reflect the general content of this section.

Comment [A222]: The paragraph of text in ICH E3 Section 9.7.1 which refers to endpoint derivation detail has been omitted from here and integrated with CORE Reference content in Section 9.5.1 (Efficacy and Safety Measurements Assessed and Schedule of Assessments) as it is deemed endpoint derivation detail rather than analysis methods.

Comment [A223]: ICH E3 text does not explain the development of statistical analysis planning from the protocol to the SAP.

Comment [A224]: ICH E3 text ‘which ones were’ is clarified as ‘the ones that were’.
The final SAP will have incorporated any changes covered by protocol amendments and any changes to planned analyses made prior to study unblinding that were not considered to require a protocol amendment.

The following example subheadings may be used:

9.7.1.1 General Approaches
9.7.1.2 Primary Efficacy Endpoint Methodology
Include the methodology for the primary analysis, which may also include methods for sensitivity analyses of the primary endpoint.

9.7.1.3 Secondary Efficacy Endpoint Methodology
9.7.1.4 Other Efficacy Endpoint Methodology
If applicable also include the methodology for exploratory endpoint(s).

9.7.1.5 Safety Endpoint Methodology
9.7.1.6 Pharmacokinetic and Pharmacodynamic Endpoints Methodology
Include if applicable.

9.7.1.7 Other Endpoint Methodology
Include if applicable.

Comment [A225]: Further detail is added to clarify what is meant by the statistical analyses and tests that were planned (as mentioned in ICH E3 text above), and that changes to analyses agreed prior to study unblinding are considered ‘planned analyses’. All this detail should be included in the SAP, which is again referenced.

The description of these changes should be placed in, for example, Section 9.8 (Changes in the Conduct of the Study and Planned Analyses).

Comment [A226]: Suggested subheadings are based on the sections commonly used in SAPs regarding statistical methodology, and matched to Section 9.5 (Efficacy and Safety Variables) subheadings. It is clarified that the information in these example sub-sections should relate to statistical methodologies.

Comment [A227]: Awareness comment pending finalisation of ICH guidance: Final concept paper E9(R1) Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/E9__R1_Final_Concept_Paper_October_23_2014.pdf which generally provides detailed guidance for ‘An improved framework…[to] focus the sensitivity analyses…’ (mid page 4); discusses some types of supportive analyses (start page 5) and states in ‘Background to the Proposal’ that ‘Reporting results from sensitivity analyses is relevant for ICH E3’ (start page 5).

Such analysis aspects are expected to be considered at the study design stage, may be described in the protocol and/or SAP, and should be considered for inclusion in this section if applicable to individual study design, and if available.

Comment [A228]: The definition of a treatment-emergent AE (TEAE) should be included within the content of this section.

Comment [A229]: Suggest that this text is sub-sectioned to match the safety sub-sections in, for example, Section 9.5.1 (Efficacy and Safety Measurements Assessed and Schedule of Assessments).
The final SAP text should be used to place the study results in statistical context. If more than one analytical approach is plausible, e.g., changes from baseline response, slope analysis, life table analysis, the planned approach should be identified. Also, whether the analyses are to include adjustment for covariates should be specified. Methodologies described in the final SAP to deal with statistical issues should be included. These may be related to one or more than one endpoint. If those methodologies were implemented or revised after the final SAP, they should be addressed together with changes in the conduct of the study or planned analyses. 

Comment [A230]: Clarification to indicate the text is always sourced from the SAP. ICH E3 does not explicitly state this.

Comment [A231]: Suggest using the SAP text to populate the CSR text in Section 9.7.1 (Statistical Plans). The final SAP (in Appendix 16.1.9) should also be cross-referenced. 

A suggested approach is that a brief description of each endpoint can precede the details of the planned statistical analysis methods or an appropriate cross-reference can be made to, for example, Section 8.2 (Endpoints), as required. Statistical methodologies should be described for all planned analyses, with a cross-reference to, for example, Section 9.8 (Changes in the Conduct of the Study or Planned Analyses), or as applicable; brief descriptions can also be included for methods of summarising data.


Estimands are expected to be considered at the study design stage, may be described in the protocol and/or SAP, and should be considered for inclusion in this section or a cross-reference may be added to Section 8 (Study Objectives and Endpoints) and Section 9.2 (Discussion of Study Design Including the Choice of Control Groups), as applicable.

Comment [A233]: ICH E3 text: ‘If critical measurements were made more than once, the particular measurements (e.g. average of several measurements over the entire study, values at particular times, values only from study completers, or last on-therapy value) planned as the basis for comparison of test drug/investigational product and control should be specified’ is relocated from here to Section 9.5 because it refers to endpoint derivation detail rather than analysis methods.

Comment [A234]: ICH E3 text: ‘If there were any planned reasons for excluding from analysis patients for whom data are available, these should be described. If there were any subgroups whose results were to be examined separately, these should be identified’ is subordinated (see ‘Examination of subgroups’ below).

Comment [A235]: Text relocated here from ICH E3 Section 11 (because this paraphrases 11.4.2 of ICH E3 it is shaded as ICH E3 text) as it deals with methods for dealing with statistical issues.

Comment [A236]: ICH E3 integrates statistical methodological text and statistical results-related text and presents within a single location Section 11.4.2 - Statistical/analytical issues. The text is actually more logically separated so the methodological text sits here, and the results-related text sits in Section 11. See comments below for specific details of relocated text.
Method(s) for Statistical Issues Encountered During the Analysis

Adjustments for Covariates:
Methods for selection of, and adjustments for, demographic or baseline measurements or prior treatment, or any other covariate or prognostic factor, including stratification factors used in the randomisation, should be explained.

Handling of Withdrawals, Discontinuations and Missing Data:
The results of a clinical trial should be assessed not only for the subset of patients who completed the study, but also for the entire patient population as randomised or at least for all those with any on-study measurements. Several factors need to be considered and compared for the treatment groups in analysing the effects of withdrawals or discontinuations; the reasons for the withdrawals or discontinuations, the time to withdrawal or discontinuation, and the proportion of withdrawals or discontinuations among treatment groups at various time points. Planned methodologies for assessing time to withdrawal or discontinuation, such as survival data methods, should be explained.

Comment [A237]: A header, or a statement - to remind that methods only (not results) are presented - may be useful.

Comment [A238]: ICH E3 text: ‘The statistical analysis used should be described for clinical and statistical reviewers in the text of the report, with detailed documentation of statistical methods presented in Appendix 16.1.9. Important features of the analysis including the particular methods used, adjustments made for demographic or baseline measurements or concomitant therapy, handling of dropouts and missing data, adjustments for multiple comparisons, special analyses of multicentre studies, and adjustments for interim analyses, should be discussed. Any changes in the analysis made after blind breaking should be identified. In addition to the general discussion the following specific issues should be addressed (unless not applicable)’ is relocated to, and modified in CORE Reference Section 11.2 where the results content for these issues are described.

Comment [A239]: ICH E3 text includes concomitant therapy as a possible covariate but this would be a post-baseline measurement. Replaced ‘concomitant therapy’ with ‘prior treatment’ as a possible covariate since covariates should be pre-dosing measurements. Reference ICH E9: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guide line.pdf Section 5.7 “It is not advisable to adjust the main analyses for covariates measured after randomisation because they may be affected by the treatments.”

Comment [A240]: Clarified that stratification factors may be covariates requiring discussion.

Comment [A241]: Statistical issues methodological text is consolidated and relocated here from ICH E3 Section 11.4.2.1.

Comment [A242]: ICH E3 text ‘Although not part of the individual study report, comparisons of covariate adjustments and prognostic factors across individual studies may be an informative analysis in a summary of clinical efficacy data.’ is omitted as this is not relevant for the CSR.

Comment [A243]: Clarification of terminology for consistent use of withdrawal and discontinuation, because in practice, the term used in ICH E3 i.e. dropout, is often used in relation to the sample size calculation (dropout rate).

Comment [A244]: ICH E3 text is relocated here from Section 11.4.2.2 (Handling of Dropouts or Missing Data) because this describes the methodology rather than results.

Comment [A245]: Inclusion of such data methods as not covered by ICH E3.
Planned methods for dealing with missing data, e.g. use of estimated or derived data, should be described. Detailed explanation should be provided as to how such estimations or derivations were done and what underlying assumptions were made.


Interim Analyses and Data Monitoring:

The process of examining and analysing data accumulating in a clinical trial, either formally or informally, can introduce bias and/or increase Type I error. Therefore, all interim analyses, formal or informal, pre-planned or ad-hoc, by Sponsor/designee or data monitoring group should be described in full, even if the treatment groups were not identified. The methodologies include frequency and nature of any planned interim analysis, including “cut-off date(s)”, any specified circumstances under which the study would be terminated and any statistical adjustments to be employed because of interim analyses. Any operating instructions or procedures used for such interim analyses should be described, with particular reference to how it was ensured that only those conducting the interim analysis were unblinded.

The minutes of meetings of any data monitoring group and any data reports reviewed at those meetings, particularly a meeting that led to a change in the protocol or early termination of the study, may be helpful and should be provided in the appropriate appendix. Data monitoring conducted on blinded data should also be described, even if this kind of monitoring is considered to cause no increase in Type I error.

ICH E3 text | ICH E3 2012 Q&A text | CORE Reference text | [Right margin comment=RATIONALE]
Multicentre Studies:
A multicentre study is a single study under a common protocol, involving more than one centre (e.g. clinics, practices, hospitals) where the data collected are intended to be analysed as a whole (as opposed to a post-hoc decision to combine data or results from separate studies). The planned methods such as inclusion of centre and treatment-by-centre interactions in statistical models should be presented.

Multiple Comparison/Multiplicity:
False positive findings increase in number as the number of significance tests (number of comparisons) performed increases. If there was more than one primary endpoint (outcome variable), more than one analysis of particular endpoint, or if there were multiple treatment groups or subsets of the subject population being examined, the statistical analysis should reflect awareness of this and either explain the statistical adjustment used for Type I error criteria or give reasons why it was considered unnecessary. These methodologies can be presented.

Examination of Subgroups:
If there were any planned reasons for excluding subjects for whom data are available from analysis, these should be described. If there were any subgroups whose results were to be examined separately, these should be identified. Appendix 16.1.9 should describe all analysis methods used (whether planned or post-hoc) in full detail, again clearly identifying those that were post-hoc.

Annex IV and Appendix 16.1.9 give further guidance on the content of this section.

Comment [A256]: “… more than one” replaces ICH E3 text of “several” as the correct definition of multicentre is “more than one centre”.
Comment [A257]: ICH E3 instructional text is consolidated to remove duplicate statements about presenting data by centre.
Comment [A258]: ICH E3 text relocated here from ICH E3 Section 11.4.2.4 (Multicentre Studies) as relates to methodology and not to results.
Comment [A259]: Text relocated here from ICH E3 Section 11.4.2.5 (Multiple Comparisons/Multiplicity) as this relates to methodology and not results.
Comment [A260]: Clarified to indicate that multiple testing should be described as part of the methods of analysis of primary endpoint(s).
Comment [A261]: Include these if not already presented in the methods for analysing primary endpoint(s).
Comment [A262]: Added existing ICH E3 subheading from ICH E3 Section 11.4.2.8 for clarification of topic.
Comment [A263]: ICH E3 text surrounding the role of the DMC has been relocated from here to Section 9.4.3.2 (Blinding and unblinding) as it is not deemed to be statistical methods.
Comment [A264]: ICH E3 Section 9.7.1 moved from here: “If categorical responses (global scales, severity scores, responses of a certain size) were to be used in analysing responses, they should be clearly defined” because detailed descriptions of the variables/endpoints are actually covered in the SAP.
Comment [A265]: As suggested in Section 11.1, placement of post-hoc analyses – either embedded in efficacy sections with clear indication they are post-hoc, or presented in a separate section, or appended – will be study-specific. Align the post-hoc analysis methods with the post-hoc results presentation.
Comment [A266]: Do not overlook ICH E3 Annex VIB/CORE Reference Annex IV for SAP authoring.
Annexes are located towards the end of CORE Reference.
9.7.2 Determination of Sample Size

The planned sample size and the basis for it, such as statistical considerations or practical limitations, should be provided (summarised from the protocol and/or final SAP).

Methods for sample size calculation should be given together with their derivations or source of reference. Estimates used in the calculations should be given and explanations provided as to how they were obtained. For a study intended to show a difference between treatments, the difference the study is designed to detect should be specified. For a positive control study intended to show that a new therapy is at least as effective as the standard therapy, the sample size determination should specify the difference between treatments that would be considered unacceptably large and therefore the difference the study is designed to be able to exclude. The power needed for the study may also be stated.

9.8 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES

Any change in the conduct of the study or planned analyses implemented after the start of the study, should be summarised with reference to the protocol amendments and SAP for more detailed descriptions and clear distinction made in every section of the report between procedures or analysis methods planned in the protocol versus amendments or additions. In general, changes made prior to breaking the blind have limited implications for study interpretation. It is therefore particularly critical that the timing of changes relative to blind breaking and availability of outcome results are also well characterised. Changes in conduct of the study and changes in planned analyses should be described, for example, in Section 9.8.1 (Changes in the Conduct of the Study) and Section 9.8.2 (Changes in the Planned Analyses), respectively. Changes made after study unblinding should be described separately.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
9.8.1 Changes in the Conduct of the Study

Changes in the conduct of the study can include, but are not limited to, dropping a treatment group, changes in entry criteria or drug (Investigational Product or non-Investigational Product treatment) dosages, adjusting the sample size, and changes in assessment schedules. These changes would require a protocol amendment and can therefore be cross-referenced to the summary of protocol amendment changes, often included in Appendix 16.1.1, to avoid duplication. If a summary of the change is included in the CSR text, the following information should be included: details of the change(s) and the time(s) and reason(s) for the change(s), with a cross-reference, for example to the Appendix 16.1.1 protocol amendment(s) for further details. In the event any changes were made to the study conduct without a corresponding protocol amendment, then this summary should also include why it was agreed not to amend the study protocol and who approved this decision. Personnel changes do not need to be included. It is expected that changes in study conduct would be made while the study is still blinded but this should be corroborated and confirmed in the CSR text.

Any possible implications of the change(s) for the interpretation of the study should be discussed briefly in this section and more fully in other appropriate sections of the report.

9.8.2 Changes in the Planned Analyses

Changes in the planned analyses may have been included in a protocol amendment, in which case they may be handled as described for example, in Section 9.8.1 (Changes in the Conduct of the Study). If changes were made to the analyses planned in the protocol but a protocol amendment was not required, then the changes should have been documented in a separate section of the final SAP entitled for example, ‘Changes from the planned analyses’. Those changes can be described using the suggestions made in Section 9.8.2 (Changes in the Conduct of the Study or Planned Analyses). In the case of changes to analyses documented in a protocol amendment or in the final SAP, the CSR text must state whether these changes were made based on blinded or unblinded data. Protocol amendments and SAPs must be final prior to study unblinding, although decisions to change planned analyses may have been made based on results from unblinded interim analyses. Timing of events must be described with clarity.

9.8.3 Changes Following Study Unblinding and Post-hoc Analyses

Changes made to the planned analyses after study unblinding should be avoided due to the impact of bias on results. If assumptions about the study data have not been met then alternative analyses to be used in that situation should have been described in the final SAP. Any other changes made to the planned analyses following study unblinding should be documented appropriately (e.g. SAP addendum, SAP amendment etc.) and described in the CSR text, noting that all results from these analyses must be interpreted with caution due to the decision to change the methods having been taken after study unblinding. Alternative analyses should generally be supplemental to, rather than in place of, the originally planned analysis.

Comment [A272]: ICH E3 text states: ‘In every case of protocol amendment or modification, a summary of the changes be documented appropriately (e.g. SAP addendum, SAP amendment etc.) and described in the CSR text, noting that all results from these analyses must be interpreted with caution due to the decision to change the methods having been taken after study unblinding. Alternative analyses should generally be supplemental to, rather than in place of, the originally planned analysis.’
If post-hoc analyses (e.g. exploration of sub-groups of data not previously planned) were conducted, the statistical methods should be summarised and the results presented, for example, in Section 11 (Efficacy and Other Evaluations). Alternatively, post-hoc analyses may only be included in Appendix 16.1.9. The CSR text must note that results from these analyses should be interpreted with caution as the analysis methods were not pre-specified prior to study unblinding.

Comment [A280]: Suggest that in such cases, a cross-reference is provided in the CSR text to Appendix 16.1.9.
10. **STUDY SUBJECTS**

General notes for all results sections: The CSR text should present the results from the statistical outputs. When extracting results from a larger end-text table into an in-text table, care must be taken not to omit any information that would change the interpretation of the results. In general, do not repeat in-text tabulated summary data by additionally describing it in text.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

Comment [A281]: Consider for PPD impact:
All aggregated data in the ‘primary use CSR’ should be evaluated for possible redaction in the ‘secondary use CSR’ for public disclosure. See Preface for explanation about the risk of de-anonymisation from aggregated data.

Comment [A282]: In ICH E3, much of the instruction pertaining to listings creation is embedded in separate sub-sections of the results section of the guideline. However, these instructions are actually applicable to all data listings presentations. The content has been drawn together and presented directly before the ‘Explanation of Annexes’ section (towards the end of CORE Reference) for clarity.

Comment [A283]: Consider for PPD impact:
Consideration of data presentations that achieve anonymity in the ‘primary use CSR’ for regulatory review will minimise the need for piecemeal redaction in the ‘secondary use CSR’ for public disclosure. Note that the CORE Reference assumption is that data including, for example, patient identification numbers, are not proactively anonymised. However, if proactively anonymised data has been used to author the ‘primary use CSR’, then certain redactions may not be necessary in the ‘secondary use CSR’ for public disclosure. See, for example, Pharmaceutical Users Software Exchange (PhUSE) De-Identification Working Group, “De-Identification Standards for CDISC SDTM 3.2,” 2015 (http://www.phuse.eu/Data_Transparency_downloads.aspx) for listed direct and quasi identifiers potentially found in clinical data, and that can facilitate identification of variables in clinical reports.

Comment [A284]: Consider for PPD impact:
Subject numbers may be created using a centre identifier component. Subject re-identification, particularly for centres entering small numbers of study subjects, may be possible through a subject number that includes a centre identifier component. Where individual subject numbers are presented in the ‘primary use CSR’, it is recommended that these are fully redacted in the ‘secondary use CSR’ for public disclosure. In all cases, the entire subject number, including any centre identifier component, should be redacted.

Comment [A285]: Consider for PPD impact:

Chapter 3, Section 5 (EMA recommendations to MAHs/applicants on how best to achieve anonymisation) supports the general approaches to presentation of subject level information suggested in CORE Reference.
10.1 DISPOSITION OF SUBJECTS

Study enrolment is the entry of a subject into a clinical trial, usually following the signing of the informed consent form, although in some cases, this may be study-specific. Once a subject has been enrolled, the protocol applies to that subject. Study randomisation requires assignment to an intervention. “Withdrawal” is applied to withdrawal from treatment and protocol-defined procedures; “discontinuation” is applied to stopping of treatment only.

There should be a clear accounting of all subjects who entered the study, using figures or tables in the text of the report. The numbers of subjects who were randomised and who entered and completed each phase of the study (or each week/month of the study), should be provided, as well as the reasons for all post-randomisation discontinuations and withdrawals, grouped by treatment and by major reason (AE, unsatisfactory efficacy, response, failure to return, lost to follow-up, etc.). A clear distinction should be made between discontinuations (i.e., stop treatment), where the subject remains in the study and completes some or all of the protocol-defined procedures, and withdrawals (i.e., stop treatment and stop all protocol-defined procedures) from the study, where no further information is collected on the subject. Whether subjects are followed for the duration of the study, even if Investigational Product is discontinued, should be made clear. It may also be relevant to provide the number of subjects screened for inclusion and a breakdown of the reasons for excluding subjects during screening, if this could help clarify the appropriate subject population for eventual drug use. A flow chart or table is often helpful and should be included (see Example Figure 10.1).

In Appendix 16.2.1, there should also be a listing of all subjects who were withdrawn from the study and subjects who discontinued Investigational Product after enrolment, broken down by centre and treatment group, giving a subject identifier, the specific reason for discontinuation, the treatment (Investigational Product and dose), cumulative dose (where appropriate) and the duration of treatment before discontinuation. Whether or not the blind for the subject was broken at the time of discontinuation should be noted. It may also be useful to include other information, such as critical demographic data (e.g., age, sex, race), concomitant medication and the major response variable(s) at termination. See Annex II for an example of such a listing.

<Deliberate white space to allow Example Figure 10.1 to be shown on a single page>
Example Figure 10.1: Disposition of Subjects in Protocol xxx

Footnotes:

Percentages are based on number of subjects receiving double-blind treatment.

'Discontinued' applies to subjects who stopped treatment. In some cases it may be appropriate to add another row for subjects withdrawn from the study. 'Withdrawn' applies to subjects who stopped treatment and who stopped all protocol-defined procedures.

(Data Source: xxx)
10.2 PROTOCOL DEVIATIONS

All important deviations related to study inclusion or exclusion criteria, conduct of the study, subject management or subject assessment should be described. In Appendix 16.2.2, individual subjects with these observations should be listed, broken down by centre for multicentre studies. An example of such a listing is provided in Annex III.

In the body of the text, important protocol deviations should be appropriately summarised by centre and grouped into different categories, such as:

- Subjects who were enrolled (as determined by the protocol) in the study even though they did not satisfy the entry criteria.
- Subjects who developed/discontinuation or withdrawal criteria during the study but were not discontinued or withdrawn.
- Subjects who received the wrong treatment or incorrect dose.
- Subjects who received an excluded concomitant treatment.

Those protocol deviations that are not considered important can be referenced in the end of the text listing.

**Definitions:**

A protocol deviation is any change, divergence, or departure from the study design or procedures defined in the protocol.

Important protocol deviations, sometimes referred to as protocol violations or major protocol deviations, are a subset of protocol deviations, where a change, divergence or departure from the study requirements, whether by the subject or Investigator, resulted in a subject’s withdrawal from study participation, or were regarded as severe enough to result in a subject’s exclusion from one or more analysis sets (for example, per-protocol).

Comment [A298]: ICH E3 Annex VI listing of Subjects and Observations Excluded from the study – clarification provided to reference the ICH E3 Annex VI end text listing. In addition, its number is changed from Annex VI to Annex III in ICH E3 CORE Reference.

Comment [A299]: Consider for PPD impact: By-centre grouping in the ‘primary use CSR’ enables data integrity to be assessed. However, by-centre grouping in the CSR text could compromise subject anonymity, particularly at low-recruiting centres. Analyses may not be performed, even in Phase 2 and 3 studies. From Annex IV, a Subject Disposition of ICH E3 guidance – and as referenced in ICH E3 2012 Q & A, which explains that this was the intended meaning of ‘protocol violation’ in ICH E3.

Comment [A300]: Clarification added on how to address those protocol deviations that are not considered important.

Comment [A301]: Adapted to ‘enrolled’ to align terminology with that used in the CDISC Glossary and CORE Reference.


Comment [A303]: From Annex IV, Subject Disposition of ICH E3 guidance – and as referenced in ICH E3 2012 Q & A, which explains that this was the intended meaning of ‘protocol violation’ in ICH E3.

Comment [A304]: In some studies, important protocol deviations may not be identified until the analysis phase when it is too late to withdraw the subject – rather, they would be excluded from one or more analysis sets. This means that the ICH E3 text, reiterated in ICH E3 2012 Q & A text that states “…resulted in a subject’s withdrawal from the study” is incomplete, and is therefore clarified here to account for late identification of protocol deviation, and the exclusion of such subjects from the relevant analysis population(s).

Examples to show why “…resulted in a subject’s withdrawal from study participation” also holds true. Some clinical pharmacology studies do not exclude subjects from analysis populations unless a subject did not receive study drug. In efficacy studies, analyses may not always be done on subsets (per protocol analyses may not always be performed, even in Phase 2 and 3 studies).
**10.3 DATA SETS ANALYSED**

It is assumed that all subjects who received at least one dose of the treatment are included in the safety analysis; if that is not so, an explanation should be provided.

Exactly which subjects were included in each analysis set should be precisely defined, e.g. all subjects receiving any Investigational Products, all subjects with any efficacy observation or with a certain minimum number of observations, only subjects completing the study, all subjects with an observation during a particular time window, only subjects with a specified degree of compliance, etc. It should be clear, if not defined in the study protocol, when (relative to study unblinding), and how inclusion/exclusion criteria for the data sets analysed were developed, to ensure that a proper accounting of all subjects included in the analysis populations takes place. The procedure and criteria for allocation of subjects to a particular dataset (or exclusion from a dataset) should be specified in the SAP. Inclusion or exclusion of subjects into a particular dataset should be determined before database lock and documented in the TMF. Generally, even if the Sponsor’s proposed primary analysis is based on a reduced subset of the subjects with data, there should also be, for any study intended to establish efficacy, an additional analysis using all randomised (or otherwise entered) subjects with any on-treatment data (i.e. an intention-to-treat analysis). For each analysis set, it should be clearly specified whether it was analysed “as assigned” or “as treated”. A summary table of the subject evaluation groups/analysis populations should be presented in the CSR text.

There should be a listing of all subjects, visits and observations excluded from the defined analysis provided in Appendix 16.2 (see Annex III). The reasons for exclusions should also be analysed for the whole treatment group over time. Such a summary of exclusions from analysis populations is provided in Example Table 10.1.

<table>
<thead>
<tr>
<th>ICH E3 text</th>
<th>ICH E3 2012 Q&amp;A text</th>
<th>CORE Reference text</th>
<th>[Right margin comment=RATIONALE]</th>
</tr>
</thead>
</table>

**Comment [A305]:** Note: the term ‘protocol violation’ is common in device trials.

**Comment [A306]:** The direction to not use the term ‘protocol violations’ is not aligned with CDISC since the ICH E3 2012 Q & A takes precedence here over CDISC.

**Comment [A307]:** ICH E3 Section 11.1 (Data Sets Analysed) is relocated here. This is suggested because this section describes the subject population and is not part of the Efficacy Evaluation.

**Comment [A308]:** Clarification of ICH E3 text which states ‘all patients entered into treatment’ is duplicative and is removed.

**Comment [A309]:** ICH E3 Section 12.1 (Extent of Exposure) final paragraph is more appropriately placed in CORE Reference Section 10.3 (Data Sets Analysed) so is relocated here. A cross-reference may be added in (CORE Reference) Section 10.6 (Extent of Exposure) to here if this adds clarity to the accounting of safety analysis subjects.

**Comment [A310]:** ICH E3 does not include any text around the fact that decisions about inclusion/exclusion of subjects from a dataset should be made before database lock and the decisions documented – instructional text has been adapted to include this.

**Comment [A311]:** From ICH E3, it is not clear how subjects who received the wrong treatment are handled so clarification is added about this.

**Comment [A312]:** ICH E3 does not explicitly state that subject evaluation groups/analysis populations should be summarised in a table and presented in text – suggest this should be presented.

**Comment [A313]:** The ICH E3 word ‘tabular’ is omitted as considered redundant.

**Comment [A314]:** ICH E3 states: ‘..see Annex VII of the guideline for an example’. The reference to the appendix and annex are modified.

**Comment [A315]:** ICH E3 Annex VII relocated in text (as Example Table 10.3). It is not referenced within the ICH E3 results text.
Example Table 10.1. Exclusions From Analysis Sets in Protocol xxx

<table>
<thead>
<tr>
<th>Reason</th>
<th>Treatment Group</th>
<th>Time point 1</th>
<th>Time point 2</th>
<th>Time point x</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
<td>N=x</td>
<td>n excluded</td>
<td>n excluded</td>
<td>n excluded</td>
</tr>
</tbody>
</table>

TOTAL

Data source: xxx

10.4 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Group data for the critical demographic and baseline characteristics of the subjects, as well as other factors arising during the study that could affect response, should be presented in this section and comparability of the treatment groups for all relevant characteristics should be displayed by use of tables or graphs in Section 14.1 (Demographic Data). The data for the subject sample included in the “all subjects with data” analysis should be given first. This can then be followed by data on other groups used in principal analyses, such as the “per-protocol” analysis or other analyses, e.g. groups defined by compliance, concomitant disease/treatment, or demographic/baseline characteristics. When such groups are used, data for the complementary excluded group should also be shown. In a multicentre study, where appropriate, comparability should be assessed by centre or region, and centres or regions should be compared.

The critical variables will depend on the specific nature of the disease and on the protocol but will usually include:

- Demographic variables
  - age
  - sex
  - race
- Disease factors
  - specific entry criteria (if not uniform), duration, stage, severity of disease and other clinical classifications and sub-groupings in common usage or of known prognostic value
  - baseline values for critical clinical measurements carried out during the study or identified as important indicators of prognosis or response to therapy
  - concomitant illness at study initiation, such as renal disease, diabetes, heart failure
  - relevant previous illness
  - relevant previous treatment for illness treated in the study
  - concomitant treatment maintained even if the dose was changed during the study, including oral contraceptive and hormone replacement treatment; treatments stopped at entry into the study period (or changed at study initiation); and concomitant treatments started during the study period. Treatment group differences, and trends with increasing dose, should be noted, if applicable. Note: prior medications are those that start and finish prior to first administration of Investigational Product. Concomitant medications are those that start prior to first administration of Investigational Product and finish or are ongoing on or after first administration of Investigational Product. Concomitant treatments are those that start prior to first administration of Investigational Product and finish or are ongoing on or after first administration of Investigational Product.

ICH E3 text CORE Reference text

[Right margin comment=RATIONALE]
administration of Investigational Product, or those that start on or after first administration of Investigational Product but no later than the last dose of Investigational Product. Medications that start after the last dose of Investigational Product are considered post-treatment. A window may be defined after last dose of Investigational Product where a medication may still be considered concomitant. The length of the window defined should be study-specific.

- Other factors that might affect response to therapy (e.g. weight, renin status, antibody levels, metabolic status)
- Other possibly relevant variables (e.g. smoking, alcohol intake, special diets) and, for women, menstrual status and date of last menstrual period, if pertinent for the study.

In addition to tables or graphs giving group data for these baseline variables, relevant individual subject demographic and baseline data, including laboratory values, and all concomitant medication for all individual subjects randomised (broken down by treatment and by centre for multicentre studies) should be presented in by-subject listings in Appendix 16.2.4. Although some regulatory authorities will require all baseline data to be presented elsewhere in listings, the appendix to the study report should be limited to only the most relevant data, generally the variables listed above.

This content may be sub-sectioned, for example:

10.4.1 Demography

10.4.2 Baseline Disease Characteristics

10.4.3 Medical History and Concurrent Illnesses

10.4.4 Prior and Concomitant Treatments

10.5 MEASUREMENTS OF TREATMENT COMPLIANCE

Treatment compliance describes the degree to which a subject takes their intended full dose of Investigational Product and may be expressed as a percentage. Extent of treatment exposure describes the cumulative dose amount received by the subject and should be included, for example, in Section 10.6 (Extent of Exposure). If any randomised subjects were excluded from analysis due to non-/poor compliance to treatment it should be explained.

Any measurements of compliance of individual subjects with the treatment regimen under study and drug concentrations in body fluids should be summarised, analysed by treatment group and time interval and tabulated in Appendix 16.2.5.

10.6 EXTENT OF EXPOSURE

Analysis of safety- and efficacy-related data should take into account the extent of exposure (dose, duration, number of subjects) to determine the degree to which safety and efficacy can be assessed from the study.
The extent of exposure to the Investigational Product(s) should be characterised according to the number of subjects exposed, the duration of exposure, and the dose to which they were exposed.

- **Duration**: Duration of exposure to any dose can be expressed as a median or mean, but it is also helpful to describe the number of subjects exposed for specified periods of time, such as for one day or less, two days to one week, more than one week to one month, more than one month to six months, etc. The numbers exposed to Test Product(s) for the various durations should also be broken down into age, sex, and racial subgroups, and any other pertinent subgroups, such as disease (if more than one is represented), disease severity, concurrent illness.

- **Dose**: The mean or median dose used and the number of subjects exposed to specified daily dose levels should be given; the daily dose levels used could be the maximum dose for each subject, the dose with longest exposure for each subject or the mean daily dose. It is often useful to provide combined dose-duration information, such as the numbers exposed for a given duration (e.g. at least one month) to the most common dose, the highest dose, the maximum recommended dose, etc. In some cases, cumulative dose might be pertinent. Dosage may be given as the actual daily dose or on a mg/kg or mg/m² basis, as appropriate. The numbers of subjects exposed to various doses should be broken down into age, sex and racial subgroups, and any other pertinent subgroups.

It is assumed that all subjects who received at least one dose of the treatment are included in the safety analysis; if that is not so, an explanation should be provided.

Subject exposure to Investigational Product also impacts the assessment of efficacy. Definition of exposed subjects evaluable for efficacy is study-dependent. Details should be provided.

--Deliberate white space to allow comments on right hand side of this page to be shown in full--
11. EFFICACY AND OTHER EVALUATIONS

The example section headings should be adapted to reflect study design.

11.1 EFFICACY RESULTS

Treatment groups should be compared for all measures of efficacy described in the protocol (primary, secondary, and other [including exploratory endpoints]) and the results presented. The results of analysis of drug concentration (PK) and PD (including biomarkers) endpoints should be presented (for example in Section 11.3 [Pharmacokinetic, Pharmacodynamic and Other Analyses Results]).

If a planned analysis is to be conducted at a later date so that results are not included in this CSR (e.g. a follow-up for survival after one year), this should be stated.

In general, the results of all analyses contemplated in the protocol and an analysis including all subjects with on-study data should be performed in studies intended to establish efficacy. The analysis should show the size (point estimate) of the difference between the treatments, the associated confidence interval and, where utilised, the results of hypothesis testing.

If an active control study is intended to show equivalence (i.e. a difference not exceeding a specified size) between the Test Product and the active comparator (control), the analysis should show the confidence interval for the comparison between the two agents for critical endpoints and the relation of that interval to the prespecified degree of inferiority that would be considered unacceptable. (See, for example, Section 9.2 [Discussion of Study Design, Including the Choice of Control Groups] for important considerations when using the active control equivalence design.)

Note that the title 'text has been relocated from here to Section 11.3 (Efficacy and Other Analyses) can be changed if necessary, e.g. for a study in which PK is a primary endpoint.

Comment [A339]: See Clarification on general approach to reporting content in Section 9.3. Note that the title 'Efficacy and Other Evaluations' can be changed if necessary, e.g. for a study in which PK is a primary endpoint.

Comment [A340]: ICH E3 Section 11.1 (Data Sets Analyzed) relocated to Section 10.3 because the Data Sets Analyzed content describes the subject population and is not exclusively part of the Efficacy Evaluation.

Comment [A341]: ICH E3 ‘and Tables of Individual Patient Data’ is omitted from the end of this title.

Comment [A342]: ICH E3 ‘benefit/risk assessment’ text has been relocated from here to Section 13 (Discussion and Overall Conclusions) as it was deemed more relevant to place this text in the conclusion section.

Comment [A343]: ICH E3 instructional text states only ‘primary and secondary endpoints; pharmacodynamic endpoints studied’ and therefore may not cover all potential analyses or make it clear that the analyses produced should relate to the endpoints stated and analyses planned in the protocol. Clarification is added to cover primary, secondary and other (including exploratory) analyses of efficacy and to specify where results from each of these should be presented, incl PK/PD analyses.

Comment [A344]: ICH E3 mentions PD endpoints. Suggest these are better placed in Section 11.3.

Comment [A345]: ICH E3 instructional text does not cover how to handle planned analyses not yet performed at time of reporting – clarification added.

Comment [A346]: ICH E3 text: (i.e. lack of a difference greater than a specified size) in clarified.

Comment [A347]: ICH E3 state 'between the test drug/investigational product and the active control/comparator'. The language is clarified here.

Comment [A348]: ICH E3 Section 11.4.2.7 (Active-Control Studies Intended to Show Equivalence) text relocated here with minor modifications, as non-inferiority studies would have primary analysis designed to test this hypothesis with results presented in Section 11.1 rather than ICH E3 Section 11.4.2.7.
The endpoints defined for the study may consist of continuous variables (e.g. mean blood pressure or depression scale score), categorical responses (e.g. cure of an infection), or survival data (time-to-progression in an oncology study) amongst others. Results may need to be presented from different analyses in order to address the primary and secondary objectives of the study. Results from analysis of related variables or additional timepoints may be presented to support the primary and secondary analyses. For example even if one variable receives primary attention (e.g. in a blood pressure study, supine blood pressure at Week x), other reasonable measures (e.g. standing blood pressure and blood pressures at other particular times) should be assessed, at least briefly. In addition, the time course of response should be described, if possible.

If any critical measurements or assessments of efficacy or safety outcomes were made by more than one party (e.g. both the Investigator and an expert committee may offer an opinion on whether a subject had an acute infarction), overall differences between the ratings should be shown and each subject having disparate assessments should be identified, without compromising subject identity. The data for these individual subjects with disparate assessments must not be displayed by centre, nor must verbatim text be reproduced in the CSR text. The assessments used should be clear in all analyses.

In many cases, efficacy and safety endpoints are difficult to distinguish (e.g. deaths in a fatal disease study). Many of the principles addressed below should be adopted for critical safety measures as well.

Any analyses not specified in the protocol or SAP (i.e. post-hoc analyses) must be distinguished from pre-planned analyses, for example, in Section 11 (Efficacy and Other Evaluations), or these may be included in Appendix 16.1.9. Further guidance on Appendix 16.1.9 may also be found in Annex IV.

For a multicentre study, where appropriate, data display – especially the larger sites – has been omitted as this is covered in Section 11.2.4 (ICH E3 Section 11.4.2.4 Multicentre Studies).

Comment [A349]: ICH E3 text ‘Analyses based on…’ is clarified as meaning ‘The endpoints defined for the study may consist of…’

Comment [A350]: Added ‘survival data’ to show variables are not limited to continuous and categorical.

Comment [A351]: Rewording emphasises that CSR may need to present results from different types of analyses to address all protocol objectives.

Comment [A352]: ICH text ‘Efficacy and Other Evaluations)’ is clarified as meaning ‘The endpoints defined for the study may consist of…’

Comment [A353]: Consider for PPD impact: Subject numbers may be created using a centre identifier component. Subject re-identification, particularly for centres entering small numbers of study subjects, may be possible through a subject number that includes a centre identifier component. Where individual subject numbers are presented in the ‘primary use CSR’, it is recommended that these are fully redacted in the ‘secondary use CSR’ for public disclosure. In all cases, the entire subject number – including any centre identifier component – should be redacted.

Comment [A354]: Consider for PPD impact: Investigator verbatim text may include clues to the identity of the subject. If relevant verbatim text is paraphrased in ‘primary use CSR’, this will minimise the need for piecemeal redaction in the ‘secondary use CSR’.

Comment [A355]: ICH E3 does not mention possible post-hoc efficacy analyses. Clarification is added to ensure reporting of post-hoc analyses - in the main CSR or Appendix 16.1.9, as the Sponsor deems appropriate – is not overlooked. In some cases, it may be preferable to fully integrate post-hoc results and conclusions, (e.g. if a better sequencing or genotyping method becomes available after database lock, and post-hoc analyses use this new method to more precisely define subject subgroups) so that post-hoc data are located within the appropriate results section. There must be clear identification that these are post-hoc data. It should be noted that with such an integrated results presentation, there is risk of losing the distinction that some of those results (post-hoc) are subject to a greater degree of bias than those results for pre-planned analyses - because they were performed post-unblinding.

Comment [A356]: ICH text ‘Core Reference text’ is clarified as meaning ‘The endpoints defined for the study may consist of…’
The presentation of results may be split into example sub-sections, the inclusion and order of which should reflect the design of the individual study.

11.1.1 Primary Efficacy Endpoint

11.1.2 Secondary Efficacy Endpoints

11.1.3 Other Efficacy Endpoints

If applicable. Include exploratory efficacy endpoints.

11.1.4 Post-hoc Analyses

If applicable, and if not integral to, for example, Sections 11.1.1-11.1.3.

11.2 RESULTS OF STATISTICAL ISSUES ENCOUNTERED DURING THE ANALYSIS

The statistical analysis used should be described for clinical and statistical reviewers in the text of the report, with detailed documentation of statistical methods (see Annex IV) presented in Appendix 16.1.9 and outlined in, for example, Section 9.5 (Efficacy and Safety Variables). Important features of the analysis including adjustments made for demographic or baseline measurements or concomitant therapy; handling of withdrawals, discontinuations, and missing data; adjustments for interim analyses; special analyses of multicentre studies; and adjustments for multiple comparisons should be discussed. Any changes in the analysis made after unblinding should be identified. In addition to the general discussion, the afore-mentioned specific issues should be addressed (unless not applicable) including the results of any analyses performed to address those specific statistical issues. If no such issues arose during the study, then a statement can be added to the effect of ‘No statistical issues arose during the analysis of the study data.’

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
11.2.1 Adjustments for Covariates

The results of analyses investigating the impact of covariates should be discussed here with supportive information (e.g., analysis of covariance [ANCOVA] or Cox regression output) included in the detailed documentation of statistical methods in Appendix 16.1.9. If the covariates or methods used in these analyses differed from those planned in the SAP, the differences should be explained and the results presented.\[\]

11.2.2 Handling of Withdrawals, Discontinuations or Missing Data

There are several factors that may affect withdrawal and/or discontinuation rates. These include the duration of the study, the nature of the disease, the efficacy and toxicity of the drug under study and other factors that are not treatment related. Ignoring the subjects who withdrew or discontinued and drawing conclusions based on the results of any such repeat analyses should be presented by centre, even though the combined analysis is the primary one. If the covariates or methods used in these analyses differently from those planned in the SAP, this should be noted and discussed, considering such possibilities as the effect of centre, may be difficult to determine, possible effects should be explored as fully as possible.

Analyses may be repeated for the population of randomised subjects with any different covariates or methods used in these analyses differed from those planned in the study report (e.g. ANCOVA or Cox regression output) should be included in the detailed documentation of statistical methods. This is clarified.

11.2.3 Interim Analyses and Data Monitoring

A summary of the results from any interim analyses or a cross-reference to the results (e.g. an interim study report) should be included.\[\]

11.2.4 Multicentre Studies

If appropriate, demographic, baseline and post-baseline data, as well as efficacy data, may be presented by centre, even though the combined analysis is the primary one. The effect of centre, the significance of the interaction term and any extreme or opposite results among centres should be noted and discussed, considering such possibilities as differences in study conduct, subject characteristics or clinical settings. The centres should have sufficient numbers of subjects to make such analysis feasible.\[\]
ICH E3 Section 11.2.5 text

**Multiple Comparison/Multiplicity**

If adjustments for multiple comparisons/multiplicity have been made, the results of the analyses may have already been presented as part of the results for primary, and secondary if applicable, endpoints. If not already presented elsewhere then results arising out of multiple testing may be presented here.

**Use of an “Efficacy Subset” of Subjects**

Particular attention should be devoted to the effects of excluding subjects with available data from analyses because of poor compliance, missed visits, ineligibility, or any other reason considered to constitute an important protocol deviation, and the results presented. An analysis using all available data should be carried out for all studies intended to establish efficacy, and the results presented. In general, it is advantageous to demonstrate robustness of the principal study conclusions with respect to alternative choices of subject populations for analysis. Any substantial differences resulting from the choice of subject population for analysis should be explicitly discussed.

**Examination of Subgroups**

If the size of the study permits it, pre-defined subgroups based on important demographic or baseline data should be examined for unusually large or small responses and the results presented, e.g. comparison of effects by age group, sex, or race, by severity or prognostic groups, by history of prior treatment with a drug of the same class, etc. If these analyses were not carried out because the study was too small it should be noted. These analyses are not intended to “salvage” an otherwise non-supportive study but may suggest hypotheses worth examining in other studies or be helpful in refining labelling information, subject selection, dose selection, etc. Where there is a prior hypothesis of a treatment effect in a particular subgroup, this hypothesis and its assessment should be part of the planned statistical analysis reported, for example, in Section 9.7 (Statistical Methods Planned in the Protocol and Determination of Sample Size).

*Deliberate white space to allow comments on right hand side of this page to be shown in full*
11.2.8 Tabulation of Individual Response Data

In addition to tables and graphs representing group data, individual response data and other relevant study information should be presented in tables.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

Include only a cross-reference to Appendix 16.2.6 that presents the individual efficacy response data.

11.3 PHARMACOKINETIC, PHARMACODYNAMIC AND OTHER ANALYSES RESULTS

Pharmacokinetic and PD (including biomarkers) data, etc. may be included using the following (or adapted) example subheadings.

Comment [A386]: The text in this section from ICH E3 Section 11.4.3 relates to creation of listings and is primarily used by statisticians. It does not appear in any other guidance document than ICH E3. Clarification is given that only a cross-reference is required to the relevant data in the text of the CSR. The actual relevant ICH E3 Section 11.4.3 (Tabulation of Individual Response Data) text and for ICH E3 Section 11.4.6 (By-patient displays) is relocated to Annex IV.

Comment [A387]: Consider for PPD impact: For studies that examine small subpopulations using genetic markers, particularly at a centre level, it will be virtually impossible to prevent subject de-identification. Caution is advised to avoid de-identification, particularly in such cases. See also March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 36 of 91, which states: ‘Clinical trials conducted on rare diseases and on small populations may have a high risk of re-identification. Therefore, specific attention should be given to these scenarios…. This approach is also applicable to genetic information and low frequency events (e.g. rare events, extreme values, unusual treatments, pregnancy outcomes).’

Comment [A388]: Consider for PPD impact: Consideration of data presentations that achieve anonymity in the ‘primary use CSR’ for regulatory review will minimise the need for piecemeal redaction in the ‘secondary use CSR’ for public disclosure.

Comment [A389]: ICH E3 Section 11.3 (Measurements of Treatment Compliance) relocated to Section 10.5. Treatment compliance relates to all study subjects, not just those with efficacy data.

Comment [A390]: Section title is added to add clarity on where to report PK, PD and other data, remembering that if any of these represent the primary objective/endpoint of the study, adapt report structure accordingly: see Clarification on general approach to report structuring note in Section 9.5.
11.3.1 Drug Dose, Drug Concentration and Relationships to Response

Include reporting of the results of drug concentration (PK) data.

When the dosage in each subject can vary, the actual doses received by subjects should be shown and individual subject’s doses should be tabulated. Although studies not designed as dose-response studies may have limited ability to contribute dose-response information, the available data should be examined for whatever information they can yield. In examining the dose response, it may be helpful to calculate dose as mg/kg body weight or mg/m² body surface.

Drug concentration information, if available, should also be tabulated (Appendix 16.2.5), analysed in PK terms and, if possible, related to response. If any PK data (e.g. concentration at the time of an event, Cmax, AUC) is pertinent in individual subjects for correlation with AEs or changes in laboratory values (Appendix 16.2.5), this should be mentioned.


If any PK modelling has been undertaken, the top-line results should be included.

11.3.2 Drug-Drug and Drug-Disease Interactions

Any apparent relationship between response and concomitant therapy and between response and past and/or concurrent illness should be described.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
11.3.3 Other Endpoints

Other study-specific endpoints (for example, PD [which may include biomarkers], pharmacogenomics, quality of life and pharmacoeconomic endpoints) may be described.

11.4 EFFICACY RESULTS SUMMARY

Include a bullet list summarising the main efficacy (and/or other relevant) results of the study, and without interpretation or drawing of conclusions.

Comment [A399]: To allow inclusion of 'other endpoints' such as those listed


Comment [A401]: Suggest to adapt the title to suit study design. For e.g. a study with no efficacy but with a PK component, the heading could be renamed 'Pharmacokinetic Results Summary'.

Comment [A402]: ICH E3 has Section 11.4.7 (Efficacy Conclusions). Suggest the inclusion of 'Efficacy Results Summary' and 'Safety Results Summary' sub-sections, directly after the respective main results sections. Note that these suggested sections do not include the word 'conclusions' and should not include any interpretation or conclusions but should merely (bullet) summarise the main results. Such summaries are useful for writing the Synopsis and other related sections (e.g. Discussion and Overall Conclusions).

It should be noted that these example sub-sections can be omitted if desired. The important point is NOT to have conclusions drawn in 2 separate places in the report.
12. SAFETY EVALUATION

Analysis of safety-related data can be considered at three levels. First, the extent of exposure (dose, duration, number of subjects) should be examined to determine the degree to which safety can be assessed from the study. Second, the more common AEs, laboratory test changes, etc. should be identified, classified in some reasonable way, compared for treatment groups and analysed, as appropriate, for factors that may affect the frequency of adverse reactions/events, such as time dependence, relation to demographic characteristics, relation to dose or drug concentration, etc. Finally, SAEs and other clinically meaningful AEs should be identified, usually by close examination of subjects who left the study prematurely because of an AE, whether or not identified as drug related, or who died.

The ICH E2A Guideline on Clinical Safety Data Management; Definitions and Standards for Expedited Reporting (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf) defines SAEs as follows: A “serious adverse event” (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

For the purpose of this guideline, “other clinically meaningful AEs” include marked haematological and other laboratory abnormalities plus any AEs that led to an intervention, including withdrawal of drug treatment, dose reduction or notable additional concomitant therapy.

In the following sections, three kinds of analysis and display are called for:

1) Summarised data, often using tables and graphical presentations presented in the main body of the report
2) Listings of individual subject data, and
3) Narrative statements of events of particular interest. Narratives may include verbatim Investigator text or text combinations that may contribute to de-anonymisation.

Comment [A403]: See Clarification on general approach to report structuring note in Section 9.5.

Comment [A404]: Extent of exposure may also be relevant for analysis of efficacy-related data and is therefore more appropriately relocated to Section 10. (Study Subjects). Consider cross-referencing to content on “Study Subjects”.

Comment [A405]: ICH E3 uses ‘other significant AEs’. Suggest not to use the term ‘significant’ by itself. Use a descriptor before significant, e.g. statistically significant, clinically significant. Alternative phraseology could include ‘clinically relevant’ or ‘clinically meaningful’ – latter is used in CORE Reference. Explain any wording choices.

Comment [A406]: Clarification – ‘other clinically meaningful AEs’ includes discontinuations due to AEs and other AEs of special interest (which include marked haematological and other laboratory abnormalities and AEs leading to intervention, dose reduction or notable additional concomitant treatment) – as indicated in 3rd paragraph of this section (below).

Comment [A407]: ICH E3 uses ‘other significant AEs’.

Comment [A408]: Consider for PPD impact: ICH E3 states that narratives may be placed in Section 12.3.2 (i.e. integral to the main CSR text; CORE Reference Section 12.2.2) or in Section 14.3.3 (i.e. in the end-of-text tables section, subordinate to the main CSR text). Suggest that placement in Section 14.3.3 could ease redaction in the ‘secondary use CSR’ for public disclosure in regions where the entire Section could be redacted. Note that in the EU, March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) Chapter 2, Section 2.2 states that ‘Case narratives should not be removed or redacted in full regardless of their location within the clinical reports (body of the report or listings). They should be instead anonymised’. For narratives it is particularly important to consider data presentations that maintain data meaning, remain in context, AND conform to current minimum standards for de-identifying data.

In regions where full narrative redaction is not allowed (i.e. EU), for studies with large numbers of narratives, the narratives should be placed in Section 14.3.3 so as not to interrupt the flow of CSR text.
If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

In all tabulations and analyses, events associated with Test Product and/or Control Product should be displayed.

All AEs for each subject, including the same event on several occasions, should be listed in Appendix 16.2.7, giving both preferred term and the original (verbatim) term used by the Investigator.

The listing should be by Investigator and by treatment group and should include:

- Subject identifier
- Age, race, sex, weight (height, if relevant)
- The AE (preferred term, verbatim term)
- Duration of the AE
- Severity (e.g. mild, moderate, severe)
- Seriousness (serious/non-serious)
- Action taken (e.g. none, dose reduced, treatment stopped, specific treatment instituted etc.)
- Outcome (e.g. Council for International Organisations of Medical Sciences [CIOMS] format)
- Causality assessment (e.g. related/not related). How this was determined should be described in the protocol.
- Date of onset or date of clinic visit at which the event was discovered
- Timing of onset of the AE in relation to last dose of Investigational Product (when applicable)
- Duration of Investigational Product treatment
- Investigational Product at time of event or most recent Investigational Product taken
- Investigational Product dose in absolute amount, mg/kg or mg/m² at time of event.

Any abbreviations and codes should be clearly explained at the beginning of the listing or, preferably, on each page.
12.1 ADVERSE EVENTS

Where AE summarisations are presented, the counting rules must be clearly explained (e.g. in a footnote). It should also be clearly stated if all AEs are included or just treatment-emergent AEs (TEAEs). The definition of a TEAE should be provided, for example, in Section 9.7 (Statistical Analysis Methods Planned in the Protocol and Determination of Sample Size). If there is a prior agreement with the regulatory authority to consider specified events differently, it should be documented, for example, in Section 7 (Introduction) and Section 9.5.1 (Efficacy and Safety Measurements Assessed and Schedule of Assessments). The tables should include changes in vital occurrence and laboratory changes that were considered serious TEAEs or other significant TEAEs. If relevant to the study, pre- and post-study AEs can also be presented or referenced in the end-of-text Section 14 (Tables and Figures) tables.

The ‘all AEs’ tabular summarisation should be restricted to Section 14 (Tables and Figures) and referenced in-text. It should not be duplicated in the main CSR text. All TEAEs (including events likely to be related to the underlying disease or likely to represent concomitant illness) should be displayed in summary tables (Section 14.3.1 [Displays of Adverse Events]).

The end-of-text tables in Section 14 (Tables and Figures) should list each AE, the number of subjects in each treatment group in whom the event occurred and the rate of occurrence (i.e. AEs must be presented at both the subject and the event level). When treatments are cyclical, e.g. cancer chemotherapy, it may also be helpful to list results separately for each cycle. AEs should be grouped by Medical Dictionary for Regulatory Activities (MedDRA) system organ class. Each event may then be divided into defined severity categories (e.g. mild, moderate, severe), or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grades if these were used. The tables may also divide the AEs into those considered at least possibly related to Investigational Product use and those considered not related, or use some other causality scheme (e.g. unrelated or possibly, probably or definitely related). Even when such a causality assessment is used, the tables should include all AEs, whether or not considered Investigational Product-related, including events thought to represent concurrent illnesses. It should be clear whether the causality assessment was made by the Investigator or by the Sponsor. Subsequent analyses of the study or of the overall safety database may help to distinguish between AEs that are, or are not, considered Investigational Product-related. So that it is possible to analyse and evaluate the data in these tables, it is important to identify each subject having each AE. An example of such an end-of-text tabular presentation is shown in Annex V.

Comment [A418]: General information regarding treatment of AEs is in ICH E3 Sections 12.2.1 (Brief Specification of Adverse Events), 12.2.2 (Display of Adverse Events) and 12.2.3 (Analysis of Adverse Events), but actually applies to all AE sections. Therefore general information regarding treatment of AEs is moved to CORE Reference Section 12.1 (Adverse Events) since the text is applicable to all subsequent sub-sections.

Comment [A419]: The ICH E3 text ‘treatment-emergent signs and symptoms (TESS)’ has been replaced with the more common term ‘treatment-emergent AEs (TEAEs)’.

Note that “TEAE” may be used in statistical output, but it is reasonable in the CSR text to use “AE”, and define that as meaning treatment-emergent, for consciousness and readability.

Comment [A420]: Any prior agreement with the regulatory authority to consider specified events differently than TEAEs should be documented. Clarification is given to state that if there is a prior agreement with the regulatory authority to consider specified events differently, it should be documented, for example, in Section 9.5.1 (Efficacy and Safety Measurements Assessed and Schedule of Assessments) and in Section 7 (Introduction).

Comment [A421]: This text is very long and can be summarised in a table if the CSR, so recommend it is placed in Section 14 if more than 1 page long. It may additionally be included in text if it is less.

Comment [A422]: ‘Rate of occurrence’ should prompt for events to be summarised at both the subject and event level. Clarification is given that both subjects and events should be summarised.

Comment [A423]: The ICH E3 term ‘body system’ is clarified, and the coding dictionary is named for clarity. See: http://icd.who.int.

Comment [A424]: Clarification to allow for (commonplace) use of grades, and that the standard grading system for AEs is CTCAE. See: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/icc.htm.

Comment [A425]: Suggest to document in whose opinion causality is assigned. See note below on FDA perspective on causality assessment.

Comment [A426]: The entire paragraph is ICH E3 Section 12.2.2 (Display of Adverse Events) text with clarifications.

Comment [A427]: Relocation of the in situ tabular presentation to Annex V as this refers to an end-of-text table.
In presenting TEAEs, it is important both to display the original terms used by the Investigator (verbatim term) in the listings and to attempt to group related events (i.e. events that probably represent the same phenomena) in the summary tables, so that the true occurrence rate is not obscured. One way to do this is with a standard adverse reaction/events dictionary. The dictionary used, including version number, should be specified in a footnote to each listing or table. The MedDRA is a user-responsive technology. If dictionary terms do not fit study requirements, MedDRA encourages submission of a Change Request. See http://www.meddra.org/sites/default/files/page/documents/6282-330_changereq_info.pdf.

12.1.1 Brief Summary of Adverse Events

The overall AE experience in the study should be described in a brief narrative. Inclusion of a brief summary table is encouraged if this adds clarity, supported by more detailed tabulations and analyses.

The brief summary table should describe the overall AE experience in the study and should include the numbers of subjects with at least one TEAE, related TEAE and severe TEAE; and the numbers of subjects who died and who experienced a treatment-emergent SAE, or discontinued Investigational Product or withdrew from the study due to a TEAE. Relevant treatment group differences and trends with increasing dose should be mentioned.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
12.1.2 Most Frequently Reported Adverse Events

The main presentation required is that of the most frequently reported TEAEs, regardless of relationship to treatment, at the subject and event level comparing treatment and control groups, not including subject identifying numbers or verbatim AE terms. The presentation should be limited to relatively common TEAEs (e.g. those in at least 1% or 5% of the treated group, or another defined threshold appropriate to the study).

12.1.3 Categorisation of All Adverse Events

The categorisation of AEs requires summarisations of all TEAEs by relationship/causality to Investigational Product by severity, together with any other analyses of all TEAEs thought to be relevant. Categorisation of all TEAEs will facilitate review of AE occurrence in all treatment groups. For large studies, it may also be appropriate to present these analyses by the most frequently reported TEAEs.

The basic display of TEAE rates, located in Section 14.3.1 (Displays of Adverse Events) of the report, should be used to compare rates in treatment and control groups, combining the event severity categories and the relationship/causality categories, leading to a simpler side-by-side comparison of treatment groups.

Comment [A438]: ICH E3 Section 12.2.2 (Display of Adverse Events) versus Section 12.2.3 (Analysis of Adverse Events). It is not sufficiently clear what content should be presented in each. Adaptation of the section titles, together with more explicit instruction on content is provided in line with ICH E3 2012 Q & A guidance. This section summarises the main presentation of interest, namely the most frequently reported TEAEs.

Comment [A439]: See ICH E3 2012 Q & A, Point 6 which clarifies that the full listing of AEs with subject IDs should NOT be included in the main CSR body. ICH E3 Q & A 2012 states: "The body of the CSR should include a summary table of relatively common adverse events – those occurring in at least a particular percentage of subjects who received the investigational drug. This summary tabulation compares treatment and control groups and does not include subject identifying numbers or verbatim adverse event terms. Note that ICH E3 2012 Q & A states that verbatim terms and subject IDs should be included in the listings. Further: "Of the example table provided in Section 12.2.2 of the guideline is not meant to be presented in Section 12.2.2 of the report in Section 14.3.1, which is not part of the text of the clinical study report where 'the guideline' referred to is ICH E3."

Comment [A440]: As stated above, ICH E3 is not clear in what should be presented in ICH E3 Sections 12.2.2 and 12.2.3. CORE Reference Section 12.1.3 (Categorisation of All Adverse Events) summarises ALL TEAEs, by relationship/causality and severity.

Comment [A441]: For submissions in the US, FDA holds that the Sponsor (rather than Investigator) should make final decisions on causality given their access to a complete dataset of safety data across multiple sites. See NEJM Perspective article from key FDA CDER leaders: http://www.nejm.org/doi/full/10.1056/NEJMp1103052 that explains the reporting regulation 21 CFR 312.32 (c) (A): http://www.ecfr.gov/cgi-bin/text-idx?SID=a27a333f18babca571f1a6f545dce&mc=true&node=se21.5.312.328&rgn=div8 associate d with the (at that time) new requirements for clinical trial safety reports.

Comment [A442]: ICH E3 does not include a sub-section for discontinuations due to AEs and these may be grouped under ‘Other Clinically Meaningful Adverse Events’. To include these in the main AE section is a perfectly reasonable approach. An alternative (shown below) is to pull discontinuations due to AEs out as a separate subsection leaving ‘other clinically meaningful adverse events’ to include other (marked) abnormalities.

Comment [A443]: ICH E3 specifies ‘AEs’. Clarified as ‘TEAEs’ in this and subsequent paragraphs.

Comment [A444]: ICH E3 Section 12.2.3 text presented here is consolidated with no loss of meaning.
In addition, although this is usually best done as a pooled analysis across multiple studies, if study size and design permit, it may be useful to examine the more common TEAEs that seem to be related to Investigational Product–related for relationship to dosage and to mg/kg or mg/m² dose, to dose regimen, to duration of treatment, to total dose, to demographic characteristics (such as age, sex, race), to other baseline features (such as renal status), to efficacy outcomes and to Investigational Product concentration.

It may also be useful to examine time of onset and duration of TEAEs and describe prevalence over time. A variety of additional analyses may be suggested by the study results or by the pharmacology of the Investigational Product.

It is not intended that every TEAE be subjected to rigorous statistical evaluation. It may be apparent from initial display and inspection of the data that a relationship to demographic or other baseline features is not present. If the studies are small and if the number of events is relatively small, it may be sufficient to limit analyses to a comparison of Test Product and Control Product.

Under certain circumstances, life table or similar analyses may be more informative than reporting of crude TEAE rates. When treatments are cyclical, e.g. cancer chemotherapy, it may also be helpful to analyse results separately for each cycle.

Groups of AEs that might warrant further investigation should be mentioned.

Present a reference to the relevant named end-of-text AE listings in Appendix 16.2.7.

12.2 ANALYSIS OF DEATHS, OTHER SERIOUS ADVERSE EVENTS, AND OTHER CLINICALLY MEANINGFUL ADVERSE EVENTS

Deaths, other serious AEs, and other clinically meaningful AEs – which may include discontinuations due to AEs and other AEs of special interest – deserve special attention.

12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse Events and Other Adverse Events of Special Interest

Relevant listings, containing the same information as described in, for example, Section 12 (Safety Evaluations), should be provided for deaths, other SAEs, and clinically meaningful AEs, which may include AEs leading to permanent discontinuation of Investigational Product and other AEs of Special Interest – in Section 14.3.2 (Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events).

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
12.2.1.1 Deaths

All deaths during the study, including the pre-treatment (Screening) period, post-treatment follow-up period, and deaths that resulted from a process that began during the study, should be listed by subject in Section 14.3.2 (Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events). Consider distinguishing deaths that are the result of an AE (automatically an SAE) from deaths due to disease progression (this is permissible in some studies, e.g. studies where death is an endpoint). Describe deaths as the data allows. If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

12.2.1.2 Other Serious Adverse Events

All SAEs (other than death but including the SAEs temporally associated with or preceding the deaths) should be listed in Section 14.3.2 (Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events). The listing should include laboratory abnormalities, abnormal vital signs and abnormal physical observations that were considered SAEs. Describe (non-death) SAEs as the data allows. If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

12.2.1.3 Discontinuations Due to Adverse Events

Discontinuations of Investigational Product due to AEs should be described. In some cases it may be relevant to separate out AEs leading to discontinuation of Investigational Product (i.e. Test Product or Control Product) and AEs leading to withdrawal of the subject from the study.

<Deliberate white space to allow comments on right hand side of next page to be shown in full>
12.2.1.4 Other Adverse Events of Special Interest

Marked haematological and other laboratory abnormalities (other than those meeting the definition of serious), and events that led to an intervention, including dose reduction or those that needed notable concomitant therapy (other than those reported as serious), should be listed in Section 14.3.2 (Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events). Sponsor-defined AEs of special interest may also be described here. Describe other AEs of special interest as the data allows. If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

12.2.2 Narratives of Deaths, Other Serious Adverse Events, and Certain Other Clinically Meaningful Adverse Events

There should be brief clinical narratives describing each death and each other SAE, unless it has been pre-agreed with the regulatory authority that narratives are not needed in some cases (e.g. deaths due to underlying disease or in studies where death is an endpoint). In cases of Regulatory Authority waiver or non-applicability, this should be explained.

Narratives for discontinuations due to AEs and those of the other clinically meaningful adverse events that are judged to be of special interest because of clinical importance should also be provided, as appropriate.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
These narratives should be subject-based and can be placed either in the text of the report or in Section 14.3.3, depending on their number. Events that were clearly unrelated to the Test Product may be omitted or described very briefly. In general, the narrative should include the following: the nature and intensity of event, the clinical course leading up to the event, with an indication of timing relevant to Investigational Product administration, relevant laboratory measurements, whether the Investigational Product was stopped and when, countermeasures, event outcome, post mortem findings, Investigator’s opinion on causality and Sponsor’s opinion on causality, if appropriate.

Comment [A471]: There is a need to distinguish between ‘safety’ narratives (per Suspect Adverse Reaction Reports required for direct regulatory reporting: e.g. CIOMS: http://www.cioms.ch/index.php/cioms-form) and MedWatch (http://www.fda.gov/Consumer/ConsumerUpdate/ucm110496.htm) and ‘clinical’ narratives (per CSR). Currently, some Sponsors reconcile the safety/pharmacovigilance database with the clinical database and provide the final Suspect Adverse Reaction Reports (CIOMS or MedWatch) in place of writing clinical CSR narratives. The difference between these two types of narratives is that the Suspect Adverse Reaction Reports are event-based and can have a string of updated information included as more information becomes available. In contrast, clinical CSR narratives are subject-based, and only the final information is presented. The widespread practice of including (clinical database reconciled) Suspect Adverse Reaction Reports in place of writing CSR narratives is therefore questionable and requires definitive instruction.

Note that Health Canada agree with subject-based narratives, adding that they ‘...should be comprehensive and include all the necessary information to present the full picture of the case. Sponsors may not comply with the request to include subject-based narratives, such as for very large trials with many narratives.

Comment [A472]: Consider for PPD impact: ICH E3 states that narratives may be placed in Section 12.3.2 (i.e. integral to the main CSR text; CORE Reference Section 12.2.2) or in Section 14.3.3 (i.e. in the end-of-text tables section, subordinate to the main CSR text). Suggest that placement in Section 14.3.3 could ease redaction in the ‘secondary use CSR’ for public disclosure in regions where the entire Section could be redacted. Note that in the EU, March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf. Chapter 2, Section 2.2) which states that ‘Case narratives should not be removed or redacted in full regardless of their location within the clinical reports (body of the report or listings). They should be instead anonymised.’ For narratives it is particularly important to consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data. In regions where full narrative redaction is not allowed (i.e. EU), for studies with large numbers of narratives, the narratives should be placed in Section 14.3.3 so as not to interrupt the flow of CSR text.

Comment [A473]: ICH E3 ‘test drug/investigational product’ clarified as ‘Test Product’.

Comment [A474]: Modified from ‘Test Drug/Investigational Product’.

Comment [A475]: Modification of ICH E3 term ‘drug’ to appropriate CORE Reference terminology.

Comment [A476]: Added ‘outcome’.

<table>
<thead>
<tr>
<th>ICH E3 text</th>
<th>ICH E3 2012 Q&amp;A text</th>
<th>CORE Reference text</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>[Right margin comment=RATIONALE]</td>
</tr>
</tbody>
</table>
Additional information can be obtained from the event-based Suspect Adverse Reaction Report, but these event-based safety narratives should not be used in place of the subject-based clinical narratives, even if the source safety/pharmacovigilance database is reconciled with the definitive study reporting clinical database.

In addition, the following narrative information, which may be tabulated, should be included:

- Subject identifier
- Age and sex of subject; general clinical condition of subject, if appropriate
- Disease being treated (if the same for all subjects, this is not required) with duration (of current episode) of illness
- Relevant concomitant/previous illnesses with details of occurrence/duration
- Relevant concomitant/previous medication with details of dosage
- Investigational Product administered, and dose, if this varied among subjects, and length of time administered.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.


Comment [A478]: To allow for tabulation of certain narrative information at the beginning of each narrative in order to ease reader comprehension.

Comment [A479]: Modification of ICH E3 term ‘Test Drug/investigational Product’ to appropriate CORE Reference terminology.

Comment [A480]: Omitted ICH E3 word ‘drug’.

Comment [A481]: Consider for PPD impact: Consideration of data presentations that achieve anonymity in the ‘primary use CSR’ for regulatory review will minimise the need for piecemeal redaction in the ‘secondary use CSR’ for public disclosure.

Comment [A482]: Consider for PPD impact: One particular example of how careful narrative data presentation in the ‘primary use CSR’ can maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data follows:

Calendar dates for narrative events would not be allowed in the ‘secondary use CSR’ for public disclosure as these may increase the chance of subject re-identification. In the ‘primary use CSR’ for regulatory review, only refer to study days and do not refer to calendar dates. This approach captures event timing (necessary to inform the assessment of temporal association) in the ‘primary use CSR’ without increasing reduction need in the ‘secondary use CSR’. 

Note however, that this may need special consideration for some illnesses where dates can be important, for example, allergy and seasonal affective disorder where alternative presentations should be considered that still avoid the actual date.

Comment [A483]: ICH E3 Section 12.3.3 (Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events) has been omitted as this separate subsection was not deemed necessary in light of the suggested content included in, for example, Section 12.2 above.
12.3 CLINICAL LABORATORY EVALUATION

12.3.1 Individual Laboratory Measurements by Subject and Abnormal Laboratory Values

Cross-reference to the relevant named end-of-text laboratory listings in Section 14 (Tables and Figures).

12.3.2 Evaluation of Laboratory Values

The necessary evaluation of laboratory values must in part be determined by the results seen, but, in general, the following analyses should be provided. For each analysis, comparison of the treatment and control groups should be carried out, as appropriate, and as compatible with study size.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A484]: ICH E3 Section 12.4.1 title mentions 16.2.8 and 14.3.4, but these may add confusion so have been omitted, as has the word "Listing" from the title of this section. This entire section actually relates to the end text Appendix 16.2 listings, so all that is ever included in CSR text per ICH E3 Section 12.4.1 (Listing of Individual Laboratory Measurements by Patient and Abnormal Laboratory Values) is a cross-reference to the Appendix 16.2 listings. The text is moved to Annex IV because it informs statisticians on how to present the laboratory data listings, and is not relevant directly to creation of CSR text.


'EMA notes that under ICH E3, the CSRs may contain individual patient data listings … even within the body of the report. For example, these … may be contained in CSR section 14.3.4 Abnormal Laboratory Value Listing (Per Patient/per Visit), as well as elsewhere in the CSR body … EMA considers that each per patient/per visit line listings fall outside the scope of phase 1 of the Policy (0070) and, therefore, it is acceptable to have them removed from the clinical reports prepared for publication at this stage of the implementation. All these per patient/per visit line listings will be falling in the scope of phase 2 of the Policy.'

Per page 6 of 91, Policy 0070 is in two phases. Phase 1 (01 January 20 pertains to publication of CSRs only. Phase 2, which will be implemented at a later stage, pertains to the publishing of individual patient data.

Comment [A485]: The text in ICH E3 Section 12.4.1 relates to Appendix 16.2 listings, and not to what should appear in CSR text. The text is therefore relocated to Annex IV Section C.

Comment [A486]: ICH E3 Section 12.4.2 title (Evaluation of Each Laboratory Parameter) is adapted.

Comment [A487]: Consider for PPD impact: In case individual cases are described in the 'primary use CSR', protect subject anonymity in the 'secondary use CSR' for public disclosure. Also consider the possibility that individual subject laboratory numerical data in the 'primary use CSR' may, in the 'secondary use CSR', require full redaction or modification by substitution with more general text such as 'elevated', 'normalised' etc. This will depend on the individual Sponsor.

Comment [A488]: ICH E3 text 'In addition, normal laboratory ranges should be given for each analysis' has been omitted as it is not possible to ascribe normal ranges for analyses – i.e. summary laboratory data. Normal ranges can only ever apply to individual subject results. This is mentioned in Annex IV.

Comment [A489]: Consider for PPD impact: Consideration of data presentations that achieve anonymity in the 'primary use CSR' for regulatory review will minimise the need for piecemeal redaction in the 'secondary use CSR' for public disclosure.
Within each of the following topic areas (see for example Section 12.3.2.1 [Laboratory Values Over Time], Section 12.3.2.2 [Individual Subject Changes in Laboratory Values] and Section 12.3.2.3 [Individual Clinically Meaningful Laboratory Abnormalities]), it may add clarity to separate haematology, chemistry and urinalysis, or any other laboratory test categories applicable to the study. Alternatively, present all analyses for a particular category of laboratory values first followed by similar presentations for the other categories.

12.3.2.1 Laboratory Values Over Time

For each parameter at each time over the course of the study (e.g. at each visit) the following should be described: the group mean or median values and/or change from baseline (absolute or percentage change as appropriate to the data) over time, and the range of values. Note any change within the treatment groups over time. Relevant treatment group differences. Graphical presentation of laboratory values may be used and can be preferable, especially where the number of samples allows for such a presentation.

12.3.2.2 Individual Subject Changes in Laboratory Values

An analysis of individual subject changes by treatment group should be given. A variety of approaches may be used, including:

1. “Shift tables” – These tables show the number of subjects who are low, normal or high at baseline and then at selected time intervals. These selected time intervals may be scheduled visits or a derived time point such as the most extreme on-treatment value. Applicable laboratory results may be categorised based on NCI CTCAE grades.

2. Tables showing the number or proportion of subjects who had a change in parameter of a predetermined size at selected time intervals. For example, for blood urea nitrogen (BUN), it might be decided that a change of more than 10 mg/dL BUN should be noted, or laboratory values twice the upper limit of normal, five times the upper limit etc. (choices should be explained). For this parameter, the number of subjects having a change less than this or greater than this would be shown for one or more visits, usually grouping changes of a certain size at selected time intervals.

3. A graph comparing the initial value and the on-treatment values of a laboratory measurement for each subject by locating the point defined by the initial value on the abscissa and a subsequent value on the ordinate. If no changes occur, the point representing each subject will be located on the 45° line. A general shift to higher values will show a clustering of points above the 45° line. As this display usually shows only a single time point for a single treatment, interpretation requires a time series of these plots for treatment and control groups. Alternatively, the display could show baseline and a derived time point such as most extreme on-treatment value. Data may be presented using the observed values or may be expressed as multiples of the normal range limits. These displays identify outliers readily (it is useful to include subject identifiers for the outliers).

Discussion of these outputs should mention common (≥XX% subjects) shifts in the active treatment group from normal at baseline to an abnormal result post-baseline at the timepoint of interest. The focus should be on laboratory changes that are clinically

Comment [A490]: The structure for content in ICH E3 Section 12.4.2 (Evaluation of Each Laboratory Parameter) is not clear. CORE Reference suggests content breakdown into hematology, chemistry and urinalysis within each of the 3 examples (Section 12.3.2.1-12.3.2.3). Alternatively, present all analyses for haematology values first (means over time, shifts, potentially clinically meaningful abnormalities) followed by similar presentations for chemistry and urinalysis parameters.

Comment [A491]: ICH E3 text on upper limits is relocated more appropriately to the content of the section below.

Comment [A492]: Clarification on detail of data presentation is provided.

Comment [A493]: Clarification that use of graphs, which can be visually more informative than tables, if sample numbers allow – is acceptable.

Comment [A494]: Health Canada recommend keeping reference to shift tables, although reportedly many medical writers question their value.

Comment [A495]: ICH E3 instructional text does not state if the worst value or last value is of interest here. Clarified to suggest that worst value (most extreme on-treatment assessment) is of interest in most cases.

Comment [A496]: ICH E3 text does not mention that shifts in CTCAE toxicity grades may also be explored. Clarification is added.

Comment [A497]: Clarification of the ICH E3 term ‘fraction of patients’.

Comment [A498]: Clarification to suggest shifts of interest (detail is included in ICH E3 text under Section 12.4.2.1 [Laboratory Values Over Time]) but is more appropriately placed here.

Comment [A499]: Expansion of the existing detail on graphical presentations as it did not specify the values that might be presented, e.g. may use values expressed as multiples of normal range limits.

Comment [A500]: Consider for PPD impact.

In-text presentations of such displays must give careful consideration to inclusion of subject identifiers (which should not include centre identifier or any other information that could potentially compromise subject anonymity). Care with presentation in the ‘primary use CSR’ for regulatory review will minimise the need for redaction in the ‘secondary use CSR’ for public disclosure.

Comment [A501]: Clarification to distinguish between values outside the normal laboratory range compared to clinically meaningful values and changes.
meaningful. Relevant treatment group differences that raise potential safety issues should also be discussed.

12.3.2.3 Individual Clinically Meaningful Laboratory Abnormalities

Clinically meaningful changes (defined by the Sponsor) should usually be discussed. A narrative of each subject whose laboratory abnormality was considered an SAE and, in certain cases, led to discontinuation of Investigational Product or was considered to be an ‘other clinically meaningful AE’, should be provided under Section 12.2.2 or Section 14.3.3.

Two common approaches are used to assess individual clinically meaningful abnormalities. A clear description of the approach used is required:

The first approach uses Sponsor-defined abnormality criteria or an established toxicity grading scale such as the NCI CTCAE [http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm](http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm). When toxicity grading scales are used (e.g. NCI CTCAE), changes graded as at least severe (Grade 3 or above) should be discussed regardless of seriousness.

The second approach uses the Investigator’s assessment of whether an abnormal value was clinically meaningful or not (usually a check box next to the laboratory abnormality in the CRF). In this case, the same abnormality may be judged clinically meaningful for one subject but not for another by the same Investigator, and may be judged clinically meaningful by one Investigator but not by another.

An in-text table with a list of subjects with clinically meaningful changes should be sourced from the by-subject listing of all abnormal laboratory values in Section 14.3.4 (Abnormal Laboratory Values Listing [Each Subject] – see Annex VI) and presented in text. An analysis of clinically meaningful changes, together with a recapitulation of discontinuations due to laboratory measurements, should be provided for each parameter. The trends and importance of any changes and likely relation to the Investigational Product should be assessed, e.g. by analysis of such features as relationship to dose, relationship to Investigational Product concentration, disappearance on continued therapy, positive dechallenge, positive rechallenge and the nature of concomitant therapy.

"[Deliberate white space to allow comments on right hand side of this page to be shown in full]"

---

ICH E3 text | ICH E3 2012 Q&A text | CORE Reference text | [Right margin comment=RATIONALE]

---

Comment [A502]: ICH E3 term ‘significant’ is standardised to ‘meaningful’ in CORE Reference.

Comment [A503]: Clarification: added the word ‘usually’ because it may not always be informed of certain abnormal findings, as for example, in a liver cancer study, it would not be expected to discuss all Grade 3 elevated liver function test values.

Comment [A504]: Consider for PPD impact: ICH E3 states that narratives may be placed in Section 12.3.2 (i.e. integral to the main CSR text; CORE Reference Section 12.2.2) or in Section 14.3.3 (i.e. in the end-of-text tables section, subordinate to the main CSR text). Suggest that placement in Section 14.3.3 could ease redaction in regions where the entire Section could be redacted. Note that in the EU, March 2016 EMA guidance on use of Policy 0070 [http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202612.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202612.pdf) states that ‘Case narratives should not be removed or redacted in full regardless of their location within the clinical reports (body of the report or listings). They should be, instead, anonymised.’ For narratives it is particularly important to consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data. In regions where full narrative redaction is not allowed (i.e. EU), for studies with large numbers of narratives, the narratives should be placed in Section 14.3.3 so as not to interrupt the flow of CSR text.

Comment [A505]: Gradating of laboratory events: the alternatives of Sponsor-defined or official grading scale (NCI CTCAE) versus Investigator assessment of clinical significance is explained for clarity, including (in the next paragraph) the need to capture abnormal clinically meaningful laboratory values at the time they arise (in the CRF).

Comment [A506]: Omission of ‘WHO’ and addition of ‘CTCAE’ for clarity.

Comment [A507]: This table (in reality a listing) may be far too long to place in-text for a late-phase study. If very long, the overview that it is meant to provide can be lost. Unless there are unusual findings, consider that this table/listing might be better left out of the CSR text. The decision will be study-dependent.

Comment [A508]: ICH E3 wording: The significance of the changes and likely relation to the treatment should be assessed” is clarified. The ICH E3 word ‘significance’ is substituted here with ‘importance’.
If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

12.4 VITAL SIGNS, PHYSICAL EXAMINATIONS, AND OTHER OBSERVATIONS RELATED TO SAFETY

Vital signs, physical examinations and other observations related to safety should be analysed and presented in a way similar to laboratory values. If there is evidence of an Investigational Product effect, any dose-response or Investigational Product concentration-response relationship or relationship to subject variables (e.g., disease, demographics, concomitant therapy) should be identified and the clinical relevance of the observation described. Particular attention should be given to changes not evaluated as efficacy variables and to those considered to be AEs.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

Example sub-sections may be as follows:

12.4.1 Vital Signs

Vital signs data may be described as for laboratory data, namely vital signs over time, individual subject changes and individual clinically meaningful abnormalities, if applicable.

12.4.2 Physical Examination Findings

Physical findings may be described noting treatment group differences and trends with increasing dose, if applicable.

12.4.3 Other Observations Related to Safety

Examples of safety assessments discussed may include: ECG, electroencephalography, x-ray, etc. The results may include means over time, shifts, incidence of marked/clinically meaningful abnormalities, etc. depending on the type of analyses used.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
12.5 SAFETY RESULTS SUMMARY

Include a bullet list summarising the main safety results of the study, and without interpretation or drawing of conclusions.

13. DISCUSSION AND OVERALL CONCLUSIONS

13.1 DISCUSSION

A good discussion section examines the implications of the data.

Explain any limitations of the trial, e.g. short treatment period, difficult to follow protocol, sources of potential bias and imprecisions that led to deviations and inconsistencies (e.g. delays in delivery of supplies to sites, large numbers of subjects in one or more sites that were not familiar with local language etc.).

If a structured benefit-risk methodology was used, this should be noted. If allowed concomitant therapy affected the outcome (see, for example, Section 9.4.6 [Prior and Concomitant Therapy]) due to drug-drug interaction or to direct effects on the study endpoints, discuss this and explain how the independent effects of concomitant and study therapies were ascertained.

The efficacy and safety results of the study and the relationship of risks and benefit should be briefly summarised and discussed, referring to specific data from the in-text tables, in-text figures and sections above as needed. Where data are referred to, there should be no cross-referencing to the CSR results sections. Instead, the actual data should be briefly presented in the text of, for example, Section 13 (Discussion and Overall Conclusions), alongside any discussion. The presentation should not simply repeat the description of results nor introduce new results, but explain what the results mean or what they may imply. The conduct of any relevant post-hoc analyses may be mentioned (clearly stating that the results are post-hoc), together with an explanation of their relevance for the current study results.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A519]: Discussion and conclusion sections may be merged if preferred. Here a suggestion is made to separate the two.

Comment [A520]: Added to provide clarification of the detail about benefit-risk assessment to include in the Discussion. The underlined text from the following ICH E3 extract is relocated from ICH E3 Section 11.4.1 (Analysis of Efficacy) as it is more appropriately placed in the Discussion. Treatment groups should be compared for all critical measures of efficacy (primary and secondary end-points, any pharmacodynamic end-points studied), as well as benefit/risk assessment(s) in each patient where these are utilized further. The underline text is paraphrased.

Comment [A521]: ICH E3 Section 9.4.7 (Prior and Concomitant Therapy) text is relocated more appropriately here to ensure discussion about possible drug interactions is not overlooked. Minor changes to the wording do not affect the meaning.

Comment [A522]: ICH E3 is unclear if referencing tables, figures and other sections within Section 13 (Discussion and Overall Conclusions) is acceptable - clarification that specific data from the preceding CSR sections may be presented in Section 13 if discussed in this section. Further clarification that Section 13 should stand alone without cross-reference to other CSR sections.

Comment [A523]: Addition to ensure relevant post-hoc findings are placed into context.
The discussion and conclusions should clearly identify any new or unexpected findings (without presenting any results not already presented in the CSR text sections above), comment on their importance and discuss any potential problems such as inconsistencies between related measures. The clinical relevance and importance of the results should also be discussed in the light of other relevant existing data. Without including a complete review of the therapeutic area, results should be placed in context with all relevant existing data. Any specific benefits or special precautions required for individual subjects or at-risk groups and any implications for the conduct of future studies should be identified. The impact of exclusions on the generalisability of the study should be discussed. Alternatively, such discussions may be reserved for summaries of safety and efficacy referring to the entire dossier (integrated summaries). The discussion section should be between two and five pages in length (although may be longer if there are multiple issues to address or shorter for early development studies).

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
The importance of deaths, other SAEs and clinically meaningful AEs leading to discontinuation of Investigational Product, dose reduction or institution of concomitant treatment should be assessed with respect to the safety of the Investigational Product. ‘Other clinically meaningful AEs’ may also include those of particular relevance because of clinical importance, depending on the treatment and the indication. Particular attention should be paid to whether any of these events may represent a previously unsuspected important adverse effect of the Investigational Product. For SAEs that appear of particular importance, it may be useful to use analyses to show their relation to time on Investigational Product and to assess their risk over time.

13.2 CONCLUSIONS

Conclusions should address the objectives of the study. They should be supported by the data in the report, taking into account statistical power considerations. The important conclusions concerning efficacy should be concisely stated in one or two short paragraphs. Any relevant post-hoc analysis conclusions may be presented but must be clearly indicated as being based on post-hoc analyses that must be interpreted with caution.

The overall safety evaluation of the Test Product should be determined with particular attention to events resulting in changes of dose or need for concomitant medication, SAEs, events resulting in discontinuation or withdrawal, and deaths. Any subjects or subject groups at increased risk should be identified and particular attention paid to potentially vulnerable subjects who may be present in small numbers, e.g. children, pregnant women, frail elderly, people with marked abnormalities of drug metabolism or excretion etc. There is a need to consider genetic markers, particularly if they predispose the subject to respond or to be resistant to the Test Product, or to experience SAEs. The implication of the safety evaluation for the possible uses of the Test Product should be described. Numerical data should not be specified in detail, but rather the overall conclusions should be drawn from these data.

Consider using bullet points for each objective/endpoint to ensure that the conclusions are clear and concise and that each objective/endpoint is addressed.

ICH E3 text
ICH E3 2012 Q&A text
CORE Reference text

[Right margin comment=RATIONALE]
14. TABLES AND FIGURES

Figures should be used to visually summarise the important results or to clarify results that are not easily understood from tables.

Important demographic, efficacy, safety data and any other data relevant to the study should be presented in summary tables or figures in the text of the report. All data presented in the CSR text must be available in Section 14 (Tables and Figures) and/or Appendix 16.2 (Subject Data Listings), and all tables and figures provided in Section 14 (Tables and Figures) should be referenced in the CSR. Tables and figures in Section 14 (Tables and Figures) that are not presented in the CSR text, because they are considered obtrusive because of size or number, should be presented here, cross-referenced in the text, along with supportive or additional figures, tables or listings.

The following information may be presented in this section of the core CSR. The following example sub-sectioning may be used:

14.1 DEMOGRAPHIC DATA

Summary tables and figures.

14.2 EFFICACY DATA

Summary figures and tables.

14.3 SAFETY DATA

Summary figures and tables.

14.3.1 Displays of Adverse Events

All AEs occurring after initiation of study treatments (including events likely to be related to the underlying disease or likely to represent concomitant illness, unless there is a prior agreement with the regulatory authority to consider specified events as disease related) should be displayed in summary tables (Section 14.3.1). The tables should include changes in vital signs and any laboratory changes that were considered SAEs or other clinically meaningful AEs.

In most cases, it will also be useful to describe TEAEs in such tables.

14.3.2 Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events

Any listings information presented in this section of the ‘primary use CSR’ for regulatory review should fully support the review process. Listings data presented in this section in the ‘secondary use CSR’ for public disclosure should conform to current minimum standards for de-identifying data through piecemeal redaction, or may be fully redacted, depending on current requirements of the region.

ICH E3 text  ICH E3 2012 Q&A text  CORE Reference text  [Right margin comment=RATIONALE]
14.3.3 Narratives of Deaths, Other Serious Adverse Events and Certain Other Clinically Meaningful Adverse Events

Narratives may be presented in this section.

If it is necessary to discuss any individual subject level information in text, consider data presentations that maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data.

Comment [A555]: In ICH E3 terminology is ‘significant’. Terminology standardised to ‘clinically meaningful’.

Comment [A556]: Also see full information on creation of narratives in Section 12.2.2 (Narratives of Deaths, Other Serious Adverse Events and Certain Other Clinically Meaningful Adverse Events).

Comment [A557]: Consider for PPD impact: ICH E3 states that narratives may be placed in Section 12.3.2 (i.e. integral to the main CSR text; CORE Reference Section 12.2.2) or in Section 14.3.3 (i.e. in the end-of-text tables section, subordinate to the main CSR text). Suggest that placement in Section 14.3.3 could ease redaction in the ‘secondary use CSR’ for public disclosure in regions where the entire Section could be redacted. Note that in the EU, March 2016 EMA guidance on use of Policy 0070. ([http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf). Chapter 2, Section 2.2) which states that ‘Case narratives should not be removed or redacted in full regardless of their location within the clinical reports (body of the report or listings). They should be instead anonymised’

In regions where full narrative redaction is not allowed (i.e. EU), for studies with large numbers of narratives, the narratives should be placed in Section 14.3.3 so as not to interrupt the flow of CSR text.

Comment [A558]: Consider for PPD impact: One particular example of how careful narrative data presentation in the ‘primary use CSR’ can maintain data meaning, remain in context AND conform to current minimum standards for de-identifying data follows:

Calendar dates for narrative events would not be allowed in the ‘secondary use CSR’ for public disclosure as these may increase the chance of subject re-identification. In the ‘primary use CSR’ for regulatory review, only refer to study days and do not refer to calendar dates. This approach captures event timing (necessary to inform the assessment of temporal association) in the ‘primary use CSR’ without increasing reduction need in the ‘secondary use CSR’.

Note however, that this may need special consideration for some illnesses where dates can be important, for example, allergy and seasonal affective disorder where alternative presentations should be considered that still avoid the actual date.
14.3.4 Data Listings (Each Subject) for Abnormal Clinically Meaningful Laboratory Values, Vital Signs, Physical Examinations and Other Observations Related to Safety

Any listings of information presented in this section of the ‘primary use CSR’ for regulatory review should fully support the review process. Listings data presented in this section in the ‘secondary use CSR’ for public disclosure should conform to current minimum standards for de-identifying data through piecemeal redaction, or may be fully redacted, depending on current requirements of the region.

14.4 OTHER DATA

Other data, for example, PD (which may include biomarkers), pharmacogenomics, quality of life and pharmacoeconomic endpoints data etc. may be presented.

Comment [A559]: The ICH E3 section title is: ‘Abnormal Laboratory Value Listing (Each Patient)’. Clarification that these listings should capture only clinically meaningful abnormal values to avoid it becoming a data dump with little value.

Abnormal clinically meaningful vital signs and ECG data may also be listed because capture of “interesting” safety data should not be limited to laboratory data only. The section title should be adapted to reflect the listings actually presented.

Comment [A560]: Consider for PPD impact: March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 87 of 91 states: ‘EMA notes that under ICH E3, the CSRs may contain individual patient data listings … even within the body of the report. For example, these … may be contained in CSR section 14.3.4 Abnormal Laboratory Value Listing (Per Patient/per Visit), as well as elsewhere in the CSR body … EMA considers that such per patient/per visit line listings fall outside the scope of phase 1 of the Policy (0070) and, therefore, it is acceptable to have them removed from the clinical reports prepared for publication at this stage of the implementation. All these per patient/per visit line listings will be falling in the scope of phase 2 of the Policy. Per page 6 of 91, Policy 0070 is in two phases. Phase 1 (01 January 20) pertains to publication of CSRs only. Phase 2, which will be implemented at a later stage, pertains to the publishing of individual patient data.

Comment [A561]: Consider for PPD impact: Any “other” data should be integrated into the end of text tables and figures section as is most appropriate to the study. Placement here is only an example.

Consider for PPD impact: March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 87 of 91 states: ‘EMA notes that under ICH E3, the CSRs may contain individual patient data listings … even within the body of the report. For example, these … may be contained in CSR section 14.3.4 Abnormal Laboratory Value Listing (Per Patient/per Visit), as well as elsewhere in the CSR body … EMA considers that such per patient/per visit line listings fall outside the scope of phase 1 of the Policy (0070) and, therefore, it is acceptable to have them removed from the clinical reports prepared for publication at this stage of the implementation. All these per patient/per visit line listings will be falling in the scope of phase 2 of the Policy. Per page 6 of 91, Policy 0070 is in two phases. Phase 1 (01 January 20) pertains to publication of CSRs only. Phase 2, which will be implemented at a later stage, pertains to the publishing of individual patient data. “Other data” may fall into the category described above and therefore the same rules may be applied by EMA.
15. **REFERENCE LIST**

A list of articles from the literature pertinent to the evaluation of the study, and cited in the CSR text, should be provided below. These may include conference abstracts and posters based on the study, as well as papers. Copies of important references may be attached in Appendices 16.1.11 and 16.1.12. All publications must be available and with the Sponsor at the time of filing of the submission.

Web addresses and digital object identifiers (DOIs) should be provided where possible.

References should be given in accordance with the internationally accepted standards of the International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: Sample References: [http://www.nlm.nih.gov/bsd/uniform_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html).

16. **APPENDICES**

This section should be prefaced by a full list of all appendices available for the study report. It is also acceptable to have the list of appendices integrated into the report table of contents. Where permitted by the regulatory authority, some of the following appendices need not be submitted with the report but need to be provided only on request.

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A562]: CORE Reference is a user manual and is not a template. The example sectioning and sub-sectioning is just that – an example. The Reference List may sit equally well before Section 14 Tables, to directly follow the main CSR text. The practical implications of switching the order of level 1 ICH E3 section headings in CORE Reference – here a Section 15 and Section 14 switch – are too far-reaching in terms of other external documents (including industry guidance documents) to make the switch within CORE Reference anything other than confounding.

Comment [A563]: Clarification that conference abstracts and posters may be included.

Comment [A564]: ICH E3 word 'publications' is substituted with 'references' here.

Comment [A565]: A cross link may be added in Appendix 16.1.11 and Appendix 16.1.12 to Section 15 (Reference List) as appropriate.

Comment [A566]: ICH E3 states that copies should be attached. However, guidance on inclusion of appendices for (European) MAA submissions clearly states ‘for pivotal trials where these represent study end-points and otherwise on request’. This is also the case for FDA. In some regions, references may need to be attached with each CSR in 16.1.11 and 16.1.12. These appendices therefore need only be included and populated as appropriate.

Comment [A567]: Web addresses and digital object identifiers (DOIs): Do not use active web links in the ‘primary use CSR’ for regulatory submission – just non active web addresses. This is because there is a risk of dossier validation problems when the CSR is submitted, sometimes years later.

The web addresses can subsequently be active in the ‘secondary use CSR’ for public disclosure.

Comment [A568]: ICH E3 mentions “…1979 Vancouver Declaration on “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” or the system used in “Chemical Abstracts.” These older standards have been superseded by the International Committee of Medical Journal Editors (ICMJE) guideline cited here.

Comment [A569]: Such an example list is included in the following pages.
The Sponsor should therefore clearly indicate those appendices that are submitted with the report. Optimal documentary requirements are tabulated below.

Additional appendices may be created if the study necessitates this.

Note: In order to have appendices available on request, they should be finalised by the time of filing of the submission.

Comment [A570]: See ICH E3 2012 Q & A Point 3 for CSR appendices.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/ICH-E3-R1-atlas.pdf which states: "Documentation should be submitted in the marketing application. Documents that provide critical information on a study, such as in the protocol (16.1.1); statistical methods (16.1.9); list of investigators and study sites and sample case report forms, would always be needed by reviewers assessing a study and should be included in the trial report even if they are in a TMF."

These are integrated into the table below.

Comment [A571]: Suggest to include a table for the list of appendices, with details.

Comment [A572]: There are certain requirements, especially in Appendix 16.1 Study Information, for MAA validation and for FDA (especially for studies do not come under an Investigational New Drug [IND] programme) that are not described in ICH E3, but are actually required. These are detailed in ‘EMA pre-authorisation procedural advice for users of the centralised procedure’ 31 Mar 2016. EMA/339324/2007: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500044369.pdf

Relevant section for CSR appendices is 3.2. How are initial MAAs validated at the EMA: ‘How to avoid most common GCP validation issues’. The points listed in this document are transcribed below for information. Disregard for non EU studies.

Comment [A573]: Consider for PPD and CCI impact: In the EU, CSR Appendices 16.1.1, 16.1.2 and 16.1.9 will be publicly disclosed (EMA Policy 0070 effective 1 Jan 2015: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/10/WC500174796.pdf) and March 2016 EMA guidance on use of Policy 0070 (http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/03/WC500202621.pdf) page 88 of 91: ‘To be noted that the same CCI, PPD and publication principles will apply to EU as well as non-EU studies in the context of Policy 0070’. See Preface for further detail on CCI, PPD and related topics.

Comment [A574]: See FDA Guidance on FDA Acceptance of Foreign Clinical Studies not Conducted Under an IND – Frequently Asked Questions:

Additional appendix requirements may be necessary e.g. Investigator CVs, and action dates of IRB/IEC approvals (e.g. initial approval date, date of approval of study amendments/modifications), master ICF. Suggest to collect the PI signature as a separate document submitted in MAA dossiers. This separates signature collections from CSR publishing, which may bring efficiencies when timelines are tight.
Supportive documents, such as Investigator CVs, ethics committee approvals, informed consent forms, and batch numbers per subject are in the TMF or clinical supply database and should generally not be included in the CSR appendices. Any documents not submitted and subsequently requested by the regulatory authority would be expected to be provided promptly.

<table>
<thead>
<tr>
<th>Appendix number</th>
<th>Content</th>
<th>Provide in appendix</th>
<th>To be available on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1</td>
<td>Study Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.1.1</td>
<td>Protocol and protocol amendments</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>[Need not be signed copies; amended protocol versions subsequent to the original protocol are acceptable in place of actual protocol amendments, if available]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.1.2</td>
<td>Sample case report form (may include unique pages only)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>[Including sample subject diary card or equivalent data collection tools]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.1.3</td>
<td>List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority)</td>
<td>Yes (list only)</td>
<td>Yes (IEC/IRB approvals)</td>
</tr>
<tr>
<td></td>
<td>[Deliberate wider line spacing below to allow optimal presentation of ICH E3 2012 Q&amp;A text]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comment [A575]: ICH E3 2012 Q & A Point 3.

Comment [A576]: i.e. in Sponsor’s files.

Comment [A577]: Consider for CCI and PPD impact. In the EU, Appendix 16.1.1 will be publicly disclosed, so information included in this appendix may be redacted for the ‘secondary use CSR’ for public disclosure.

Comment [A578]: ICH E3 requirement of ‘Representative written information for patient and sample consent forms’ is omitted due to the ICH E3 2012 Q & A clarification Point 3.

<Deliberate white space to allow comments on right hand side of the next page to be shown in full>
<table>
<thead>
<tr>
<th>Appendix number</th>
<th>Content</th>
<th>Provide in appendix</th>
<th>To be available on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1.4</td>
<td>List and description of Investigators and other important participants in the study</td>
<td>Yes (list only)</td>
<td>Yes (CVs)</td>
</tr>
</tbody>
</table>

[By-centre list of Investigators should show linkage of centres to the number of subjects enrolled and their IDs.] ‘Other important participants’ including the CSR author and biostatistician may be included but need not be limited to individuals affiliated to CROs, central laboratories and other relevant specialist service providers.  

<Deliberate wider line spacing below to allow optimal presentation of ICH E3 2012 Q&A text>

CVs are in the TMF and are not required in Appendix 16.1.4.  

<Deliberate white space to allow comments on right hand side of this page to be shown in full>
### Appendix Content

<table>
<thead>
<tr>
<th>Appendix number</th>
<th>Content</th>
<th>Provide in appendix</th>
<th>To be available on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1.5</td>
<td>Signatures of Principal (for single-centre studies) or Coordinating Investigator(s) (for multi-centre studies) and/or Sponsor’s responsible medical officer (depending on the Regulatory Authority’s requirement) and signature of responsible biostatistician</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>16.1.6</td>
<td>List of Investigational Products(s) batch numbers (Per subject batch number linkage is in the clinical supply database and not required in Appendix 16.1.6)</td>
<td>Yes (list only)</td>
<td>Yes (batch numbers linked to subject numbers)</td>
</tr>
<tr>
<td>16.1.7</td>
<td>Randomisation scheme and codes (subject identification and treatment assigned)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>16.1.8</td>
<td>Audit certificates (if necessary [region and/or country-specific], and if available)</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Comment [A583]: i.e. in Sponsor’s files.

Comment [A584]: Addition of ‘and/’ to ICH E3 text is to clarify that all regions per ICH E3 require the Principal or Coordinating Investigator signature OR the Sponsor’s responsible medical officer signature. Historically and globally, the medical officer signature became the standard choice. Later, in 2001, the EMEA issued its Note for Guidance on Coordinating Investigator signature of CSRs: https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003656.pdf, which states ‘CSRs submitted as part of Marketing Authorisation Application… should be signed by the Investigator or in the case of multicentre studies the Coordinating Investigator… the signature Coordinating Investigator should be defined in the protocol…’. The final outcome is that in all regions, the Sponsor’s responsible medical officer should sign the CSR. In the EU, the Investigator should additionally sign (EU Sponsors are unlikely to have the Investigator but not their own medical officer sign, which is why both signatures are usually required for EU studies). Also see CORE Reference Annex I.

Comment [A585]: See ICH E9 Statistical Principles for Clinical Trials: http://www.ich.org/fileadmin/Public_Web_Site/IC/HC_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline_en.pdf. Section 7.1 final paragraph which states ‘…the trial statistician should be a member of the team responsible for the clinical study report, and should approve the clinical report.’ Also see CORE Reference Annex I.

Comment [A586]: ICH E3 requirement of subject batch number linkage is omitted due to the ICH E3 2012 Q & A clarification Point 3: Supportive documents, such as investigator CVs, ethics committee approvals, informed consent, forms and batch numbers per subject are in TMF or clinical supply database and should generally not be included in the CSR appendices. "Investigational Product" includes Test Product and Control Product which may include placebo or active comparator. For terminology related to Investigational Product see Preface.

Comment [A587]: Include internal or external auditing procedures if used. Do not include audit reports.

Comment [A588]: Clarification that regional and country-specific requirements must be adhered to.

Comment [A589]: Per ICH E3 2012 Q & A Point 5: Certain documents may be required for the CSR by individual countries or regions, in which case they should be included. For example, according to ICH GCP: an audit certificate (16.1.8) should be provided when required by applicable law or regulation. If there is any uncertainty about whether documents should be included or not, the appropriate regulatory agency may be consulted.
<table>
<thead>
<tr>
<th>Appendix number</th>
<th>Content</th>
<th>Provide in appendix</th>
<th>To be available on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1.9</td>
<td>Documentation of statistical methods</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>[Need not be a signed copy]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[Post-hoc analyses (including post-hoc analysis methods and results if conducted and available by final CSR date) if not included in the main CSR text]</td>
<td>Yes (if available by final CSR date)</td>
<td>Yes (if not available by final CSR date)</td>
</tr>
<tr>
<td>16.1.10</td>
<td>Documentation of inter-laboratory standardisation methods and laboratory QA procedures if used (depending on the Regulatory Authority’s requirement)</td>
<td>Yes – (pivotal studies only)</td>
<td>Yes (all non-pivotal studies)</td>
</tr>
<tr>
<td></td>
<td>[For pivotal studies where these represent study endpoints]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.1.11</td>
<td>Publications based on study</td>
<td>Preferred</td>
<td>Yes (actual publications)</td>
</tr>
<tr>
<td>16.1.12</td>
<td>Important publications referenced in the report</td>
<td>Preferred</td>
<td>Yes (actual publications)</td>
</tr>
</tbody>
</table>

Comment [A590]: i.e. in Sponsor’s files.

Comment [A591]: Clarification on signatures. There is no regulatory requirement for signature(s).

Comment [A592]: Clarification on post-hoc analyses.

Comment [A593]: Clarification that the included documentation of QA procedures should relate to laboratories.

Comment [A594]: Laboratory validation procedures and/or certificates, equipment calibration, internal QC or external QA procedures. No laboratory manuals required. Applies to central, local and specialist laboratories.


Comment [A596]: In practice, this appendix may often be unpopulated. Cross check with the information provided in the Synopsis (which notes posters and abstracts should be included). Posters and abstracts are particularly hard to obtain years later so it is sensible to have them available at CSR finalisation.

Comment [A597]: Actual PDFs of references are required in Module 5 of a submission dossier.

Comment [A598]: Can be all of or a subset of the references listed in Section 15.

Comment [A599]: Consider that a). The CSR may be final many years before the dossier is submitted, and b). Only a small number of CSRs ever end up in a submission dossier. In light of this, including the actual references in Appendices 16.1.11 and 16.1.12 may avoid possible complications subsequent to CSR finalisation. NOTE: In practice, only one set of references are actually required in a regulatory dossier submission.

Comment [A600]: The intent of Appendices 16.1.11 and 16.1.12 is to gather actual references so they are “available” at the time of CSR finalisation.

Comment [A601]: Actual PDFs of references are required in Module 5 of a submission dossier.
<table>
<thead>
<tr>
<th>Appendix number</th>
<th>Content</th>
<th>Provide in appendix</th>
<th>To be available on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1.13</td>
<td>Optional Appendix e.g. Data Monitoring Committee. (Stand-alone reports, e.g. PK report, PRO report)</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Comment [A602]: i.e. in Sponsor’s files.

Comment [A603]: If DMC materials are included, the DMC charter and key meeting minutes should suffice.

Comment [A604]: An additional appendix, for example, Appendix 16.1.13, is suggested for the inclusion of stand-alone reports, as appropriate.

Comment [A605]: ICH E3 2012 Q & A Point 4 encourages inclusion of relevant stand-alone reports, as necessary. Other topics should be used referenced in the CSR body and clearly identified in the Table of Contents. Current submission options include: 1) Stand alone reports. These can be placed in “parallel” with the main CSR in the eCTD. For example, a clinical pharmacology study might have the CSR, a PK report, and an assay validation report. For an efficacy study with patient reported outcome (PRO) measures, there might be a PRO report. Each of these reports can be referenced under the same heading in the eCTD and placed alongside one another in the eCTD folder for that study. Be sure to clearly describe the nature of the information in the title of the document that is provided through the eCTD. 2) If a region where study tagging files are used, it is recommended that a file tag option from the “valid values list” be used, for example, safety report, antibacterial, special-pathogen, etc. (see Specifications for Study Tagging Files, http://www.ich.org/products/electronic-standards.html). Alternatively, if a file tag that adequately describes the material you are planning to submit is not available, you may request that a new file tag be made available. This request should be submitted to your regional authority. In the event that this change cannot be accommodated within your timeframe you may place the document with the main body of the report, i.e., the document would be tagged with the “study-report-body” file tag. The nature of the information should be contained in the title of the document that is provided through the eCTD. Please refer to the most recent version of the “valid values list” as it is periodically updated as changes are requested.
### Appendix number | Content | Provide in appendix | To be available on request |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16.2</td>
<td>Subject Data Listings</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>16.2.1 Discontinued Subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.2 Protocol Deviations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.3 Subjects Excluded from the Efficacy Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.4 Demographic Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.5 Compliance and/or Drug Concentration Data (if available)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.6 Individual Efficacy Response Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.7 Adverse Events Listings (each Subject)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.2.8 Listing of Individual Laboratory Measurements by Subject When Required by Regulatory Authorities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.3</td>
<td>Case Report Forms</td>
<td>Yes (for narrative subjects only)</td>
<td>Yes (all other CRFs)</td>
</tr>
<tr>
<td></td>
<td>16.3.1 CRFs for deaths, other SAEs and withdrawals for AE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.3.2 Other CRFs submitted (only if applicable)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.4</td>
<td>Individual Subject Data Listings (US archival listings)</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

**Comment [A606]**: i.e. in Sponsor’s files.

**Comment [A607]**: See CORE Reference Annex IV text relevant to creation of Appendix 16.2 listings content, gathered together from various places in ICH E3 and presented below for the use, primarily, of statisticians.

**Comment [A608]**: For FDA submissions, Subject Data Listings need not necessarily be produced due to the common practice of submission of searchable SAS data sets to authorities. See FDA resources for data standards: [http://www.fda.gov/ForIndustry/DataStandards/](http://www.fda.gov/ForIndustry/DataStandards/).

**Comment [A609]**: In practice, it seems CRFs are not always submitted and this depends on the study. Advice is to check with your regulatory agency/authority before filing.

**Comment [A610]**: US Archival Listings need not be produced due to the common practice of submission of searchable SAS data sets to authorities. See FDA resources for data standards: [http://www.fda.gov/ForIndustry/DataStandards/](http://www.fda.gov/ForIndustry/DataStandards/).

Archival listings are not usually required by other regulatory authorities. This may however depend on the drug and therapeutic area. Confirmation from the respective regulatory authority is advised. Some regulatory authorities may require certain listings only (e.g. SAE).
## Explanation of Annexes in ICH E3 and in CORE Reference

<table>
<thead>
<tr>
<th>Annex number – Title (in ICH E3)</th>
<th>Position in CORE Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>I – Synopsis</td>
<td>Example synopsis table is included in Section 2 (Synopsis) of CORE Reference (so Annex I Synopsis is removed from annexes)</td>
</tr>
<tr>
<td>II – Principal or Coordinating Investigator(s) Signature(s)</td>
<td>Renumbered Annex I and included below</td>
</tr>
<tr>
<td>IIIa – Study Design and Schedule of Assessments</td>
<td>Example Table 9.1 in CORE Reference is derived from Annexes IIIa and IIIb (which are therefore omitted from annexes)</td>
</tr>
<tr>
<td>IIIb – Study Design and Schedule of Assessments</td>
<td></td>
</tr>
<tr>
<td>IVa – Disposition of Patients</td>
<td>Example Figure 10.1 in CORE Reference is derived and amended from Annexes IVa and IVb (which are therefore omitted from annexes)</td>
</tr>
<tr>
<td>IVb – Disposition of Patients</td>
<td></td>
</tr>
<tr>
<td>V – Study # (Data Set Identification) Listing of Patients Who Discontinued Therapy</td>
<td>Renumbered Annex II and included below</td>
</tr>
<tr>
<td>VI – Study # (Data Set Identification) Listing of Patients and Observations Excluded From Efficacy Analysis</td>
<td>Renumbered Annex III and included below</td>
</tr>
<tr>
<td>VII – Study # (Data Set Identification) Number of Patients Excluded from Efficacy Analysis</td>
<td>Example Table 10.2 in CORE Reference is derived and amended from Annex VII (which is therefore omitted from annexes)</td>
</tr>
<tr>
<td>VIII – Guidance for Section 11.4.2 – Statistical/Analytical Issues and Appendix 16.1.9</td>
<td>Section 11.4.2 in the body of CORE Reference is now renumbered Section 11.2 (Results of Statistical Issues Encountered During The Analysis) Annex VIII is renumbered Annex IV and included below with text adaptations. Notes per ICH E3 Section 11.4.3 (Tabulation of Individual Response Data), and Section 12.4.1 (List of Individual Laboratory Measurements by Patient and Each Abnormal Laboratory Value), which are actually relevant to creation of Appendix 16.2 listings generally, are appended to this annex. These notes are more appropriately annexed than placed in the body of CORE Reference as are relevant to the statistician only</td>
</tr>
<tr>
<td></td>
<td>Annex V is new and shows ‘Adverse Events: Number Observed and Rate, with Subject Identifications’. This is in ICH E3 Section 12.2.2 (Display of Adverse Events) but does not appear in CSR text, but rather is usually appended, so is more appropriately relocated to new Annex V</td>
</tr>
<tr>
<td></td>
<td>Annex VI is new and shows ‘List of Laboratory Measurements’. This is in ICH E3 Section 12.4.1 (Listing of individual laboratory measurements by subject [16.2.8] and each abnormal laboratory value [14.3.4]) but does not appear in CSR text, but rather is usually appended, so is more appropriately relocated to new Annex VI, and is additionally redesigned more appropriately to two tables that might be used</td>
</tr>
</tbody>
</table>
## PRINCIPAL OR COORDINATING INVESTIGATOR(S) SIGNATURE(S) (AND/OR) SPONSOR’S RESPONSIBLE MEDICAL OFFICER SIGNATURE AND STATISTICIAN’S SIGNATURE

<table>
<thead>
<tr>
<th>STUDY TITLE:</th>
<th>STUDY NUMBER:</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPORT VERSION: Final (Date)</td>
<td></td>
</tr>
<tr>
<td>STUDY AUTHORS:</td>
<td>I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study</td>
</tr>
<tr>
<td>PRINCIPAL/COORDINATING INVESTIGATOR:</td>
<td></td>
</tr>
<tr>
<td>SIGNATURE:</td>
<td>AFFILIATION:</td>
</tr>
<tr>
<td>DATE:</td>
<td></td>
</tr>
<tr>
<td>SPONSOR’S RESPONSIBLE MEDICAL OFFICER:</td>
<td></td>
</tr>
<tr>
<td>SIGNATURE:</td>
<td>AFFILIATION:</td>
</tr>
<tr>
<td>DATE:</td>
<td></td>
</tr>
<tr>
<td>STATISTICIAN:</td>
<td></td>
</tr>
<tr>
<td>SIGNATURE:</td>
<td>AFFILIATION:</td>
</tr>
<tr>
<td>DATE:</td>
<td></td>
</tr>
</tbody>
</table>

**Comment [A611]:** Annex II in ICH E3.

**Comment [A612]:** Addition of ‘and/or’ to ICH E3 text is to clarify that all regions per ICH E3 require the Principal or Coordinating Investigator signature OR the Sponsor’s responsible medical officer signature. Historically and globally, the medical officer signature became the standard choice. Later, in 2001, the EMEA issued its Note for Guidance on Coordinating Investigator signature of CSRs: [Link](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500010529.pdf) which states ‘CSRs submitted as part of Marketing Authorisation Application... should be signed by the investigator or in the case of multicentre studies the Coordinating Investigator... the signatory Coordinating Investigator should be defined in the protocol...’. The final outcome is that in all regions, the Sponsor’s responsible medical officer should sign the CSR. In the EU, the Investigator should additionally sign (EU Sponsors are unlikely to have the Investigator but not their own medical officer sign, which is why both signatures are collected as standard for EU studies).

**Comment [A613]:** See ICH E9 Statistical Principles for Clinical Trials: [Link](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/E9_Guideline.pdf) Section 7.1 final paragraph which states: ‘...the trial statistician should be a member of the team responsible for the clinical study report, and should approve the clinical report.’

**Comment [A614]:** ICH E3 States in Section 6: Where signatures of the Principal or Coordinating Investigators are required by regulatory authorities, these should be included in Appendix 16.1.5. Where these are not required, the signature of the Sponsor’s responsible medical officer should be provided in Appendix 16.1.5.

For EU studies only, include Principal/Coordinating Investigator signature as well as Sponsor’s medical officer signature. Omit if not applicable.

**Comment [A615]:** Added per ICH E9 requirement.
Annex II (Appendix 16.2.1)
Listing of Subjects Who Discontinued Treatment (Data Set Identification)

<table>
<thead>
<tr>
<th>Centre:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigational Product</td>
</tr>
<tr>
<td>Test Product</td>
</tr>
<tr>
<td>Control Product (may include active comparator or placebo)</td>
</tr>
</tbody>
</table>

Day is relative to first dose of Investigational Product.
Data source: xxx
(Repeat for other centres)

Comment [A616]: ICH E3 Annex V.
Comment [A617]: Content is essentially the same as ICH E3 Annex V, with adapted presentation.
Comment [A618]: Terminology around Investigational Product is aligned with terminology in the CORE Reference Preface.
Comment [A619]: This is a listing and will not appear in this form in the CSR text. It is expected that the protocol number will appear in the data source of all statistical output. This aids regulators who may copy these into their own documents. Output without a study number (included as part of the source) may cause confusion.
### Annex III (Appendix 16.2.3)

**Listing of Subjects and Observations Excluded from the Efficacy Analysis**

**Centre:**

<table>
<thead>
<tr>
<th>Investigational Product</th>
<th>Subject Number</th>
<th>Sex</th>
<th>Age</th>
<th>Observation Resulting in Exclusion</th>
<th>Reason(s) for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Product</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control Product (may include active comparator or placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data source: xxx

(Repeat for other centres)

---

**Comment [A620]:** ICH E3 Annex VI.

**Comment [A621]:** Content is essentially the same as ICH E3 Annex VI, with adapted presentation.

**Comment [A622]:** Terminology around Investigational Product is aligned with terminology in the CORE Reference Preface.

**Comment [A623]:** This is a listing and will not appear in this form in the CSR text. It is expected that the protocol number will appear in the data source of all statistical output. This aids regulators who may copy these into their own documents. Output without a study number (included as part of the source) may cause confusion.
A. STATISTICAL CONSIDERATIONS

Details of the statistical analysis performed on each efficacy variable should be presented in an appendix. Details reported should include at least the following information:

a) A statement of the clinical claim tested in precise statistical terms, e.g. in terms of null and alternative hypotheses.

b) The statistical model underlying the analysis. This should be presented precisely and completely, using references if necessary. If any model fitting was performed, this should be described noting all terms included in the original model, any terms removed because they were not statistically significant and the terms fitted in the final model. The method of model fitting as specified in the final SAP (e.g. stepwise regression with backward elimination) should be stated. Model fitting should only be performed if planned in the final SAP. The risk of bias introduced by making unplanned changes to the model should be clearly stated.

c) The assumptions underlying the planned statistical methods. It should be shown, insofar as statistically reasonable, that the data satisfy crucial assumptions, especially when necessary to confirm the validity of an inference. In the event that the assumptions are not met, then the alternative methods should be detailed. These may include:

   (i) Transformation of the data such that the assumptions of the planned model are met.

   (ii) Performing an alternative analysis where the data do meet the assumptions.

Any alternative methods should be detailed in addition to details of the originally planned analysis method. It should be clearly stated whether the alternative approaches were planned (stated as an alternative in the final SAP) or whether the decision to use alternative methods was taken after study unblinding. The risk of bias introduced by making unplanned changes to the model should be clearly stated.

d) The statistical methods applied to estimate effects, construct confidence intervals, etc. Literature references should be included where appropriate. If data have been transformed prior to analysis, then it should also be stated how to interpret treatment effects.

e) The test statistic, the sampling distribution of the test statistic under the null hypothesis, the value of the test statistic, significance level (i.e. p-value) and intermediate summary data, in a format that enables the regulatory authority’s statistical reviewer to verify the results of the analysis quickly and easily. The p-values should be designated as one- or two-tailed. The rationale for using a one-tailed test should be provided.

For example, the documentation of a two-sample t-test should consist of the value of the t-statistic, the associated degrees of freedom, the p-value, the two sample sizes, mean and variance for each of the samples and the pooled estimate of variance. The documentation of multi-centre studies analysed by variance techniques should include, at a minimum, an analysis of variance table with terms for centres, treatments, their interaction, error and total. For crossover designs, the documentation should include information regarding

ICH E3 text  ICH E3 2012 Q&A text  CORE Reference text  [Right margin comment=RATIONALE]
sequences, subjects within sequences, baselines at the start of each period, washouts and length of washouts, dropouts during each period, treatments, periods, treatment by period interaction error and total. For each source of variation, aside from the total, the table should contain the degrees of freedom, the sum of squares, the mean square, the appropriate F-test, the p-value and the expected mean square.

Intermediate summary data should include the demographic data and response data, averaged or otherwise summarised, for each centre-by-treatment combination (or other design characteristic such as sequence) at each observation time.

Comment [A632]: The following ICH E3 text is omitted as is outdated. The only agency (FDA) who actually does do such a thorough review receives SAS transport files:

B. FORMAT AND SPECIFICATIONS FOR SUBMISSION OF DATA REQUESTED BY REGULATORY AUTHORITY'S STATISTICAL REVIEWERS

In the report of each controlled clinical study, there should be data listings (tabulations) of patient data used by the Sponsor for statistical analyses and tables supporting conclusions and major findings. These data listings are necessary for the regulatory authority's statistical review and the Sponsor may be asked to supply these subject data listings in a computer-readable form.
B. GUIDANCE FOR APPENDIX 16.2 LISTINGS – GENERAL NOTES:

For a controlled study in which critical measurements or assessments (e.g., blood or urine cultures, pulmonary function tests, angina frequency or global evaluations) are repeated at intervals, the data listings accompanying the report should include, for each subject, a subject identifier, all measured or observed values of critical measurements, including baseline measurements, with notation of the timing during the study expressed relative to a fixed point (e.g., day relative to first dose of Investigational Product, and time of day if relevant) when the measurements were made, the drug/dose at the time (if useful, given as mg/kg), any measurements of compliance and any concomitant medications at the time of, or close to the time of, measurement or assessment. If, aside from repeated assessments, the study included some overall responder versus non-responder evaluation(s) (bacteriologic cure or failure), these should also be included. In addition to critical measurements, the tabulation should note whether the subject was included in the efficacy evaluation (and which evaluation, if more than one), provide subject compliance information (if collected) and a reference to the location of the CRF, if included. Critical baseline information such as age, sex, weight, disease being treated (if more than one in the study) and disease stage or severity, is also helpful. The baseline values for critical measurements would ordinarily be included as zero time values for each efficacy measurement.

Comment [A633]: In ICH E3, details pertaining to listings creation in Section 11.4.3 (Tabulation of Individual Response Data) are applicable more generally to all data listings presentations. The content is of relevance for statisticians and is presented here for clarity.

Comment [A634]: ICH E3 Section 11.4.3 text first paragraph is omitted because the FDA is the only agency who has previously requested this and now they receive SAS transport files—so this belongs to a bygone era.

ICH E3 text omitted: 'Some regulatory authorities may require all individual data in archival case report tabulations. What needs to be included in the report will vary from study to study and from one drug class to another and the Sponsor must decide, if possible after consultation with the regulatory authority, what to include in the appendix to the study report. The study report should indicate the material that is included as an appendix; the more extensive archival case report tabulations, if required by the regulatory authority, and what is available on request'.

Comment [A635]: The word 'efficacy' is omitted.

Comment [A636]: Consider for PPD impact: ICH E3 text specifies that subject identifiers should be present on listings. Subject numbers may be created using a centre identifier component. Subject re-identification, particularly for centres entering small numbers of study subjects, may be possible through a subject number that includes a centre identifier component. Where individual subject numbers are presented in the ‘primary use CSR’, it is recommended that these are fully redacted in the ‘secondary use CSR’ for public disclosure. In all cases, the entire subject number— including any centre identifier component— should be redacted.

Comment [A637]: Consider for PPD impact: Calendar dates would not be allowed in the ‘secondary use CSR’ for public disclosure as these may increase the chance of subject re-identification. In the ‘primary use CSR’ for regulatory review, only refer to study days and do not refer to calendar dates. This approach captures event timing (necessary to inform the assessment of temporal association) in the ‘primary use CSR’ without increasing redaction need in the ‘secondary use CSR’.

Note however, that this may need special consideration for some illnesses where dates can be important, for example, allergy and seasonal affective disorder where alternative presentations should be considered that still avoid the actual date.

Comment [A638]: ICH E3 text: ‘(e.g., days on therapy)’ is clarified.
The listings described should usually be included in Appendix 16.2 of the study report, rather than in the more extensive case report tabulations required by some regulatory authorities, because it represents the basic data supporting the summary tables. However, such a thorough tabulation can be unwieldy for review purposes and it is expected that more targeted displays will be developed as well. For example, if there are many measurements reported, tabulations of the most critical measurements for each subject (e.g. the blood pressure value might be more important at certain visits than others) will be useful in providing an overview of each individual’s results in a study, with each subject’s response summarised on a single line or small number of lines.

While individual subject data ordinarily can be displayed in listings, it has, on occasion, been helpful to construct individual subject profiles in other formats, such as graphic displays. These might, for example, show the value of a particular parameter(s) over time, the drug dose over the same period and the times of particular events (e.g. an AE or change in concomitant treatment). Where group mean data represent the principal analyses, this kind of “case report extract” may offer little advantage; it may be helpful, however, if overall evaluation of individual responses is a critical part of the analysis. If such profiles are presented, these should be cross-referenced in the CSR text.

C. GUIDANCE FOR APPENDIX 16.2 LISTINGS – LABORATORY DATA:

When required by regulatory authorities, the results of all safety-related laboratory tests should be available in listings, using a display where each entry represents a patient visit at which a laboratory study was done, with patients grouped by investigator (if more than one) and treatment group, and columns include critical demographic data, drug dose data, and the results of the laboratory tests, similar to the example in Annex VI. As not all tests can be displayed in a single table, they should be grouped logically (haematological tests, liver chemistries, electrolytes, urinalysis, etc.). In addition, normal laboratory ranges should be given for each laboratory parameter.

Abnormal values should be identified and graded according to an established toxicity grading scale, or designated clinically meaningful or not clinically meaningful, according to the Investigator’s judgment at the time the result became available. These listings should be submitted as part of the registration/marketing application, when this is required, or may be available on request. Examples of such listings are presented in Annex VI.

For all regulatory authorities, there should be a by-subject listing of all abnormal laboratory values presented in Section 14.3.4 (Data Listings: Each Subject) for Abnormal Clinically Meaningful Laboratory Values, Vital Signs, Physical Examinations and Other Observations Related to Safety, using the formats described above.

For laboratory abnormalities of special interest (abnormal laboratory values of potential clinical importance), it may also be useful to provide additional data, such as normal values and after the abnormal value, and values of related laboratory tests. In some cases, it may be desirable to exclude certain abnormal values from further analysis. For example, single, non-replicated, small abnormalities of some tests (e.g. uric acid or electrolytes) or occasional low values of some tests (e.g. transaminase, alkaline phosphatase, BUN etc.) can probably be defined as not clinically meaningful and excluded. Any such decisions should be clearly explained, however, and the complete list

ICH E3 text | ICH E3 2012 Q&A text | CORE Reference text | [Right margin comment=RATIONALE]
of values provided (or available to authorities on request) should identify every abnormal value.

Annex V (Appendix 16.2.7)

Adverse Events: Number Observed and Rate, With Subject Identifications

<table>
<thead>
<tr>
<th>Treatment Group X, N=50</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Related*</th>
<th>NR</th>
<th>Related*</th>
<th>NR</th>
<th>Related*</th>
<th>NR</th>
<th>Related*</th>
<th>NR</th>
<th>Related*</th>
<th>NR</th>
<th>Related*</th>
<th>NR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Body System A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N11**</td>
<td>6 (12%)</td>
<td>2 (4%)</td>
<td>3 (6%)</td>
<td>1 (2%)</td>
<td>3 (6%)</td>
<td>1 (2%)</td>
<td>12 (24%)</td>
<td>4 (8%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N12</td>
<td>N21</td>
<td>N31</td>
<td>N41</td>
<td>N51</td>
<td>N61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N13</td>
<td>N22</td>
<td>N32</td>
<td>N52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N14</td>
<td>N33</td>
<td>N53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Event 2

NR = not related.
* Related could be expanded, e.g. as definite, probable, possible
** Subject identification number

Data source: xxx

Comment [A651]: This table is in ICH E3 Section 12.2.2. It is annexed per ICH E3 2012 Q & A Point 6 (see below). This also avoids inclusion of the subject IDs in the main CSR in-text table.

The ICH E3 Section 12.2.2 text suggests that the regulatory authorities are interested in the subject numbers.

Comment [A652]: ICH E3 2012 Q & A Point 6 states: "Note: the example table provided in Section 12.2.2 of the guideline is not meant to be presented in Section 12.2.2 of the report, but in Section 14.3.1.3, which is not part of the text of the clinical study report."

The ICH E3 Guideline did not attempt to display all possible presentations of adverse event information, but rather outlined the summary table intended for Section 12.2.2 and provided an illustration of the far more detailed display that would be placed in Section 14.3.1. The example provided for Section 14.3.1, however, does not try to illustrate all possibilities, but shows individuals with adverse events by body system, severity, and perceived drug-relatedness, for treatment groups.

Events should also display investigator’s verbatim terms for each event and could be used to show demographic or disease-specific information, dosage, duration of treatment, or treatment cycles for cancer chemotherapy because it can be impractical to display all of this information in a single listing. Such analyses can be presented in additional tables if e.g. by dose or other subgroup of interest. When adverse event data are presented by subgroup, however, a display of overall adverse events should also be included. For example, for a drug for subjects with chronic kidney disease, adverse events could be tabulated separately for subjects receiving or not receiving dialysis, but a table that includes adverse events in all subjects should also be included. The listings that provide more comprehensive adverse event information, specifically subject identifiers and verbatim terms for each adverse event, should be provided in the study report, in Sections 14.3.1 and 16.2.7. If each adverse event is to be characterized extensively, i.e., many items in the listing, electronic approaches may be needed.

Comment [A653]: This is a listing and will not appear in this form in the CSR text. It is expected that the protocol number will appear in the data source of all statistical output. This aids regulators who may copy these into their own documents. Output without a study number (included as part of the source) may cause confusion.
### Listing of Laboratory Measurements

<table>
<thead>
<tr>
<th>Subject number and demographic data</th>
<th>Days on treatment</th>
<th>Dose</th>
<th>Test parameter (unit)</th>
<th>Reference range</th>
<th>Test result</th>
<th>Toxicity grade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Footnote to describe toxicity grading scale

Data source: xxx

<Deliberate white space to allow comments on right hand side of this page to be shown in full>

Comment [A654]: ICH E3 ‘Listing of Individual Laboratory Measurements by Patient (16.2.8) and Each Abnormal Laboratory Value (14.3.4)’ is adapted to more accurately reflect the content of both listings.

The basis for these suggested tables is ICH E3 Section 12.4.1 ‘List of laboratory measurements – tabular presentation’ with ICH E3 text.

Consider for PPD impact: The tabulations presented below include demographic data per the ICH E3 tabulation. Consider that data transcribed from these tables into the 'primary use CSR' text may require redaction in the 'secondary use CSR' for public disclosure.

Comment [A655]: ICH E3 Section 12.4.1 describes a display: ‘…where each row represents a patient visit at which a laboratory study was done, with patients grouped by investigator (if more than one) and treatment group, and columns include critical demographic data, drug dose data, and the results of the laboratory tests.’ These tables are designed accordingly.

Comment [A656]: Consider for PPD impact: The data included in this (or any similar) listings will necessitate careful consideration when transcribing data into the CSR. Data included in the ‘primary use CSR’ for regulatory review must be sufficient to support the review and may need to be redacted in the ‘secondary use CSR’ for public disclosure to protect subject anonymity.

Comment [A658]: Timepoints may be shown.

Comment [A657]: Demographic data may include age, sex, race, weight etc.

Comment [A659]: This is a listing and will not appear in this form in the CSR text. It is expected that the protocol number will appear in the data source of all statistical output. This aids regulators who may copy these into their own documents. Output without a study number (included as part of the source) may cause confusion.
OR:

**Listing of Laboratory Measurements**

<table>
<thead>
<tr>
<th>Subject number and demographic data</th>
<th>Days on treatment</th>
<th>Dose</th>
<th>Test parameter</th>
<th>Reference range</th>
<th>Test result</th>
<th>Abnormal (No/Yes)</th>
<th>Clinical meaning for abnormal results only (CM/NCM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CM, clinically meaningful; NCM, not clinically meaningful

Data source: xxx

Comment [A660]: Consider for PPD impact: The data included in this (or any similar) listing will necessitate careful consideration when transcribing data into the CSR. Data included in the 'primary use CSR' for regulatory review must be sufficient to support the review and may need to be redacted in the 'secondary use CSR' for public disclosure to protect subject anonymity.

Comment [A662]: Timepoints may be shown.

Comment [A661]: Demographic data may include age, sex, race, weight etc.

Comment [A663]: The terms 'clinically significant' and 'not clinically significant' are also widely used.

Comment [A664]: This is a listing and will not appear in this form in the CSR text. It is expected that the protocol number will appear in the data source of all statistical output. This aids regulators who may copy these into their own documents. Output without a study number (included as part of the source) may cause confusion.
### LIST OF ABBREVIATIONS USED IN CORE REFERENCE

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>Analysis of Covariance</td>
</tr>
<tr>
<td>AUC</td>
<td>Area Under the Curve</td>
</tr>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>BUN</td>
<td>Blood Urea Nitrogen</td>
</tr>
<tr>
<td>CCI</td>
<td>Commercially Confidential Information</td>
</tr>
<tr>
<td>CDER</td>
<td>(FDA) Center for Drug Evaluation and Research</td>
</tr>
<tr>
<td>CDISC</td>
<td>Clinical Data Interchange Standards Consortium</td>
</tr>
<tr>
<td>CI</td>
<td>Coordinating Investigator</td>
</tr>
<tr>
<td>CIOMS</td>
<td>Council for International Organisations of Medical Sciences</td>
</tr>
<tr>
<td>Cmax</td>
<td>Maximum Plasma Concentration</td>
</tr>
<tr>
<td>CORE</td>
<td>Clarity and Openness in Reporting: E3 based</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organisation</td>
</tr>
<tr>
<td>CSR</td>
<td>Clinical Study Report</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CTR</td>
<td>Clinical Trial Regulation</td>
</tr>
<tr>
<td>CV</td>
<td>Curriculum Vitae</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic Acid</td>
</tr>
<tr>
<td>DoH</td>
<td>Declaration of Helsinki</td>
</tr>
<tr>
<td>DOI</td>
<td>Digital Object Identifier</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>eCTD</td>
<td>Electronic Common Technical Document</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EudraCT</td>
<td>European Union Drug Regulating Authorities Clinical Trials (Database)</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Council for Harmonisation</td>
</tr>
<tr>
<td>ICJME</td>
<td>International Committee of Medical Journal Editors</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive Voice Response System</td>
</tr>
<tr>
<td>MAA</td>
<td>Marketing Authorisation Application</td>
</tr>
<tr>
<td>MAH</td>
<td>Marketing Authorisation Holder</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
</tbody>
</table>

ICH E3 text | CORE Reference text | ICH E3 2012 Q&A text | [Right margin comment=RATIONALE] | 102
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>NEJM</td>
<td>New England Journal of Medicine</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>PD</td>
<td>Pharmacodynamic(s)</td>
</tr>
<tr>
<td>PET</td>
<td>Positron Emission Tomography</td>
</tr>
<tr>
<td>PhUSE</td>
<td>Pharmaceutical Users Software Exchange</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PIP</td>
<td>Paediatric Investigation Plan</td>
</tr>
<tr>
<td>PIS</td>
<td>Patient Information Sheet</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetic(s)</td>
</tr>
<tr>
<td>PPD</td>
<td>Protected Personal Data</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient Reported Outcome</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>QC</td>
<td>Quality Control</td>
</tr>
<tr>
<td>Q &amp; A</td>
<td>Questions &amp; Answers</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic Acid</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SRMO</td>
<td>Sponsor’s Responsible Medical Officer</td>
</tr>
<tr>
<td>TEAE</td>
<td>Treatment-Emergent Adverse Event</td>
</tr>
<tr>
<td>TFLs</td>
<td>Tables, Figures, Listings</td>
</tr>
<tr>
<td>TMF</td>
<td>Trial Master File</td>
</tr>
<tr>
<td>ToC</td>
<td>Table of Contents</td>
</tr>
</tbody>
</table>